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Debilitating lung disorders such as chronic pulmonary disease (COPD) and 
bronchopulmonary dysplasia (BPD) are presently incurable. The World Health 
Organization (WHO) predicts that by 2030, COPD will rise to become the third 
leading cause of death. Much of the increase in COPD is associated with the 
increase in tobacco use and the exposure to smoke combustion from fuel. COPD 
includes chronic bronchitis and emphysema. It is caused not only by inhalation of 
polluted air, but also by infections as well as genetic predispositions.  
 
To protect the respiratory airways, goblet cells in the bronchiole epithelium produce 
and secrete a viscous substance known as mucus along with enzymes to breakdown 
and remove inhaled toxins. Repeated and prolonged exposure to these toxins cause 
an overproduction of both mucus and enzyme secretion to become uncontrollable. 
As a result, the airway epithelium becomes scarred and fibrotic. These enzymes 
breakdown the delicate alveolar cell walls creating enlarged alveoli space. Elastic 
fibers in these cell walls are also destroyed resulting in a loss of elastic recoil 
narrowing the airways thus obstructing airflow. It becomes difficult to obtain enough 
oxygen into the blood and to remove excess carbon dioxide. These changes lead to a 
shortness of breath and other symptoms. 
 
Unfortunately, the symptoms of COPD cannot be eliminated with current treatment 
available and the condition inevitably worsens over time. Treatment available might 
not eliminate symptoms, but they can sometimes slow the progression of the disease. 
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Transplantation and oxygen therapy are two of the common forms of treatment. The 
problem with these therapies is that it requires the patient to be relatively healthy, so 
therefore assessable to few patients. One possible way to treat COPD would be to 
somehow induce regeneration in these lungs or to impart, self-heal. Unfortunately, 
adult lung tissue seems incapable of spontaneous repair therefore understanding how 
to activate repair mechanism would greatly improve the prospects of effective 
treatments and the prognosis for COPD patients.  
 
Previous studies including the use of experimental adult rat model of emphysema 
has suggested one way to induce lung regeneration is via the endogenous metabolite 
of vitamin A, retinoic acid (RA). In the current study, we have described a mouse 
model of disrupted alveolar development using a dose-dependent glucocorticoid 
steroid, dexamethasone administered postnatally to create serve loss of alveolar 
surface area. When RA is induced to these animals as adults the lung architecture is 
restored to normal. This remarkable effect may be because RA is involved in 
alveolar development.  
 
We also provide evidence that RA and its agonists are required for the ongoing 
maintenance of alveolar structure and function because rats deprived of dietary 
retinol lose alveoli and show pathological features of emphysema. Alveolar 
regeneration with RA and its agonists may therefore be an important part of a novel 
therapeutic approach for the treatment of respiratory diseases characterized by 
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1.1. LUNG DEVELOPMENT: The lung is composed of branched tubes that that 
conduct air to a complex gas-exchange system. The gas-exchange surface is 
composed of sacs called alveoli, which are lined by a series of blood capillaries 
(Burri 2006). The development of the lung involves complex mesenchymal-
epithelial interactions (Kumar, Lakshminrusimha et al. 2005, Tebockhorst, Lee et al. 
2007). Based on histological features, the development of the lung can be classified 
into different stages (Fig 1.1). The embryonic stage; characterised by the formation 
of the lung bud as a simple budding of the epithelium from the ventral diverticulm of 
the foregut into the surrounding mesenchyme. The resulting bud undergoes rapid 
dichotomous branching via a complex epithelium-mesenchyme interaction. This is 
the pseudoglandular stage, characterised by the formation of the conducting airway 
tree down to the terminal bronchioles (Cardoso and Williams 2001, Cardoso and Lu 
2006). Next is the canalicular stage, which shows the expansion of the airway tree 
and extensive organ growth along with differentiation of the airspace epithelium cell 
types. This stage is also marked by a vast increase in the number of capillaries in the 
primitive mesenchyme (Burri 2006). The main gas-exchange surface is formed in 
the next developing periods, the saccular and alveolar stages.  
 
Transformation of the immature saccular lung which has a limited gas-exchange 
area, to the mature lung with a much larger internal surface area, entails the thinning 
of alveolar walls; growth of a capillary network and extensive subdivision of gas-
exchange units. This period is the marked by interstitial fibroblast proliferation while 
epithelial cells flatten and decrease in numbers, resulting in a net thinning of distal 
airspace walls (Kresch, Christian et al. 1998). Concurrently, the alveolar capillary 
network becomes more complex. Alveolar septation begins as a secondary crest that 
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extends from the primary alveolar walls (Warburton and Lee 1999, Massaro and 
Massaro 2001, Burri 2006, Kim and Vu 2006). These crests or septa develop 
through deposition of new basement membranes, outgrowth of epithelial cells and 
myofibroblasts at the tips of septa and elastin deposition (McGowan and Torday 
1997). Septation is developmentally regulated, occurring primarily from postnatal 
day 4 through to day 14 in rats and mice and during the last month of gestation and 






Fig 1.1: Stages of the developing mammalian lung. The formation of the lung 
undergoes five distinct stages; each with characteristic developmental features. 




Little is known about signals for the selection of specific septation initiation sites 
over others. A number of theories have been put forward to explain the crucial steps. 
Various stimuli, including genetic factors, oxygen tension, nutrition and hormones 
have been shown to modulate distal growth of the lung (Jobe and Bancalari 2001, 
Jobe and Ikegami 2001). These stimuli exert their effects via interactions with 
specific developmentally regulated molecular pathways that have been 
evolutionarily conserved (Burri 2006).  
 
Many investigators agree that the initial deposition of elastin at specific sites in the 
walls of the developing saccules marks the onset of septa formation (Fig 1.2) (Li, 
Sorensen et al. 1999). Elastin gene expression peaks during alveolarization when 
elastin fibres localise to the tips of alveoli secondary crests, forming rings that 
surround the alveolar entrances when first expressed near the airway branching 
points during the pseudoglandular stage (Wendel, Taylor et al. 2000). With the 
alveolar walls, elastin fibres deposit into bundles. As elastic fibres are the primary 
tissue components in which mechanical stretch is stored and released in the septum, 
these fibres and elastin-expressing cells (myofibroblasts and fibroblasts) 
fundamentally determine septal mechanical properties and strain-related signal 
transduction. Mechanical stress provides signals for orientation and differentiation of 
alveolar myofibroblasts as well as directional organisation of the complex elastic 






Fig 1.2: Schematic diagram illustrating the principle of the formation 
(alveolarization). Secondary septa (3) i.e. the future interalveolar walls, emerge from 
the primary septa (1) by the folding of one of the two capillary layers (2). Elastic 
tissue (red dots), play an important role in this process. Black lines depict each 
structural stage of alveolarization.  
 
 
During the transition from the saccular to the alveolar stage, the walls of the terminal 
respiratory units become thinner by apoptosis and a single layer of capillaries 
replaces the double-capillary network (Fig 1.3) found in rudimentary alveolar walls 
(Kresch, Christian et al. 1998). For the septum to achieve its final natural 
morphology and role two pre-conditions are critical, namely the presence of a 
mature microvasculature and the thinning of the septal mesenchyme, which provides 





Fig 1.3: Schematic diagram of extensive capillary network of the alveolar 
epithelium. Formed lungs contain a large network of branching pulmonary veins and 
capillary buds, along with bronchioles and alveoli (honeycomb structure). 
 
Vascular development occurs via two processes: (1) vasculogenesis, the 
development of blood vessels from the differentiation of angioblasts in the 
mesoderm and (2) angiogenesis, which is classically described as sprouting of blood 
vessels from existing vessels, but can also occur by “intussusception” i.e. the 
formation and growth of a transcapillary tissue pillar that eventually divides an 
existing capillary segment into two parts (Burri and Moschopulos 1992, Burri and 
Djonov 2002, Djonov, Kurz et al. 2002, Parera, van Dooren et al. 2005, Makanya, 
Hlushchuk et al. 2007). The bronchial vessels develop with preacinar airways; 
development is complete by 16 weeks gestation with further growth in size to match 
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lung growth. Bronchial vessels are generally not found in the peripheral acinar 
region and thus do not normally participate in alveolar gas exchange. Pre-acinar 
pulmonary arteries, supplied by the right heart, grow simultaneously with the 
airways into the intra-acinar region and fuse with the peripheral microvasculture that 
has arisen from the mesenchyme by vasculogenesis (Hislop 2002, Hislop 2005). It is 
not yet fully understood how capillary invasion and alveolar septation interact with 
each other. The importance of vascular supply to alveolarization was demonstrated 
by studies using antiangiogenic agents, e.g. inhibitors of the vascular endothelial 
growth factor (VEGF) receptor (Tsao, Li et al. 2004, Kunig, Balasubramaniam et al. 
2005). 
 
Thinning of the mesenchymal tissue involves apoptosis. Postnatally, there is a 
substantial reduction in the number of interstitial myofibroblasts resulting from 
increased apoptosis during alveolarization (Kresch, Christian et al. 1998).  
 
 
1.2: CELLULAR COMPONENTS OF THE LUNG: The structure of the airway 
epithelium is pseudostratified in the large airways and becomes columnar and 
cuboidal in the smaller airways. There are numerous cells types in the respiratory 
system, but the main cellular types fall into the following category: ciliated, 
columnar, undifferentiated, secretory and basal cell (progenitor cells of the airway 
epithelium under certain conditions). In the large airways, cell types are ciliated, 
undifferentiated columnar, secretory and basal cells. Less common cell types in the 
large airway are cells such as cartilage, neuroendocrine cells and mucus glands. In 
the small airways, the cell types are similar to cells located in the large airways, but 
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are more ciliated and secretory cells shift to Clara cell types. The airway epithelium 
merges with alveolar epithelium type I and II (ATI and ATII).  
 
 
DIVERSE EPITHELIAL CELLS IN THE MATURE LUNG: Maturation of the 
epithelium during development starts in the proximal airways and progresses distally 
into the intrapulmonary airways (Ayers and Jeffery 1988). Epithelial cell lineages 
are arranged in a distinct proximal-distal spatial pattern in the airways and become 
morphologically apparent during the pseudoglandular stage(Ten Have-Opbroek 
1981). At least 11 different epithelial cell types have been described in the 
conducting and respiratory regions of the lung (Ayers and Jeffery 1988). The lineage 
relationship between the different cell types has not been delineated and the 
existence and identity of progenitor cells, which may play a role in lung injury and 
repair, are currently under study. There is some evidence from cell kinetic studies to 
suggest that basal cells, Clara cells and ATII cells are the primary progenitor cells 
from the pulmonary epithelium (Adamson and Bowden 1974, Evans, Cabral et al. 
1975, Evans, Cabral-Anderson et al. 1978). Lineage studies have not addressed the 
relationship of pulmonary neuroendocrine cells to the putative stem cells (ATII cells 
and Clara cells) although neuroendocrine cells differentiate morphologically before 
any other epithelial cell type (Cutz 1982).  
 
The mature mammalian lung is remarkably non-proliferative with the slow rates of 
mitosis and prolonged survival of resident cells. Nevertheless, after infection, 
resection, inflammation or toxicant exposure, the lung is capable of the rapid and 
extensive proliferation of various epithelial cell types. In the alveolar region, ATII 
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epithelial cells proliferate and differentiate rapidly into ATI cells as well as replace 
injured epithelial cells after exposure to various pathogens and toxicants (Fig 1.4). In 
conducting airways numerous cell types, including subsets of nonciliated columnar 
cells and basal cells, can proliferate. These progenitor cells or their progeny 
differentiate into other respiratory epithelial cell types, including Clara cells, goblet 
cells and ciliated cells. The respiratory epithelium is capable of rapid squamous 
metaplasia, proliferation and migration to replace the injured epithelial surface (Van 
Winkle, Johnson et al. 1999, Borthwick, Shahbazian et al. 2001, Hong, Reynolds et 




Fig 1.4: Cellular mechanism of the regeneration of ATII cells differentiating into 

















The onset of cellular differentiation is signalled by the expression of differentiated 
gene products. Lung-specific gene products include the surfactant proteins; 
surfactant proteins A, B, C and D:- SP-A, SP-B, SP-C and SP-D and Clara cell 
secretory protein (CCSP) (Singh, Singh et al. 1988, Weaver and Whitsett 1991, 
Hackett, Shimizu et al. 1992, Wert, Glasser et al. 1993). The surfactant-associated 
proteins that are expressed primarily in ATII epithelial cells although SP-A and SP-
B are also detected in subsets of nonciliated epithelial (Clara) cells of the conducting 
airways and tracheobronchial glands (Auten, Watkins et al. 1990, Phelps and Floros 
1991, Weaver and Whitsett 1991, Khoor, Gray et al. 1993, Wert, Glasser et al. 1993, 
Khoor, Stahlman et al. 1994, Kuroki and Voelker 1994). Expression of these genes 
is extinguished when ATII cells undergo terminal differentiation to ATI cells that 
constitute most of the gas exchange surface of the alveolus. For the most part, CCSP 
is a marker for the proximal Clara cells of the bronchiolar epithelium (Singh, Singh 
et al. 1988, Hackett, Shimizu et al. 1992).  
 
Early on embryonic development, undifferentiated epithelium co-express several 
lineage markers including SP-A and CCSP (Wuenschell,Sunday et al.1996).  During 
the pseudoglandular stage, pulmonary epithelial cell lineages become restricted to 
proximal and distal regions of the airways. Interestingly, after bleomycin-induced 
injury in the adult lung, there is the appearance of co-expression of these lineage-
specific markers, suggesting that a progenitor-type cell may be re-enlisted during 
epithelial repair (Daly, Baecher-Allan et al. 1998).  
 
Within a restricted time frame of development, distal lung mesenchyme can 
reprogram rat tracheal epithelium to express tracheal epithelium to express ATII cell 
31 
 
differentiation and conversely, tracheal mesenchyme can induce distal lung 
epithelium to express tracheal cytodifferentiation (Shannon 1994, Shannon, Pan et 
al. 1998). These findings underscore the importance of epithelial-mesenchymal 
interactions in coordinating the precise temporo-spatial pattern of lung development.  
 
 
TRANSCRIPTIONAL ELEMENTS: Analysis of transcriptional elements in 
surfactant protein genes and Clara cell protein has provided an understanding of the 
shared mechanisms of gene regulation and expression in respiratory epithelial cells. 
The homeodomain protein Nkx2.1 plays an essential role in several phases of lung 
development, including epithelial cell lineage determination (Guazzi, Lonigro et al. 
1994, Minoo, Hamdan et al. 1995, Minoo, Su et al. 1999). Nkx2.1 is the earliest 
marker of the developing respiratory epithelium, with an onset of expression at the 
time of lung budding formation from the foregut endoderm (Lazzaro, Price et al. 
1991). Distribution of Nkx2.1 expression in the foetal and mature lung includes 
respiratory epithelial cells of the trachea, bronchi and developing respiratory tubules 
(foetal lungs) (Lazzaro, Price et al. 1991, Ikeda, Clark et al. 1995). Expression in 
foetal lungs is most prominent in the distal alveolar cells, whereas in the mature 
lungs, the numbers in both alveolar and bronchi are almost equal.   
 
Regulatory regions of all the surfactant protein genes are controlled by Nkx2.1 
(Bohinski, Di Lauro et al. 1994, Maeda, Dave et al. 2007). Numerous experiments 
with null mutation of Nkx2.1 in mice have shown a failure to form bronchiolar and 
alveolar structures distal to the lobar bronchi and that pulmonary-specific gene 
expression including SP-B, SP-C and CCSP are turned off within transgenic lungs, 
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which do contain ciliated and mucus-secreting cells (Minoo, Su et al. 1999). Thus 
Nkx2.1 is considered by authors as a “master gene” that has the ability to induce and 
maintain cell lineages.  
 
Numerous experiments support the concept that discrete anatomic regions harbour 
progenitor cells that are relatively protected from injury (Engelhardt 2001, Kim and 
Vu 2006, Cardoso and Whitsett 2008). Progenitor cells in these regions have unique 
capacities for both self-renewal and capability of proliferation and migration to 
repair injured respiratory epithelium. For example; basal cells, cells lining the neck 
of the tracheal-bronchial glands, toxic-resistant nonciliated cells (Clara cells) 
residing near neuroepithelial bodies (NEBs) and cells within the bronchoalveolar 
duct junction have been proposed to be uniquely capable of serving as progenitor 
cells after extensive epithelial cell injury (Hong, Reynolds et al. 2004, Cardoso and 
Whitsett 2008).  
 
 
1.3: DISEASES OF THE RESPIRATORY SYSTEM: CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE (COPD) AND MANAGEMENT.  
 
RESPIRATORY DISEASES: Respiratory diseases can be classified under the 
following categories; by the way the organ of the tissue is involved, by the pattern of 
associated signs and symptoms or by the aetiology of the disease. The major types of 




1. Inflammatory lung disease: This is characterised by high neutrophil cell count 
which can be found in diseases including asthma, cystic fibrosis, emphysema, 
chronic obstructive pulmonary disorder or acute distress syndrome.  
2.  Obstructive lung diseases: Obstructive lung diseases are diseases of the lung where 
the airways (i.e. bronchi, bronchioles, alveoli) become reduced in volume or where 
free flow of gas is impeded, making it more difficult to move air in and out of the 
lung.  
3. Chronic Obstructive Pulmonary Disease (COPD): This includes emphysema as an 
example of obstructive lung disease. This is where alveoli rupture causing the air to 
be retained in the lungs and limiting the availability of space during inhalation. 
Asthma also falls into this category. 
4. Bronchopulmonary Dysplasia (BPD): BPD is a chronic lung disease, 
commonly associated with premature infants who are in need of mechanical 
ventilation and oxygen therapy, often from the result of a restricted dietary 
intake of vitamin A. It may also occur in premature infants who have had few 
signs of initial lung disease. Infants at risk of developing BPD are born below 
28 weeks gestation, at a stage where parallel processes of alveolarization of the 
distal lung saccules and development of the capillary bed are just starting to take 
form.  
5. Lung Hypoplasia: The aetiology of this disorder includes prolonged rupture of 
membranes in the lungs, foetal renal dysplasia and obstruction and foetal 
neuromuscular diseases. Lung Hypoplasia also occurs in association with congenital 
diaphragmatic hernia and congenital cystic lung lesions such as cystic adenomatoid 
malformation. High risk congenital diaphragmatic hernia survivors, who were 
mechanically ventilated, show an incidence of more than 30% in BPD (Bos, Hussain 
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et al. 1993). Pulmonary Hypoplasia or aplasia is part of the spectrum of 
malformations characterised by incomplete development of the lung (deMello 2004). 
The severity of the lesion depends on the timing of the insult in relation to the stage 
of lung development and the presence of other anatomic anomalies. The Hypoplastic 
lung consists of a carina (a malformed bronchial stump) and absent or poorly 
differentiated distal lung tissue.   
 
 
1.4: ANIMAL MODELS OF THE CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE: COPD 
 
COPD: Chronic Obstructive Pulmonary Disease (COPD) is the fifth leading cause 
of death in the UK. It is also a global respiratory problem, reaching almost epidemic 
proportions in the developing world. Molecular and cellular research into the 
mechanics of COPD and the prevention of this disease is still in its infancy and 
despite the seriousness of this disease, medically it receives very little attention 
when compared with other conditions such as heart disease and cancer.  
 
COPD is a disease characterised by airflow limitation that is not fully reversible, and 
is usually both progressive and associated with an abnormal inflammatory response 
of the lungs to noxious particles or gases. The result is an accelerated decline in lung 
function, expressed as the forced expiratory volume in one second (FEV1) and is 
ratio to the forced vital capacity (FVC) (Pauwels 2001, Brusselle, Bracke et al. 
2006). Cigarette smoke is by far the most common cause of COPD. Passive 
exposure to cigarette smoke (i.e. environmental tobacco smoke) may also contribute 
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to respiratory symptoms and COPD(Brusselle, Bracke et al. 2006). COPD does not 
only derive from tobacco smoke and environmental exposure, but genetic factors. 
Thus, the study of gene-environmental interactions is of one critical importance in 
the elucidation of the pathogenesis of this destructive disease.  It destroys alveolar 
walls by the breakdown of elastin causing irreversible enlargement of airspaces 
distal to the terminal bronchioles, usually without evidence of fibrosis.  
 
ANIMAL MODELS: Mice are generally the choice of experimental models for 
research for the following reasons: both human and mice genomes have been 
sequenced, revealing that numerous genes appear to be unique to one species or the 
other, more than 10,000 genetic markers are mapped in the mouse providing useful 
landmarks for genetic studies; the ability to alter the genetic constitution of the 
mouse, either by inserting new genes or increasing the gene expression levels by 
transgenesis or by the removal or alteration of genes through gene replacement 
techniques e.g. knockout mice. Many hundreds of inbred strains and specialised 
stocks e.g. mutants, are available and thorough knowledge of anatomy, biology and 
physiology of mice, especially with regards to the immunological system and fast 
breeding at a relatively low cost, make these animals experimentally ideal. 
 
The extensive knowledge of mouse biology and the huge genetic resources, 
including the ability to genetically manipulate mice, offers researchers the capacity 
to explore biological systems under physiological and pathological conditions 
(Hunninghake, Gadek et al. 1981, Brusselle, Bracke et al. 2006).  Animal models, 
especially rodents are the preferred tools of experimental studies as studies in 
humans are either technically impossible or morally inconceivable. The major goals 
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of using murine models of COPD enable researchers firstly, to understand the 
cellular and molecular mechanisms involved in the disease and thus to strive for 
prevention or therapeutic treatment and secondly, to develop new specific drugs for 
COPD in order to reduce the acceleration progress of lung destruction and to 
improve both clinical and functional status of COPD patients, thus ensuring 
morbidity and mortality (Brusselle, Bracke et al. 2006).    
 
For some time now in mice, the tracheal instillation of tissue-degrading enzymes has 
been used to study the development of emphysematous lung lesions as well as the 
inhalation of tobacco smoke and other noxious stimuli to induce lung tissue damage, 
although the development of emphysematous-like lesions appear to be strain-
dependent and several mouse strains with naturally occurring genetic mutations 
develop emphysema spontaneously without external stimuli, although a number of 
theses mutations lead to multi-system defects and are thus not restricted to pathology 
of lungs (Snider, Lucey et al. 1986, Shapiro 2000, Guerassimov, Hoshino et al. 
2004, Bartalesi, Cavarra et al. 2005, Brusselle, Bracke et al. 2006). Gene targeted 
mice may also show signs of airspace enlargement, but is crucial to distinguish 
airspace enlargement due to the development of abnormal lung morphogenesis from 
adult emphysema, which is characterised by the destruction of mature alveoli 
(Mahadeva and Shapiro 2002, Brusselle, Bracke et al. 2006). Here we describe in 
more detail a variety of murine models of COPD with reference to emphysema.  
 
Pulmonary emphysema: Protease/antiprotease imbalance model: An 
imbalance between proteases and their inhibitors is believed to play an essential role 
in the development of pulmonary emphysema. This imbalance may occur either by 
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an excessive release of proteases by inflammatory cells and resident lung cells, or by 
a reduced synthesis or increased breakdown of antiproteases (Brusselle, Bracke et al. 
2006). The protease/antiprotease hypothesis of emphysema was first proposed 40 
years ago, based on the observations that smokers with a deficiency of Alpha-1-
antitrypsin (α1-antitrypsin) were at increased risk for pulmonary emphysema and 
that intratracheal administration of papain, a plant protease, leads to emphysema in 
experimental animals (Gross, Pfitzer et al. 1965, Brusselle, Bracke et al. 2006).  
 
Since the initial experiments of Gross; a variety of proteases have been instilled into 
the lungs of animals. In mice, the most consistent and impressive airspace 
enlargement has been by the intratracheal instillation of porcine pancreatic elastase 
(Valentine, Rucker et al. 1983, Brusselle, Bracke et al. 2006). The development of 
emphysema after instillation of human neutrophil elastase has also been described in 
mice (Lafuma, Frisdal et al. 1991, Brusselle, Bracke et al. 2006). These rather crude 
and acute instillation models can be useful in determining the capacity of a protease 
to cause emphysema, and to study downstream events such as alveolar repair. 
However, these instillation models have some drawbacks; they cannot be used to 
explore any upstream events; they cannot give any information about which 
proteases are involved in the pathogenesis of emphysema and lastly, it is difficult to 
extrapolate the findings on the acute effects of elastase instillation to the slowly 
progressive chronic onset of the disease in humans.  
 
Transgenic mice model: Transgenic mice have artificially introduced 
alterations in their genome, resulting in expression or overexpression of the gene 
product of interest. These transgenic ‘gain-of-function’ models have added further 
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proof to the protease/antiprotease imbalance hypothesis (Brusselle, Bracke et al. 
2006).  
 
Mice that overexpressed human interstitial collagenase in their lungs spontaneously 
developed pulmonary emphysema (D'Armiento, Dalal et al. 1992, Brusselle, Bracke 
et al. 2006). Recently it has been shown that matrix metalloproteinase -1 (MMP-1) 
generated this emphysematous phenotype via the degradation of type III collagen 
(Shiomi, Okada et al. 2003, Brusselle, Bracke et al. 2006). A major disadvantage of 
this kind of model is that the gene of interest is also expressed throughout organ 
development and growth, which makes it impossible to separate developmental 
abnormalities from the structural injury in adult lungs that defines emphysema. This 
problem of constitutive expression of transgenes can be overcome by the 
construction of inducible transgenic expression models. Induced overexpression of 
interleukin 13 (IL13) or interferon-γ (IFN-γ) into the lung of mice causes a 
phenotype that mirrors human COPD (Wang, Zheng et al. 2000, Zheng, Zhu et al. 
2000). In both models, the overexpression of these inflammatory cytokines was 
associated with an increased expression of MMPs and cysteine proteases 
(cathepsins). The emphysematous changes were partly inhibited after treatment with 
MMP-inhibitors or cysteine protease inhibitors. These data further establish the role 
of proteases in lung tissue destruction, a hallmark of pulmonary emphysema 
(Brusselle, Bracke et al. 2006).  
 
Mahadeva and Shapiro reviewed data on several naturally occurring mutant mice 
that spontaneously developed emphysema due to genetic abnormalities. In some of 
these mouse strains, airspace enlargement is thought to be the result of a disturbance 
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in the balance between proteases and their inhibitors. For example, the pallid mice 
have a deficiency in α-1 antitrypsin and thus reduced elastase inhibitory capacity and 
spontaneously develop emphysema late in life (Martorana, Brand et al. 1993, 
Mahadeva and Shapiro 2002, Brusselle, Bracke et al. 2006). These histological 
changes are parallel with a decrease in lung elastin, but there is no alternation in the 
bronchial alveolar lavage cell (BAL) population (de Santi, Martorana et al. 1995). 
Chronic exposure to cigarette smoke significantly accelerated parenchymal 
destruction in pallid mice (Cavarra, Bartalesi et al. 2001, Takubo, Guerassimov et al. 
2002, Brusselle, Bracke et al. 2006). This is probably related to the diminished 
antiprotease capacity in these mice, and correlates with the enhanced risk for 
pulmonary emphysema in humans with α-1 antitrypsin deficiency. Low levels of α-1 
antitrypsin have also been demonstrated in tight skin mice. These mice develop 
emphysematous lesions at 2-4 weeks of age (Gardi, Cavarra et al. 1994, Keil, 
Lungarella et al. 1996, O'Donnell, O'Connor et al. 1999).  
 
Oxidant/antioxidant imbalance model: Cigarette smoke contains high 
concentrations of reactive oxygen species (ROS). Increased levels of ROS in the 
airways due to cigarette smoking, originate directly from oxidants in cigarette 
smoke, but also indirectly from the release of ROS by infiltrating macrophages and 
neutrophils (Pryor and Stone 1993, Rahman and MacNee 1996, MacNee 2001). This 
excess of ROS disturbs the balance between oxidants and antioxidants result in 
oxidative stress (Bowler and Crapo 2002, Brusselle, Bracke et al. 2006). Oxidative 
stress may be important in different aspects of the pathology of COPD, since it could 
amplify the inflammatory responses, induce apoptosis, impair the function of 
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protective antiproteases and reduce the activity of corticosteroids in the treatment of 
COPD (Barnes, Shapiro et al. 2003, Brusselle, Bracke et al. 2006).  
 
In other mouse models, it has been demonstrated that cigarette smoke induces 
oxidative stress (Brusselle, Bracke et al. 2006). Mice exposed to acute cigarette 
smoke showed a transient, but significant decrease in antioxidant capacity (TEAC: 
Trolox Equivalent Antioxidant Capacity) with a decrease in protein thiols and in 
ascorbic acid in BAL (Cavarra, Bartalesi et al. 2001). Cigarette smoke strongly 
affects the glutathione metabolism, which is an important feature of the antioxidant 
defence in the lung (Cantin, North et al. 1987, Teramoto, Uejima et al. 1996, 
Brusselle, Bracke et al. 2006). The crucial protective role of antioxidant system has 
been demonstrated in mice with a targeted disruption of the Nuclear factor, 
erthythroid-derived 2, like 2 (Nrf2), a redox-sensitive transcription factor that is 
involved in the regulation of many detoxification and antioxidant genes 
(Rangasamy, Cho et al. 2004, Brusselle, Bracke et al. 2006). Disruption of the Nrf2 
gene in mice led to earlier-onset and more extensive cigarette smoke-induced 
emphysema compared with wild type animals. Moreover, emphysema in Nrf2-
deficient mice exposed to cigarette smoke for 6 months was associated not only with 
an increased level of markers of oxidative stress, but also with more pronounced 
BAL inflammation and with an increased number of apoptotic alveolar septal cells 
(Rangasamy, Cho et al. 2004). This experimental emphysema model in Nrf2-
deficient mice provides a clear link between excessive oxidative stress due to an 





Pulmonary repair process/airway remodelling: Long-term exposure to 
toxic gases and particles, mostly cigarette smoke, is the primary cause of COPD. 
Host defences against these stimuli include innate immune responses (mucociliary 
clearance, epithelial repair and the acute inflammatory response) and adaptive 
immune responses (humoral and cellular components). Both types of response are 
associated with a repair process that remodels damaged tissue by restoring the 
epithelium and microvasculature and by adding connective-tissue matrix in an 
attempt to return the tissue to its previous state (Hogg 2004, Hogg, Chu et al. 2004, 
Brusselle, Bracke et al. 2006).Unfortunately, this repair process often contributes to 
the action of chronic inflammation with the complexity to pathological changes 
leading to COPD (Siafakas and Tzortzaki 2002, Brusselle, Bracke et al. 2006). 
Cigarette smoke is known to inhibit human bronchial epithelial cell repair processes, 
though normally the epithelium has a tremendous capacity to repair itself following 
injury (Knight and Holgate 2003, Brusselle, Bracke et al. 2006).  
 
Several groups have shown that the transforming growth factor-β (TGF-β), an anti-
inflammatory cytokine, is involved in airway repair (Romberger, Beckmann et al. 
1992, Hodge 2001, Brusselle, Bracke et al. 2006). In an elastase-induced murine 
model, lesions stabilise after the acute phase of tissue damage and repair (Brusselle, 
Bracke et al. 2006). Following endotracheal administration of elastase, expression of 
elastin in the lungs increased, resulting in lung elastin levels which were 30% higher 
than controls 8 weeks after challenge (Valentine, Rucker et al. 1983, Brusselle, 
Bracke et al. 2006). McGowan reported that retinoic acid receptor-γ (RARγ) 
knockout mice develop characteristics of emphysema, suggesting a role for retinoic 
acid (RA) in the generation and repair of pulmonary alveoli (McGowan 2002, 
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Brusselle, Bracke et al. 2006). Although Fujita et al reported that exogenous applied 
retinoic acid fails to reverse emphysema in adult mouse models; Ishizawa et al 
showed the opposite. In addition, they demonstrated that besides all-trans-retinoic 
acid, granulocyte colony-stimulating factor (GCSF) is able to promote lung tissue 
regeneration in this mouse model of pulmonary emphysema (Fujita, Ye et al. 2004, 
Ishizawa, Kubo et al. 2004, Brusselle, Bracke et al. 2006). Mao et al concluded that 
all-trans-retinoic acid could modulate the protease/antiprotease balance in a manner 
that may impact on emphysema pathogenesis. These results raise the possibility that 
the repair mechanism following injury may be manipulated by exogenous agents and 
might be important in the search for therapeutic agents of COPD (Mao, Tashkin et 
al. 2003, Brusselle, Bracke et al. 2006). In humans COPD is characterised by 
increased mucus production in large airways (mucous gland enlargement) as well as 
in bronchioles (goblet cell metaplasia) (Hogg 2004). In mice, submucosal glands 
were found only in the proximal regions of the trachea at the same density as in 
humans, but unlike in humans, these glands did not extend below the trachea. 
Epithelial mucous cells (i.e. goblet cells) in mice are mainly found in the proximal 
airways, but not in smaller airways such as terminal bronchioles (Evans, Williams et 
al. 2004, Brusselle, Bracke et al. 2006). Recently, goblet cell metaplasia/hyperplasia 
has been described in a murine model of COPD based on chronic cigarette smoke 
exposure. Comparing two strains of mice sensitive to oxidants, demonstrated that 
75% of the animals in the C57BI/6J group showed a positive periodic acid Schiff 
(PAS) reaction of their large or middle size bronchi at 3 to 6 months smoke 
exposure; in contrast, in the DBA/2 group there were no PAS-positive animals at 
these time points (Bartalesi, Cavarra et al. 2005, Brusselle, Bracke et al. 2006). In 
C57BI/6J mice, the goblet cell metaplasia correlated with a positive reaction in the 
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airway epithelium on Immunohistochemical staining for IL-4, IL-13 and MUC5AC. 
However, goblet cell metaplasia is a non-specific phenomenon and can be induced 
by several other stimuli including ovalbumin challenge, LPS exposure and 
intratracheal instillation of neutrophil elastase (Yanagihara, Seki et al. 2001, 
Vernooy, Dentener et al. 2002, Shahzeidi, Aujla et al. 2003, Voynow, Fischer et al. 
2004, Brusselle, Bracke et al. 2006). These in vivo models are valuable tools to 
further unravel the mechanisms involved in goblet cell metaplasia in COPD 
(Brusselle, Bracke et al. 2006).   
 
Apoptosis model: Retamales et al showed that smokers who developed severe 
emphysema had an increase in the number of macrophages, T cell lymphocytes, 
neutrophils and eosinophils in their lungs compared with people who smoked similar 
amounts of cigarettes, yet maintained normal lung function (Retamales, Elliott et al. 
2001, Brusselle, Bracke et al. 2006). This suggests that people who develop 
emphysema have an amplified inflammatory response to cigarette smoke, as 
explicitly mentioned in the definition of COPD by GOLD (Brusselle, Bracke et al. 
2006). Also in murine models of chronic cigarette smoke exposure, there is a clear 
correlation between the magnitude of the pulmonary inflammation, comprising of 
macrophages, neutrophils and T cells and the development of emphysema (d'Hulst, 
Butterworth et al. 2004, Guerassimov, Hoshino et al. 2004, Brusselle, Bracke et al. 
2006). Thus in both humans and mice, the traditional hypothesis for the pathogenesis 
of emphysema is that cigarette smoke induces an (exaggerated) influx into the lungs 
of the inflammatory cells that release ROS and proteases, causing the degradation of 
matrix with subsequent loss of attachment and death of structural cells (Brusselle, 
Bracke et al. 2006). However, at least three recent studies in mice demonstrated the 
44 
 
development of emphysema, despite a remarkable lack of inflammation (Kasahara, 
Tuder et al. 2000, Aoshiba, Yokohori et al. 2003, Petrache, Natarajan et al. 2005, 
Brusselle, Bracke et al. 2006).  
 
The first model used a single intratracheal injection of active caspase-3 was used to 
induce emphysematous changes (Aoshiba, Yokohori et al. 2003, Brusselle, Bracke et 
al. 2006). This study provides direct evidence that in the alveolar wall apoptosis 
causes pulmonary emphysema, even without the accumulation of inflammatory cells 
(Tuder, Petrache et al. 2003). In the second model, the intravascular administration 
of a vascular endothelial cell growth factor receptor -2 (VEGF-2) blocker also 
generated non-inflammatory emphysema (Kasahara, Tuder et al. 2000). Vascular 
endothelial cell growth factor (VEGF) is indeed a growth factor required for 
endothelial cell survival and blocking VEGF leads to apoptosis of endothelial cells 
(Alon, Hemo et al. 1995). Chronic VEGF-2 blockage caused alveolar septal cell 
apoptosis and airspace enlargement (Brusselle, Bracke et al. 2006). Petrache et al. 
reported that ceramide a second messenger lipid, appears to be crucial mediator of 
alveolar destruction in emphysema. Indeed, intratracheal instillation of ceramide in 
naïve mice induced emphysema, while inhibition of enzymes controlling de novo 
ceramide synthesis prevented alveolar cell apoptosis and emphysema caused by 
blockade of the VEGF receptors in both mice and rats (Petrache, Natarajan et al. 
2005, Brusselle, Bracke et al. 2006). These experimental observations in mice are in 
agreement with studies showing that smokers with emphysema have a high levels of 
apoptosis compared to smokers without emphysema (Kasahara, Tuder et al. 2000, 
Majo, Ghezzo et al. 2001, Yokohori, Ashiba et al. 2004). Also in smoke-exposed 
mouse lungs, an increase in apoptotic cells (epithelial cells and macrophages) 
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demonstrated that this was associated with enhanced expression of FasL and 
caspases, suggesting that cigarette smoke-induced apoptosis is mediated by a 
Fas/FasL death receptor apoptotic pathway (Rangasamy, Cho et al. 2004). Both 
models put forward a new concept in the pathogenesis of emphysema, whereby 
apoptosis and initial loss of epithelial or endothelial cells can trigger matrix 
destruction and alveolar space enlargement (Brusselle, Bracke et al. 2006). This 
contrasts with the traditional hypothesis of cigarette-smoke induced pulmonary 
inflammation leading to protease-mediated destruction of alveolar walls. Of course, 
both hypotheses on the pathogenesis of emphysema are not mutually exclusive and it 
is becoming progressively apparent that both excessive proteolysis (due to the 
protease/antiprotease imbalance) and apoptosis of epithelial and endothelial cells in 
the lungs interact and enforce each other’s destructive potential (Brusselle, Bracke et 
al. 2006).  
 
Elastase-induced model: Porcine pancreatic elastase (PPE) instillation was 
introduced over 40 years ago by Gross et al to develop a model of emphysema in 
hamsters (Gross, Pfitzer et al. 1965, Fehrenbach 2006). The establishment of this 
animal model had a great impact on the development of proteinase-antiproteinase 
concept of emphysema formation (Shapiro 1995, Fehrenbach 2006). Since then, this 
model has been adapted by many others. The appeal of this model is that it has 
produced the most consistent airspace enlargement in rodents, guinea pigs, dogs and 








Fig 1.5: COPD/Emphysema Elastase-induced Rat model. Alveolar airspace and cell 
walls are large and thin in appearance (Massaro and Massaro 1986).  
 
The instillation of PPE results in rapid and significant airspace enlargement followed 
by acute neutrophil and subacute macrophage accumulation within the lung 
(Heemskerk-Gerritsen, Dijkman et al. 1996, Shapiro 2000, Fehrenbach 2006). 
Airspace enlargement continues over the first month after instillation and then 
stabilizes. Elastin content initially decreases, but elastin messenger RNA (mRNA) 
expression and elastic fibre disorganisation is observed within weeks (Shapiro 
2000). However, the desired effect of elastase is frequently limited to a narrow 
window of dosage, below which no significant loss of alveoli is observed; whereas a 
higher dose may result in severe pulmonary haemorrhage and high mortality (Hayes, 
Korthy et al. 1975, Busch, Lauhala et al. 1984, Fehrenbach 2006). Work carried out 
by Massaro and Massaro with an elastase-induced rat model observed an increase in 
the mean alveolar volume by approximately 240%. This was associated with a 
Alveolar Airspace 
Alveolar Cell Wall 
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decrease in the total number of alveoli by approximately 45% after elastase 
treatment of rat lungs. Using a selector approach for quantification, total alveolar 
surface area decreased insignificantly by only 5%. Massaro and Massaro explained 
this discrepancy through the low elastic recoil of elastase-treated lungs (inferred 
from the increased fixed lung volume per body weight) which allowed an 
overexpansion of the lung (Massaro and Massaro 1997, Fehrenbach 2006). 
 
Elastase-induced emphysema remains a useful model of emphysema since it is 
relatively simple to perform and replicate many aspects of the disease. Of course, 
exposure to cigarette smoke may cause a variety of other abnormalities not observed 
in this model and indeed other models of emphysema.   
 
Glucocortocoids (Dexamethasone-induced) mouse model: The process of 
alveolar formation can be influenced by hormones such as glucocorticoids and RA. 
It has been demonstrated in postnatal rats and foetal murine lungs that 
dexamethasone can inhibit secondary septation (the microvascular maturation with 
fusion of double capillary layers into single medial layers of alveolar lumens of the 
septum and thinning of alveolar cell walls by apoptosis) in these lungs with differing 






Fig 1.6: COPD/emphysema dexamethasone-induced mouse model. As previously 
mentioned in the rat elastase-induced model, alveolar airspace and cell wall are large 
and thin in appearance.  
 
RA has been shown to induce septation long after the administration of 
dexamethasone, used to induce injury during the second stage of septation (Massaro 
and Massaro 1986, Cilley, Wesley et al. 1987, Tschanz, Damke et al. 1995, Massaro 
and Massaro 1996, Chinoy 2003). High dosage levels of dexamethasone lower the 
level of retinoic acid receptor-beta (RARβ) whereas oxygen treatment, which also 
has the capacity to inhibit septation, has the opposite effect by increasing the levels 
of RARβ (Grummer and Zachman 1995).   
 
Normally, glucocorticoids are used as critical regulators for the surfactant system in 
late foetal life and antenatal glucocorticoids are given to women at risk of preterm 
delivery, thereby decreasing the chances of respiratory distress system (RDS) in the 
Alveolar Airspace 
Alveolar Cell Wall 
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new born. Glucocorticoids are potent antiviral and anti-inflammatory agents. They 
are known to inhibit cell division as seen in lungs and are known to inhibit apoptosis 
(Morishige and Joun 1982, Jobe and Ikegami 1998). Furthermore, serum 
concentration of active glucocorticoids rises as the second phase of septation 
accelerates into the stage of alveolar thinning of the wall. This puts forward the idea 
that a rise in concentration of glucocorticoids may initiate the end of alveolar 
septation and cause acceleration of alveolar thinning of the cell wall and the 
remodelling of alveolar wall from a double capillary to a single capillary system 
(Burri 1985).  
 
Experimentally, exogenous dexamethasone (dex) prevents normal formation of 
alveoli in rats and mice (Massaro, Teich et al. 1985, Tschanz, Damke et al. 1995, 
Maden and Hind 2003, Hind and Maden 2004). In addition to blocking septation, 
dex dosing dramatically accelerates alveolar thinning of the walls and changes the 
composition of the wall (Massaro and Massaro 1986). Within 2 days of dex-
treatment, dex dosed pups have 20% thinner walls (reducing gas-exchange), 32% 
lower volume of lipid-laden fibroblasts and a 1.5 fold higher volume of ATII cells 
(Hind and Maden 2004). These experiments suggest dexamethasone treatment 
diminishes the replication of fibroblasts in alveolar walls and impairs the conversion 
of ATII cells to ATI cells, but the mechanism by which dex inhibits septation needs 
further exploration.  
 
Limitations of using Murine COPD models: In vivo murine models can offer 
valuable information on several aspects of the pathogenesis and treatment of COPD, 
in particular, emphysema. However, as for other animal species, murine models of 
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COPD have several limitations. Firstly, no model can mimic the entire COPD 
phenotype since many models can only specifically mimic one trait of this disease 
e.g. enlargement of the pulmonary alveoli due to injury to the lung parenchyma 
(pulmonary emphysema). However, the pathogenesis of progressive and fixed 
airflow limitation due to chronic airway obstruction which defines COPD has not yet 
been thoroughly addressed in murine models (Hogg 2004, Brusselle, Bracke et al. 
2006). Moreover, each murine models of emphysema has its own specific 
disadvantages. The most important disadvantages of the protease-induced 
emphysema, is the lack of significant inflammation and the absence of airway 
changes such as mucous cell metaplasia (Brusselle, Bracke et al. 2006). Although 
there is a significant inflammatory reaction in the cigarette smoke-induced 
emphysema, this murine model has also several specific limitations since there is a 
lack of standardised exposure and standardised morphometric analysis (March, 
Green et al. 2000, Brusselle, Bracke et al. 2006). Various smoking machines and 
various exposure regimens are used, but the choice of smoking regimen is often 
made arbitrarily (Rennard 2004, Brusselle, Bracke et al. 2006). In addition, 
breathing smoke generated by a machine is not the same as active smoking, but 
rather resembles passive smoking. Secondly, there are considerable differences in 
the respiratory physiology and anatomy between rodents and humans. In contrast to 
humans, rodents are obligate nose breathers and the submucosal glands in rodents 
are restricted to the trachea. During the embryonic stage of lung development, there 
are important species different from rodent and human lung morphogenesis 
including pulmonary lobation and bronchial branching (Warburton, Schwarz et al. 
2000, Brusselle, Bracke et al. 2006). Critically, pulmonary emphysema in humans is 
classified according to the distribution of airspace enlargement within the acinus: in 
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the panacinar emphysema, as seen in patients with α1-antitrypsin deficiency; 
enlargement and destruction of airspaces of the acinar unit are uniform, whereas in 
centriacinar emphysema, as seen in cigarette smokers; the airspace enlargement 
occurs primarily in three generations of respiratory bronchioles (Hogg 2004, 
Brusselle, Bracke et al. 2006). Rodents however do not have clearly defined 
respiratory bronchioles or distinct lobular architecture (March, Green et al. 2000, 
Brusselle, Bracke et al. 2006). These distinctions in anatomy have to be taken into 
account when extrapolating experimental data from murine models to human disease 
(Brusselle, Bracke et al. 2006).  
 
1.5: THE IMPORTANCE OF VITAMIN A IN LUNG DEVELOPMENT: 
Vitamin A is essential for growth and development of cells and tissues. In its active 
form, RA controls the regulation for differentiation as a ligand of the retinoic acid 
receptors, RAR/RXR and is involved in the integration of cell formation. Vitamin A 
plays a substantial role, especially in the respiratory epithelium of lungs. During 
vitamin A deficiency, the incidence for diseases of the respiratory tract is 
considerably increased and repeated respiratory infections can be influenced 
therapeutically by vitamin A supplementation. In addition to the importance of this 
vitamin for lung function, vitamin A is also responsible for the development of many 
tissues and cells as well as for embryonic lung development. Recent studies proved 
that the control occurs by different expressions of retinoid receptors as well as by 
time-dependent changes of the vitamin A metabolism respectively via cellular 
vitamin A binding proteins (CRBP: cytoplasmic retinol binding protein; CRABP: 






Fig 1.7: The metabolic pathway of vitamin A (retinol) conversion into the various 
forms retinoic acid (RA) and its three classes of enzymes (a). The cellular 
mechanism of retinoid; (b). Retinol is taken up from the blood and bound to CRBP 
(cellular retinol-binding protein) in the cytoplasm. The retinol dehydrogenase 
(RoDH0 enzyme metabolise retinol to retinal, then is metabolised to RA by the 
retinaldehyde dehydrogenases (RALDHs). RA is bound in the cytoplasm by CRABP 
(cellular RA-binding protein). RA enters the nucleus and binds to the RA receptors 
(RARs) and the retinoid x receptors (RXRs), which themselves heterodimize and 
bind to a sequence of DNA known as the RARE (RA-response element). This 




Previous studies using vitamin A deficient animal models have shown that 
disruption of retinoic acid (the active form of vitamin A) signalling may lead to lung 
agenesis (Cardoso and Whitsett 2008). This raises the possibility that in the absence 
of retinoic acid (RA) signalling, lung progenitor cells may not be specified or fail to 
expand.  
 
Retinoic acid and its receptor agonists as therapeutic agents (Regenerative 
therapies): Currently, COPD which is a progressive disease is only managed 
symptomatically. So far, the most successful treatment available for COPD is lung 
transplantation. However, finding suitable donor material is very limited and 
therefore only available to a limited number of patients. One possible way to treat 
such disease would be to induce diseased lung tissue to “self heal” or “regenerate”. 
Unfortunately, a significant barrier to such regenerative therapies is that damaged 
adult lung alveolar tissue seems incapable of spontaneous repair. Therefore, 
understanding how to activate repair mechanisms would greatly improve the 
prospect of effective treatment and prognosis for patients.    
 
RA has been demonstrated to promote alveolarization in both rat and mouse models, 
but other reports in both species show failure of RA to promote alveolarization 
(Massaro and Massaro 1997, March, Green et al. 2000). Oral therapy with All-trans-
retinoic acid (tRA) in COPD has been reported and there has been evidence 
suggesting some respiratory improvement, therefore it has been considered as a 




Another potential therapeutic agent for COPD is the granulocyte macrophage-colony 
stimulating factor (GM-CSF). GMCSF is a major regulator of both macrophage and 
neutrophil activation and survival in the lung; these cells are intimately linked to 
COPD (Fig 1.8). Experimental data using animal models indicate that neutralisation 
of GMCSF ameliorates experimental COPD and predicts therapeutic utility in 
treating stable COPD and treating exacerbations. As such, GMCSF represents an 

































2.1: MATERIALS  
ANIMAL HUSBANDRY AND TISSUE PREPARATION  
All experiments were conducted in accordance with local ethics committee 
guidelines (Kings College London) under the requisition personal (piL 70/15855) 
and project licence (PPL70/4452) obtained from the Home Office.  
 
2.1.1: WISTAR RAT BRED FOR VITAMIN A DEFICIENCY STUDIES. In 
order to test the importance and role of vitamin A for the development, structure and 
function of the respiratory system, a vitamin A deficient rat postnatal model (Wistar 
Bred from 3 months) was generated by replacing a normal laboratory chow diet with 
a commercially available diet that was lacking vitamin A (retinoids) with a SDS 
nutritional one. All animals were given access to water and a 12-hour cycle of light 
and darkness. The animals were sustained on this diet for a period of 6 months to 1 
year. Within this time frame, body weight and general health were monitored. After 
sacrifice, samples of blood serum and liver were taken for high performance liquid 
chromatography (HPLC) to confirm a reduction of retinoids in the animal’s system.  
 
2.1.2: SWISS TO MOUSE BRED FOR REGENERATIVE STUDIES. Outbred 
Swiss (TO) mice (Harlan, UK) were used to generate structural emphysematous by 
the use of the glucocorticoid, dexamethasone. All animals were given access to 
water and laboratory chow ad libitum and a 12-hour cycle of light and darkness. For 
consistency, the day of birth was deemed as postnatal day 1 (P1). In dexamethasone 
experiments, litters were reduced at birth to no more than 21 pups in an attempt to 
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reduce variation in developmental stages. For retinoic acid and its receptor agonists 
dosing experiments, postnatal age-matched female mice were used.  
 
2.1.3: TISSUE PREPARATION. Animals were culled by neck dislocation, the 
diaphragm was punctured and the thorax opened by removal of the ventral thoracic 
wall. The heart and the trachea were cut at the level of larynx. The trachea and the 
lungs were carefully removed, ensuring that no lacerations to the surface of the 
lungs. For histology, lungs were carefully dissected to maintain morphology. The 
trachea was cannulated and tied firmly in place, infused with fresh 4% formalin at a 
standard inflation pressure of 20cm H20 for at least 10 minutes. The cannula was 
then removed and the trachea ligated. The lungs were stored in 4% formalin until 












TABLE 2.1.1: PROCESSING PROCEDURES FOR PARAFFIN WAX 
EMBEDDED TISSUE.  
SOLUTIONS  PERCENTAGE (%) TIME (hrs) 
Industrial methylated spirit: (IMS) 30% 2hrs  
Industrial methylated spirit: (IMS) 70% 2hrs  
Industrial methylated spirit: (IMS) 90% 2hrs  
Industrial methylated spirit: (IMS) 100% (Absolute) 2hrs  
Industrial methylated spirit: (IMS) 100% (Absolute) 2hrs  
Industrial methylated spirit: (IMS) 100% (Absolute) 2hrs  
IMS/Xylene  50-50 2hrs  
Xylene 100% (Absolute) 2hrs  
Xylene 
 
100% (Absolute) 2hrs  
Xylene 100% (Absolute) 2hrs 










2.1.4: GENERAL SOLUTIONS. The following standard buffer blocks and 
reagents made for the techniques described below are referred to in the text by the 




10X PHOSPHATE BUFFERED SALINE (PBS: Sigma, Poole. UK) 
80g Sodium Chloride: VWR International, UK 
14.4g Sodium Phosphate: Sigma-Aldrich, Poole. UK 
20g Potassium Chloride: VWR International, UK 
2.4g Potassium Phosphate: Sigma-Aldrich, Poole. UK 
Ingredients were mixed in 1 litre of UHQ water to pH7.4 
 
ABSOLUTE XYLENE (2.5L): VWR International, UK 
INDUSTRIAL METHYLATED SPIRIT 2.5L IMS) VWR International, UK 
 
4% FORMALIN TISSUE FIXATIVE: 500ML 
50ml Formaldehyde (W/V). VWR International, UK 
50ml PBS (from 10% Stock solution: W/V) 
Ingredients were mixed with 400ml of UHQ water   
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HAEMATOXYLIN AND EOSIN (H&E) FOR GENERAL MORPHOLOGY  
500ml MAYER’S HAEMATOXYLIN: Ready-to-use. VWR International, UK 
1% EOSIN (Eosin yellowish. Ready-to-use). Raymond A Lamb, UK 
 
ALCIAN BLUE PERIODIC ACID SCHIFF’S REAGENTS (ABPAS) FOR 
ACIDIC AND NEUTRAL GLYCOPROTEINS 
12.5g Alcian Blue in 500m UHQ water (2.5%) VWR International, UK 
5g Periodic Acid in 500ml UHQ water (1%) Sigma-Aldrich. UK 
Schiff’s Reagent (Ready-to-use) VWR International, UK 
 
5M TRIS BUFFERED SALINE STOCK SOLUTION (TBS): pH7.54 
30.20g Tris VWR International, UK 
42.86g NaCl VWR International, UK 
Ingredients mixed with 500ml of UHQ 
 
2% BOVINE SERUM ALBUMIN BLOCK (BSA): 200ml  
4g BSA (12% W/V). Sigma-Aldrich. Poole, UK 
20ml TBS 10X stock solution 
2ml 10% Azide Sigma-Aldrich. Poole, UK 
Ingredients were mixed with 180ml UHQ water    
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1% TBS/TWEEN WASH (TBS-T): 500ml 
50ml 10X TBS 
5ml Tween 20 Sigma-Aldrich, Poole. UK 
Ingredients were mixed with 450ml of UHQ water 
 
ANTIGEN RETRIEVAL BUFFER SOLUTION 
CITRATE ACID pH6.0  
8ml 1M Citrate Acid BDH/MERCK, UK 
Mixed with 792ml UHQ water 
 
SDS GEL AND WESTERN BLOT SOULTIONS  
SDS-PAGE SOLUTIONS  
500ml NuPAGE MES SDS RUNNING BUFFER (20X) Invitrogen Life 
Technologies. UK 
25ml SDS-Mes Running Buffer 
475 UHQ water 
 
500ml NuPAGE TRANSFER BUFFER (20X) Invitrogen Life Technologies. UK 
25ml Transfer Buffer 
50ml-100ml Methanol VWR International 
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Ingredients were mixed with 425 or 375ml UHQ water  
 
WESTERN BLOT MATERIALS AND SOLUTIONS 
Filter paper VWR International, UK  
Nitrocellulose paper GE Healthcare, UK 
 
PREPARATION OF WESTERN BLOT 
Soak sponges in transfer buffer until saturated, remove any air bubbles. Removing 
air bubbles is essential as they block the transfer of proteins if they are not removed. 
Cut transfer membrane and filter paper to the dimensions of the gel. Place 
nitrocellulose in a weigh boat containing premade transfer buffer solution. Assemble 
the western blot “sandwich” as follows in XCell blot module and is summarised in a 
simple diagram (Fig 2.1.1):  
• 2-3 soaked sponges  
• 1-2 wetted filter papers  
• 4-12% gel containing varying MW protein samples (make sure no air bubbles 
are present) 
• Soaked nitrocellulose membrane (again make sure no air bubbles are present) 
• 1-2 wetted filter papers  





Fig 2.1.1: Western Blot is the transfer of proteins on a gel to nitrocellulose 
membrane in order to perform immunoblotting to detect the desired protein on the 
membrane. (Abcam, Cambridge. UK) 
 
BLOCKING SOLUTION FOR NITROCELLULOSE MEMBRANE.  
2% Powdered milk or BSA 
Add to TBST buffer (milk) mix well and filter (prevents spotting where tiny dark 









2.2: METHODS: EXPERIMENTAL PROCEDURES. 
2.2.1: DEXAMETHASONE AND RETINOIC ACID DOSING  
Dexamethasone (Sigma, Poole. UK) was dissolved in PBS and given as a 10µl 
subcutaneous injections at a concentration of 40µg/ml. This was administered for 10 
days (from P4 to P13) control mice received PBS. On day 46, various retinoid 
ligands were administered for 10 days with a 2 day break on P40 and P41. The 
retinoids were dissolved at a concentration of 2mg/ml in dimethylsulphoxide/peanut 
oil (1:1) and a dose of 2mg/ml was administered by intraperitoneal injection. A 10-
fold higher dose of all-trans-retinol was administered because this precursor of tRA 
is known to be less effective. Control mice received DMSO/peanut oil only. tRA 
was obtained from Sigma; the retinoic acid receptor agonist ligands (RARs) were 
obtained from CIRD Galderman (Sophia Antipolis, France): and the retinoid X 
receptor agonist ligand (RXR) was obtained from Hoffman-La Roche’s (Basel, 
Switzerland). Animals were kept for 4 weeks after the end of the retinol dosing until 





Fig 2.2.1: Experimental design for dexamethasone postnatal mouse model to induce 






Fig 2.2.2: Experimental design for retinoid-selective ligand agonists employed to 











CONTROL DEX RA 
PBS DEX (0.4mg/kg) 
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2.2.2: MORPHOLOGY AND MORPHOMETRICS  
MORPHOLOGY: Animals were weighed and their lungs were carefully removed 
and intubated with a 22 gauge cannula. Lungs were inflated to a standard pressure of 
20cm and H2O with 4% formalin for 48hrs. Lungs were washed in water and placed 
in 70% IMS (alcohol); their volumes were measured by fluid displacement. Lungs 
were then processed in ascending alcohols, embedded in paraffin wax and sectioned 
at 5µm thick. These sections were stained with H&E for morphology analysis.  
 
MORPHOMETRICS: Sections were analysed on light microscope linked to a 
digital imaging system. Images obtained were acquired at 10x objective and 
processed using ImageProPlus analysis software (Data Cell Ltd; Finchampstead. 
UK). Areas of alveolar tissue were selected and calculated (Fig 2.2.3). Five non-
overlapping fields were measured from each section of animal group. Gas exchange 
surface area was calculated from values in Lm. All data was expressed as mean ± 
standard error (SEM). Groups were statistically compared by Analysis of variance 










Fig 2.2.3: Representative diagram of the mean linear intercept (Chord) length (Lm) 
based on the intercept distribution. Test line segments are localised at the left, 
followed by a dashed line towards the right. Each time the test line intersects the 
alveolar wall, the distance (chord length) to the next wall is measured. Boundaries of 
measurements within alveolar airspace (A) or alveolar and ductal airspace together 
(D) are marked by arrows. * Blood vessel. Scale bar = 50µm (Knudsen, Weibel et al. 
2010).  
 
2.2.3: IMMUNOHISTOCHEMICAL AND IMMUNOFLUORESCENT 
STAINING FOR PARAFFIN WAX TISSUE SECTIONS  
4% formalin-fixed 5µm paraffin sections were cut and mounted onto superfrost plus 
microscopic slides and incubated overnight in a 60° oven before proceeding to stain 
the next day. The sections were treated as follows: sections were dehydrated in two 
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pots of absolute xylene then dehydrated in four pots of industrial methylated spirit 
(IMS) for approximately 3 minutes. Sections were rehydrated in distilled water and 
treated with hydrogen peroxide (H2O2) to quench endogenous peroxidase, for 10 
minutes. Preheated citric acid buffer solution (pH 6.0) was used as an antigen 
retriever to unmask formalin meshwork covering antigens of interest. Sections were 
allowed to cool down in cold tap water and incubated with 2% bovine serum 
albumin (BSA) to block endogenous biotin and incubated with a primary antibody of 
interest at room temperature, overnight. 5 minute washes with 1% tris buffer 
saline/tween (TBS-T) were applied before incubating sections with secondary 
biotinylated antibodies for 30 minutes (Dako UK). Sections were incubated with 
streptavidin biotin complex horseradish peroxidase (StreptABC-HRP. Vector 
Laboratories. UK), for a further 30 minutes. Immunoreactivity was visualised using 
a peroxidase substrate; 3.3-diaminobenzidine (DAB. Sigma Aldrich, Poole UK). 
After 10 minutes of DAB incubation, sections were counterstained with Mayer’s 
haematoxylin (nuclear Counterstain) for 30 seconds. Antibodies and dilution factors 










Table 2.2.1: Antibodies and dilution factors for IHC and Immunoblots 
Primary 
Antibody 




SP-C 1:100 1:1000 Rabbit  1:200 – 1:2000 
CC10 1:2000 1:20,000 Goat 1:200 – 1:2000 
PCNA 1:100 1:1000 Mouse  1:200 – 1:2000 
TTF-1 1:50 1:5000 Mouse  1:200 – 1:2000 
MUC2 1:100 1:1000 Mouse 1:200 – 1:2000 
MUC5AC 1:2000 1:1000 Rabbit 1:200 – 1:2000 
MUC5B 1:100 1:1000 Mouse  1:200 – 1:2000 
MUC7 1:750 1:1000 Mouse  1:200 – 1:2000 
 
Immunostained cells were counted in the alveolar epithelia or bronchiole epithelia in 




2.2.4: SDS-PAGE ELECTROPHORESIS FOR MUCIN PROFILE 
SDS –PAGE electrophoresis was performed on all samples obtained from the 
control and treated animals. Equal volumes (15μl) of heat-denatured whole lung 
protein samples were applied to each lane and electrophoresed on precast 4-12% 
Bis-Tris gels, according to the manufacturers protocol, in MES-SDS running buffer 
(Fig 2.2.4). Proteins in gels were stained with 0.2% Coomassie Brilliant Blue R20 in 
25% methanol, 10% acetic acid and water for 30 minutes and then de-stained in 10% 
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acetic acid, until the gel background was clear. Glycoproteins in the gels were 
stained with periodic acid Schiff (PAS). Gels were fixed in 25% methanol and 10% 
glacial acetic acid for 1 h, after which the gel was washed in distilled water for 20 
minute. The gel was then oxidized in 2% periodic acid for 15 minutes and then 
rinsed in distilled water. Schiff’s reagent was added neat and incubated in the dark 
with gentle agitation for 30-60 minutes or until pink stained bands appeared. The 
Schiff’s reagent was discarded and the gel was rinsed in distilled water to increase 




Fig 2.2.4: Sequence of SDS-PAGE electrophoresis. Samples were loaded onto 4-
12% Bis-Tris gel and run in SDS-MES running buffer for approximately 32 minutes.  
Abcam, Cambridge. UK  
 
SDS gels were photographed using a digital camera (Kodak DC290 Zoom Digital 
Camera; Anachem, Bedfordshire, UK) using the software Kodak Electrophoresis 
Documentation and Analysis System 290 (Anachem). Gels were scanned using the 
software, ImageJ (downloaded from National Institute of Health, 
http://rsb.info.nih.gov/ij). Lanes of PAS stained mucin glycoprotein bands were 
scanned and a lane profile plot was generated with peaks representing each mucin 
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band according to intensity. The area under each peak was measured and used to 
express the amount of mucin in PAS-stained mucin bands.  
 
 
2.2.5: WESTERN BLOTTING. Immunoblotting onto nitrocellulose membranes 
was carried out according to a standard protocol. Membranes were blocked in a 
solution of TBST milk or with 2% BSA for 1 hr at room temperature according to 
the manufacturer’s instructions. Membranes were then probed with a range of 
antibodies, diluted in 2% TBST milk or 2% BSA, for 1 hr at room temperature or 
overnight at 4°C, as recommended (Fig 2.2.5). Mouse monoclonal, Goat and Rabbit 
polyclonal antibodies were used to detect mucin glycoproteins MUC1, MUC2, 
MUC4, MUC5AC, MUC5B and MUC7 (Santa Cruz Biotechnology CA, USA. 
Development Hybrid Study Bank [DHSB], University of Iowa, USA. Labvision, 
Thermo Scientific. MI, USA. Sigma-Aldrich, Poole. UK and Ana-Spec! CA, USA). 
Rabbit and goat polyclonal antibodies, Surfactant protein-C (SP-C) and Clara cell 10 
(CC10) (Santa Cruz Biotechnology CA, USA) were used to detect airway progenitor 
cells. A mouse monoclonal proliferating cell nuclear antigen (PCNA) antibody was 
used to detect cell proliferation (DAKO Corporation, Denmark) and a mouse 
monoclonal thyroid transcription factor-1 (TTF-1) antibody (Labvision, Thermo 
Scientific. MI, USA) was used to detect Nkx2.1 regenerative cells in the alveolar 













2.2.6: IMAGEJ AND IMAGELAB ANALYSIS. Intensity of protein bands on 
SDS gels were scanned using the software ImageJ (downloaded from National 
Institute of Health, http://rsb.info.nhs.gov/ij). Lanes of PAS stained mucin 
glycoprotein bands were scanned and a lane profile plot was generated with peaks 
representing each mucin band according to intensity. The area under each peak was 
measured and used to express the amount of mucin in PAS-stained mucin bands. 
Immunoblots were analysed using the software ImageLab for the gel doc; Chemi-
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Doc (BioRad. Laboratories. UK). Images of bands of various samples were captured 
for quantitative analysis. Lanes of immunostained bands from each sample was 
measured according to intensity and density of the band to express the amount of 




























MORPHOLOGY AND MORPHOMETRIC 








OBJECTIVE: In this study, we examined morphological and morphometric 
changes caused by a dietary deficiency of vitamin A in postnatal rats for up to one 
year. We first examined animals fed on this diet for 6 months and found the 
beginnings of morphology and morphometric changes. Using a histological staining 
technique designed to illustrate morphological changes and calculating surface area 
of alveoli; the mean chord intercept (Lm) parameter we were able to determine 
changes in 6 months VAD lungs compared with 6 months controlled lungs. Alveolar 
showed signs of airway expansion (surface area) with an increase in vascularisation 
in these animals. Further experimental analysis with animals fed for up to 1 year 
showed significant changes in morphology and morphometric analysis. Lungs of 
these animals showed emphysematous-like structures, a significant increase in 
surface area (Sa). Vascularisation had also increased and cell wall thickness of 
alveoli had dramatically decreased. This data provided evidence that a chronic 
reduction of dietary vitamin A severely affects structural development and the 
functional role of the lung.  
  
3.1.1: INTRODUCTION: Postnatal lung development is characterised by stage of 
alveolarization and microvascular maturation (Frey, Egli et al. 2004). At birth, large 
gas exchanging saccules are still present and are linked by thick walls with a double 
capillary network. Postnatally, these saccules subdivide by secondary septa via the 
process of alveolarization. Numerous studies examining vitamin A have recognised 
its importance in influencing the development and growth of the respiratory system, 




VITAMIN A IN RESPIRATORY DISEASE:  Deficiency of vitamin A is known 
to have multiple effects on the epithelium of the respiratory system. In particular, the 
morphology of the trachea shows striking stratified squamous keratinised 
metaplasia; a characteristic seen in COPD patients, replacing normal mucus-
secreting epithelia of the bronchi tree and also displays a destructive manner of 
alveolar structure. This effect was most noted in weaning rats fed on a diet devoid of 
vitamin A. This structural effect has profound results on premature human newborns 
that develop the respiratory condition known as bronchopulmonary dysplasia (BPD) 
(Zachman. 1989, Chytil. 1992, Shenai and Chytil. 1996, Chailley-Heu, Chelly et al. 
1999). Many of the pathological features of BPD including atelectasis (the collapse 
of lungs), loss of ciliated cells, keratinising metaplasia and necrotising bronchiolitis, 
are similar to those pathological features found in patients with VAD (Chytil. 1992, 
Shenai and Chytil. 1994, Grummer and Zachman. 1995, Zachman and Grummer. 
1998). In animal models, complete absence of vitamin A results in preterm 
spontaneous abortions, which in turn makes it impossible to study the full course of 
foetal development, however, animals that do survive are only under partial 
deficiency (Frey, Egli et al. 2004).  
 
3.1.2: AIM. In this study, examined the morphological and morphometric effects of 
a diet deficient of Vitamin A in postnatal rat lungs from 6months up to 1 year. 
Vitamin A is essential is involved in the role of growth, development and structure 
of the lung. Chronic deficiency of this vitamin at a critical stage of postnatal growth 
in lung development results in gross abnormalities creating emphysematous-like 
features. We first looked at lungs of animals fed on this diet for 6 months. Data 
showed that there were some initial changes in the development of these lungs, with 
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the beginnings of an increase in alveolar airspace, vascularisation and alveolar septal 
damage. However, after examining rat lungs for a further 6 months (i.e. 1 year), we 
showed a longer period of this diet increased morphological features seen in 6 
months lungs, but more pronounced, identifying that vitamin A is very much an 
important aspect of structure and functioning of the lung postnatally.  
 
3.1.3: RESULTS: MORPHOLOGICAL AND MORPHOMETRIC ANALYSIS 
MORPHOLOGY: Control rats were treated with PBS and peanut oil/DMSO 
(Dimethyl Sulfoxide). They displayed lung morphology and airspace (Lm) 
measurements to be distinguishable from normal, untreated lungs; confirming that 
this animal group had no structural effect and could therefore be used as controls.  
 
Representative histological images of control and VAD animal groups of 6 months 
are shown in figure 3.1.1 (Fig 3.1.1a and b, scale bar: 100µm). VAD lung groups 
displayed subtle morphological changes when compared with 6 months control 
lungs. VAD lungs showed the beginnings of alveolar expansion accompanied by 
structural changes. This group also showed an increase in vascularisation. 
Capillaries were amplified within alveoli cell wall thinning (Fig 3.1.1b). Animals fed 
on a VAD diet for up to 1 year showed an increase in morphological changes (Fig 
3.1.3d). The enlargement in 1 year VAD lungs had markedly increased from airway 
space in 6 months VAD lungs with extensive thinning of alveoli cell walls. There 
was also septal shrinkage; were more ‘pointed’ in this group (Fig 3.1.1d). Overall 
appearance of 1 year VAD rat lungs showed a resemblance to emphysematous lung 
structure. This appearance was mostly diffused throughout the lung. The 
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morphology of its counterpart showed typical alveolar airspace structure seen in 
normal healthy lungs.   
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6 months Control Rat 6 months VAD Rat 
1 year Control Rat 1 year VAD Rat 
a. Lung Morphology b. 
c.  d.  
50µm  
100µm  
Fig 3.1.1 Lung Morphology. 
Figure shows representative 
transverse lung sections of 6 
months and 1 year VAD animals 
(H&E staining a-d). Sections 
show typical structure of alveoli 
and vascularisation seen in 
postnatal rats of 6 months and 1 
year on a diet deficient of 
vitamin A compared with control 
rats. There is a gradual increase 
in alveolar airway space and 
vascularisation between 6 
months and 1 year VAD rat lung. 
Scale bar a-b: 100µm, c-d: 50µm 
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MORPHOMETRICS ANALYSIS (MEAN AIRSPACE CHORD LENGTH: 
Lm): Morphological changes observed from H&E stained sections were used for the 
quantification of airspace using the mean chord airspace chord length (Lm) 
measurement. Calculated Lm measurements were expressed in micrometres (µm). 
Data obtained from 6 months and 1 year VAD animals indicated a gradual increase 
in alveolar airspace. The mean value of airspace in 6 months VAD lungs was 102 ± 
2.4µm this value increased to 135 ± 5.0µm in 1 year VAD lungs (Fig 3.1.2 and Fig 
3.1.3, Table 3.1.1). The significance between these lung groups was <0.05 
(p=0.007). These calculations along with morphology examination confirmed that 
dietary VAD had a defective affect in structural and hence functional lung activity. 
Lm calculations for 6 months and 1 year control lungs gave values of 84.3 ± 7.2µm 
and 92.8 ± 4.1µm, respectively (Table 3.1.1). These lower measurements taken from 
control groups not only indicated normal alveoli structure, but also suggested normal 
lung function and maintenance. The results suggest the alveolar area changing is due 






d.  c.  
b.  a. Airway Morphometrics 





6 months VAD Rat 
100µm  
1 year Control Rat 
50µm  
1 year VAD Rat 
Fig 3.1.2: Morphometrics: 
Mean Alveolar Chord Length 
(Lm). Figure 3.1.4 shows 
representative H&E sections 
demonstrating airway 
measurements taken from 6 
months and 1 year postnatal 
rat lungs. Fig b and d show 
chronic effect of VAD diet on 
alveoli airspace. The black 
lines indicate what 
parameters are measured. 
Scale bar: A and B= 100µm, 














  ** 
Fig 3.1.3: Mean (SEM ±) Chord Alveolar Airspace (Lm). Graph shows confirmation of the increase of alveolar 
airway space in VAD lungs from 6 months to 1 year. N = 5 per group. ** P<0.01 (Student unpaired t-test) 
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Table 3.1.1: Morphometric parameters of the dietary effect of VAD on Alveolar airway space in 6 months and 1 year Rat lungs   
              
  6 month Control  
 
 
6 month VAD 1 year Control 1 year VAD  
Total Lm² (µm) 
 
421.45 510 493.75 675 
Sa 100g (cm³)/10g 
 
43.1 31.1 22.0 31.1 
 
 
    
Mean 
 
84.3 102 92.8 135 
SD 
 
1.9 5.3 5.3 4.8 
SEM 
 
5.4 ± 7.4 11.6 ± 7.0 5.55 ± 0.7 14.6 ± 5.6 
  




THICKNESS OF CELL WALL: Alveolar cell wall of 6 months VAD lungs 
appeared thick compared to cell walls of 1 year VAD lungs (Fig 3.1.4b and d). 1 
year VAD cells wall thickness showed resemblance to cell wall thickness clinically 
seen in emphysematous lungs. This observation could suggest that in order for 
dietary VAD to have an effect on alveolar cell wall, the diet needs to be for a period 
longer than 6 months.    
 
 
Fig 3.1.4: Alveolar Cell Wall Thickness. Representative pictures of alveolar cell 
wall thickness in 6 months and 1 year VAD rat lungs. There is a distinct difference 




ALVEOLAR SEPTA: Observations of alveolar septa gave interesting findings. In 
1 year VAD lungs, septa seemed thin with pointed ends. Some appeared with what 
looked like ‘chopped’ ends compared with three remaining groups. The septa in 
these lungs appeared thicker with rounded ends (Fig 3.1.5a-d). Septa in 1 year VAD 
lungs appeared much further away from neighbouring septa than those seen in the 
other groups. The increase in pulmonary vascular pressure may have been 
augmented by the destruction of the pulmonary capillary bed due to the destruction 








Fig 3.1.5: Representation of alveolar septa (AS). 6 months control (a), 6 months 
VAD (b) and 1 year control (c) lungs displayed thick rounded septa. 1 year VAD 
lungs (d) displayed thin and in some areas, pointed septa.     
 
3.1.4: DISCUSSION: Starvation has long been known to induce histological 
appearances of emphysematous lungs and was noted by physicians performing post 
mortem examinations in Warsaw ghettos (Winick 1979). This phenomenon has also 
been studied in animal models of emphysema (Harkema, Mauderly et al. 1984, Kerr, 
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Riley et al. 1985, Karlinsky, Goldstein et al. 1986). Molecular mechanism(s) behind 
starvation-induced emphysema suggest that it is calorie-related and that alveolar 
destruction and regeneration occurring within a rapid timescale appear to be vitamin 
A (retinoid) – independent (Massaro, Radaeva et al. 2002). In previous studies, 
severe VAD during gestation results in multiple malformations in the foetus with 
foetal growth retardation or death (Frey, Egli et al. 2004) . In these studies, liver 
stores of vitamin A were completely drained by placing rats for 2 or 3 months 
(before mating) on a diet containing enough carotene for growth, but not for the 
storage of vitamin A (7-8 weeks are requires to deplete vitamin A from the liver) 
(Duncan, Green et al. 1993, Frey, Egli et al. 2004). These animals were transferred 
onto a diet completely free of carotene and vitamin A which was maintained 
throughout the pregnancy (Frey, Egli et al. 2004). Circulating vitamin in the mother 
and in the foetus became undetectable within a few days and resulted in severe 
developmental defects  (Frey, Egli et al. 2004). By contrast, the aim of our 
experiment was to achieve VAD diet in postnatal rats and determine whether 
deformities, characteristic of emphysematous lungs were accomplished.  
 
To examine the structural effect VAD diet had on postnatal rat lungs, we developed 
a cohort of VAD rats over a 1 year period. As previously described (Chapter 2.1), 
these rats were maintained on a retinoid (vitamin A) free diet from 12 weeks of age 





MORPHOLOGICAL AND MORPHOMETRICAL CHANGES: Light 
microscopy examination showed visible morphological changes in animals on 
deficient vitamin A from 6 months to 1 year. There were some obvious differences 
between the two groups, for example, the expansion of alveolar airway space. There 
was an exponential increase in Lm measurements from 6 months to 1 year animals, 
with an increase in vascularisation. Structural changes observed in 1 year VAD rat 
lungs resembled were characteristic of that seen in emphysematous lungs of patients 
with the disease confirming vitamin A importance in lung growth, structure and 
function. The increase in surface area is likely due to an increase in the complexity 
of vascularisation in VAD lungs and may be due to septal destruction in response to 
injury. There were clear differences between 1 year VAD and 1 year control lungs. 
VAD lungs appeared to have fewer, larger airspaces; alveolar cell walls were thinner 
with alveolar breaks and their septae were largely pointed and further away from 
neighbouring septae. There was a greater increase in vascularisation in these lungs 
than witnessed in 6 month lungs, suggesting greater activity of the repair mechanism 
taking place due to chronic tissue damage (Fig 3.1.3c and 3.1.4c and d). This effect 
was observed throughout these lungs. As no functional tests were carried out on 
these animals, we could only speculate that morphological features observed in 1 
year VAD animals were not ideal conditions for respiration and that this structural 
abnormality may easily form chronic lung diseases such as emphysema and BPD. 
To help assess this assumption, we quantified the affected airspace size of each 
animal group (6 month control with VAD and 1 year control with 1 year VAD), by 
the use of morphometric analysis. Morphometric analysis confirmed morphological 
observations between 6 months and 1 year VAD rat lungs. Average mean chord 
length measurements showed a definitive increase in alveolar airspace from 6 
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months (102 ± 2.4µm) to 1 year (135 ± 5.0) lungs. The control counterparts for each 
diet gave averages of 84.3 ± 7.2µm and 92.8 ±4.1µm. When calculating the average 
differences between control and VAD lungs, the data showed twice the expansion 
rate of Lm from 6 months VAD (9.4%) to 1 year (18.6%) VAD lungs. This increase 
in Lm was significant and demonstrated that prolonged deficiency of vitamin A 
cause detrimental damage to lung structure.  
 
Overall changes examined from morphology in VAD animals were increase in Lm, 
lug volume and surface area. These findings may reflect on a physiological 
compensation to preserve surface area that is similar to lung volume changes which 
occur in patients with emphysema. It is difficult to conclude whether VAD restricted 
diet is related to emphysema, especially as these rats used in this experiment had a 
nutritionally complete diet apart from the lack of retinoids, but experiments of 
similar design indicate that this may be the case in this model. For example, in an 
early VAD study by Sahebjami H and Vassallo CL (1979), a significant increase in 
Lm values was reported. Subsequent studies by Harkema JR et al (1984), Karlinsky 
JB et al (1986) and Sahebjami H and MaeGee J (1985) gave similar results and 
supports our 1 year VAD rat model.   
 
Although the role that vitamin A plays in the development and pathogenesis of 
COPD/emphysema is not well understood, data from animal experiments seen in 
models such as elastase-induced emphysema, suggest that vitamin A 
supplementation may help prevent adverse respiratory outcomes caused by 
emphysema. Data provided from our model and other models based on VAD diet 
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and caloric deficient diets, provide the possibility that vitamin A causes adverse 
structural abnormalities in postnatal lungs, which in effect could alter their 
respiratory function. The VAD diet results in grossly enlarged alveolar airway 
surfaces, extensive thinning of alveolar cells walls with distorted features of alveolar 
septae synonymous with pathological features of emphysema. This effect can be 
seen in a diet prolonged deficiency of vitamin A in premature infants as well as 
infants in poor environmental conditions, where its absence disrupts the performance 
of respiration. 
 
3.1.5: SUMMARY. VAD rat lungs shows severe caloric restriction lead to alveolar 
enlargement or emphysema. The effects of postnatal VAD may be species-
dependent; although starvation of hamsters caused an enlargement of airspace and a 
reduction in surface area, but it was not associated with a reduction of pulmonary 
content or evidence of alveolar wall destruction. Such differences may be due to 
differences in somatic growth at the time of the nutritional insult. In general, 
however, it appears that restricted nutrition leads to protein degradation, impaired 
cross-linking of pulmonary structural proteins and an imbalance between synthetic 
and catabolic processes, all of which may contribute to the remodelling that results 















THE EFFECT OF DEFICIENT VITAMIN A ON 












OBJECTIVE: The overall study was to characterise changes of airway progenitor 
cells; alveolar type II (ATII) cells and Clara cells in the alveolar and 
tracheobronchial epithelium of 1 year postnatal VAD rat lungs. We evaluated both 
cell population, proliferation and transcriptional alteration of these progenitor cells. 
The data obtained was accomplished by the following techniques; 
immunohistochemistry and Immunofluorescent labelling along with cell counting 
from at least 5 non-overlapping microscopic fields (at x40) and immunoblots. 
Morphological analysis of CC10 positive Clara cells demonstrated in VAD 
bronchiole epithelium showed distinct structural change in the bronchiole epithelium 
from structures of CC10 positive Clara cells in control groups. Cells were less 
columnar in shape and their classical ‘cap’ situated on top of these cells were absent, 
but there appeared to be no real change in the number of cells expressed in either 
animal group. SP-C positive ATII cells located in alveolar epithelium were small 
and irregular in shape in VAD lungs. Staining of these cells in this group were 
spatial and cell numbers had significantly decreased in comparison with control 
lungs. SP-C positive ATII cells in control lungs were more oval in shape with 
clearly defined nuclear staining. Cellular expression was more compact. There was 
also a reduction in transcriptional and proliferative activity of both Clara and ATII 
cells in VAD lungs. Conclusion: VAD diet greatly affects the airway epithelium 
and is noted by the pathophysiological response of both Clara and ATII cells in the 
respiratory tract. Both transcription and proliferation of these cells are also affected 





3.2.1: INTRODUCTION. Adequate dietary intake of vitamin A is essential for the 
up keep of the respiratory epithelium. Abnormalities exhibited in VAD rat lungs 
have been shown to have similar clinical features observed in premature infants with 
poor nutritional diet (McMenamy and Zachman 1993, Baybutt, Hu et al. 2000). 
Dietary studies have defined the role of vitamin A in tracheal epithelial cells after 
injury, suggesting that regeneration of the tracheal epithelium after injury requires 
vitamin A, but little research has looked into the effects of VAD in airway cells, in 
particularly progenitor cells (Klann and Marchok 1982, McDowell, Keenan et al. 
1984, McDowell, Ben et al. 1987, Lancillotti, Darwiche et al. 1992, Baybutt, Hu et 
al. 2000). The development of advanced biochemical tools and techniques has been 
adapted over the years for the isolation of several airway cell types including ATII 
cells and nonciliated cells or Clara cells. From this development, over 40 varied cell 
types have been uncovered in the lung (Fig 3.2.1) (Devereux 1984).  
 
Both ATII cells and Clara cells are unique to the lung and have been shown to 
secrete a protein known as surfactant which has two main functions; firstly to aid in 
the regeneration of surface tension (in the alveolar epithelium) and to act as part of 
the defence mechanism (in the bronchi and bronchiole epithelium). A major function 
of these cells is that both are progenitor cells are able to differentiate into specific 
cell types ATII cells for alveolar type I (ATI) cells and Clara cells for mucus 






Fig 3.2.1: Airway progenitor cells. Schematic representation of the airways and 
types of cells present in each region. The red arrows indicate cell types with 
progenitor cell potential. Eramo A et al. Lung Cancer stem cells: tools and targets to 





In the event that injury occurs, the epithelium is repaired by an abundant progenitor 
pool and a sequestered population of adult stem cells. Chronic lung diseases such as 
asthma, COPD and BPD are characterised by extensive epithelial remodelling 
resulting in a reduction to the number of both ATII and Clara cells, suggesting that 
epithelial repair has been compromised. In addition to effects on the epithelium, 
these diseases are also accompanied by extensive subepithelial fibroproliferation, 
mesenchymal remodelling and elevated extracellular matrix deposition as well as a 
profound increase to lung inflammation. The findings that airway epithelial cells are 
essential for modulation of innate immunity suggests that the enhanced 
inflammatory response described in chronic lung diseases may be a result of 
attenuated airway epithelial cell function.   
 
Cell turnover of the epithelium lining the pulmonary airways is a slow process in 
normal lung maintenance. Methods used to calculate the rate of epithelial turnover 
rely on direct approaches that are based upon measurements of cell proliferation and 
lineage tagging. Measurements of cell proliferation have been principally replied 
upon stable incorporation of labelled DNA precursors such as bromodexyuridine 
(BrDU) or proliferating cell nuclear antigen (PCNA) into the DNA of cells 
traversing S-phase. Data generated from continuous labelling of a steady-state 
pulmonary epithelium, demonstrates the frequency of proliferation within the 
airways to be 1% per day (Hong, Berg et al. 2001). Assuming a direct relationship 
between the rate of epithelial cell loss and replacement, this data suggests that these 




Cell turnover in the lung epithelium is replaced far more slowly than the gut or the 
epidermis, a property that is reflected in the functional characteristics of airway 
progenitor cell in resting versus proliferative states. Although proliferation and 
differentiation of ATII cells is a critical factor in the repair of the pulmonary 
epithelium, regulation of the pulmonary healing processes is not well understood. It 
may well be that transcription factors play a key role in the control of tissue 
restoration after injury (Baybutt, Hu et al. 2000). However, there have been studies 
on cell growth stimulation and proliferation using cultured tracheal cells with the 
stimulatory agent being RA (Klann and Marchok 1982, Lancillotti, Darwiche et al. 
1992, Baybutt, Hu et al. 2000). Less information is available concerning the role of 
vitamin A of the distal epithelial cells of the alveoli (Baybutt, Hu et al. 2000).  
 
Increased risk of respiratory infections is partly due to squamous metaplastic 
changes in the epithelia of the respiratory tract seen in human VAD infants (Sommer 
1983). Experimental induced injuries such as Naphthalene exposure has been 
documented in reducing Clara cell population and activating putative bronchiolar 
tissue-specific progenitor cells located within the neuroepithelial bodies (NEB) and 
bronchiolar-alveolar duct junction (BADJ) (Stripp 2008).  
 
Nkx2.1 is a 43kDa phosphorylated member of the homeodomain-containing proteins 
expressed selectively in the lung, thyroid and central nervous system (DeFelice, 
Silberschmidt et al. 2003). Nkx2.1 is embryonically found in ATII and Clara cells 
and is therefore an important role in lung formation and function, but its 
involvement in the phosphorylation and transcriptional activation of target genes and 
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in cell differentiation in target tissues is unclear (DeFelice, Silberschmidt et al. 
2003). Furthermore, Nkx2.1 expression is spatially regulated during lung 
morphogenesis, being highly expressed in peripheral regions during the process of 
lung budding with advancing development (Lazzaro, Price et al. 1991, Zhou, Lim et 
al. 1996, DeFelice, Silberschmidt et al. 2003). Because of its role in lung 
development, a large presence of this protein in treated postnatal lungs after the 
process of injury would suggest some form of lung repair/regeneration. 
 
3.2.2: AIM: Chronic airway diseases are becoming of the leading causes of morality 
worldwide. As previously mentioned, there are very few effective treatments 
available to patients especially with COPD/emphysema to reverse or cure 
symptoms. Therapies using stem cells to regenerate lung tissue is fast growing and 
there is also the prospect of using progenitor cells as a therapeutic measure. The aim 
of this study was to first determine both Clara and ATII cell’s ability to respond to 
airway injury initiated by a VAD diet and to evaluate the impact of VAD on cell 










3.2.3: RESULTS.  
CC10 Protein Expression of Clara cells: On examination of 5µm sectioned lung 
tissue, light microscopy of DAB detected staining revealed CC10-positive Clara 
cells to be localised along the tracheobronchial epithelium in VAD and control rat 
lungs. We focused on CC10-positive Clara cells located in the bronchiole epithelium 
(Fig 3.2.2a and b). In control lungs, CC10-positive Clara cells presented a classical 
columnar epithelium dome-shape (Fig 3.2.2a). Immunofluorescent labelling of these 
cells revealed in more detail these cells to contain an apical ‘cap’ and there was an 
evenly, uniform distribution of these cells (Fig 3.2.2a and c). In VAD lung, these 
structures appeared different in the bronchial epithelium. They appeared ‘plump’ in 
size, they did not seem to have apical cap appendages and distribution was 
intermittent (Fig 3.2.2b and d). Along the bronchioles of VAD lungs lay pockets of 
grouped Clara cells. This feature was at times intermittent. Quantitative analysis of 
cell counts showed a small difference between the two groups. Statistically, Clara 
cell counts gave an average difference of 203.6 ± 11.0 in VAD lungs compared with 
control lungs which gave an average Clara cell counts of 248.2 ± 11.8. This 






Fig 3.2.3: Graph displaying average cell counts of Clara cells in VAD lungs in 
comparison with control lungs. Cell counts were calculated using students t-test. The 
difference between the two groups was P<0.02 
 
SPC Protein Expression of ATII cells: Next we evaluated cell population and 
distribution of SP-C positive ATII cells located in the alveolar airway epithelium. 
ATII cells were evaluated using a rabbit polyclonal anti-SP-C antibody. IHC and IF 
staining of this antibody revealed secretory ATII cells in populated groups 
throughout the alveolar epithelium in control lungs (Fig 3.2.4a and c). There was 
positive SP-C cells situated at the ends of exposed alveolar septae; probably where 
budding was taking place. IF labelled cells made it more apparent that the staining 
pattern of these cells were prominent around the nuclei and that each cell was 




VAD lungs revealed a number of changes. Firstly, the number of positive cells was 
much reduced from 59.6% in control lungs to 40.4% in VAD lungs. Secondly, ATII 
cells in VAD lungs looked as if shrinkage had occurred (Fig 3.2.4d). IHC stained 
section for SP-C showed that cells that were positive in both animal lung groups 
appeared granulated (Fig 3.2.4a and b). This observation suggest that these cells 
were undergoing cell division and perhaps undergoing differentiation into ATI cells, 
as it has been documented in the literature that when injury has taken place, ATII 
cells not only proliferate to make more ATII cells, but differentiate to create an ATI 
population as these cells do not have the capacity to proliferate into new ATI cells. 
Furthermore, IHC staining in VAD lungs showed some unusually large cells which 
surrounds populated groups of ATII cells. These cells looked like they may be 
macrophages and were frequent throughout these lungs (Fig 3.2.4b). Statistical 
analysis confirmed the number of positive ATII cells detected by anti-SP-C (Fig 
3.2.5, Table 3.2.1). Overall, VAD lungs gave an average cell count of 156.8 ± 6, 









Fig 3.2.5: Graph showing the average number of ATII positive cells in the alveolar airway epithelium of VAD lungs in comparison to control 
lungs detected by rabbit anti-SP-C. The graph depicts a reduced number of ATII cells in VAD alveolar airway epithelium when compared with 
control lungs. Reduction of these cells could suggest cell differentiation into ATI cells. 
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Table 3.2.1: Average cell counts of CC10-positive Clara cells and SP-C positive 
ATII cells in the bronchiole and alveolar airway epithelium of VAD lungs compared 
with control lungs  
Primary Antibody Control Lungs  VAD Lungs  
CC10: Clara cells  203.6 ± 11.0 248.2 ± 11.2 
SP-C: ATII cells  231.0 ± 31 156.8 ± 6 
 
Table shows that VAD has a significant effect on ATII cell population, whereas with 
Clara cell population the effect of VAD is minimal.  
 
Nkx2.1 Protein Expression: We examined whether the presence of Nkx2.1, if any 
in postnatal lungs was altered in VAD lungs. Detection of Nkx2.1 was demonstrated 
using a mouse monoclonal anti-TTF-1 antibody. Nuclear localization of TTF-1 
positive Nkx2.1 was clearly demonstrated in alveolar and bronchiole airway 
epithelium in control lungs. Cell population of TTF-1 Nkx2.1 positivity was seen in 
large numbers and in some areas, appeared grouped in alveolar epithelium (Fig 
3.2.6a). Cell positivity for Nkx2.1 in VAD alveolar epithelium showed alteration in 
expression. Cells were darker and appeared larger and flatter and much harder to 
distinguish. Positive Nkx2.1 cells for this antibody were fewer and spacious (Fig 
3.2.6b). Cellular expression was not present around alveolar septae in VAD lungs; 
this lack of expression was not seen in control lungs. Cell counts confirmed the 
reduction in the number of TTF-1 positive Nkx2.1 in VAD alveolar epithelium. The 
average count for this group was 27.2 ± 3 compared with cell counts in control 
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alveolar epithelium, where the average was 64.4 ± 2. The P value for this was 0.01, 
which statistically was deemed significantly different (Fig 3.2.7, Table 3.2.2). In 
terms of protein reduction in VAD lungs, expression of Nkx2.1 in the bronchiole 
epithelium showed similar results observed in alveolar epithelium. Positive labelling 
in control groups were shown to surround columnar epithelial cells in the same area 
where CC10-positive Clara cells were shown to be located (Fig 3.2.5C and Fig 
3.2.2a and c) and also where goblet cells are normally situated. Staining was clear 
and uniform. The only concern about the expression pattern of this protein is that its 
labelling appeared different from published data examining Nkx2.1 in human 
bronchioles. Expression of TTF-1 positive Nkx2.1 protein in VAD groups was 
sparse with extremely weak staining (Fig 3.2.6d). The average cell counts for these 
cells located in the bronchiole epithelium were as follows, 50.0 ± 2 in control lungs 
and 20.2 ± 2 in VAD lungs (Table 3.2.2). These values also gave a significant 









Table 3.2.2: Analysis of Nkx2.1 transcriptional activity in postnatal VAD lungs  
 Control Lungs  VAD Lungs  
TTF-1 (Alveolar) 64.4 ± 2.0 27.2 ± 2.0 
TTF-1 (Bronchiole) 50.0 ± 2 202 ± 2 
 
Immunoblot Analysis of CC10, SPC and TTF-1 protein: Analysis of protein 
expression via immunoblotting using homogenates of both lung groups showed 
detection of CC10, SP-C and TTF-1 positivity (Fig 3.2.8). There were varying 
degrees of expression levels amongst these proteins. This set of results was in 
conjunction with IHC and IF labelling (Fig 3.2.2 -3.2.8). The reduction of SP-C and 
Nkx2.1 positive TTF-1 suggest that postnatally, SP-C is still regulated by Nkx2.1, 
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Proliferation Analysis of Clara and ATII cells: Finally, we examined the 
proliferation of Clara and ATII cells in VAD lungs. We know from previous 
experimental studies that chronic lung injury causes the proliferation of cells to 
greatly alter. Proliferation of progenitor cells in healthy lungs is normally slow, but 
in abnormal circumstances, such as diseased or injured lungs, proliferation can be 
either seen to increase or decrease dramatically. IF labelling with the proliferative 
antibody, PCNA with CC10 and SP-C revealed positive proliferation of SP-C 
positive ATII cells in both VAD and control alveolar epithelia (Fig 3.2.9c and d). 
There was a reduced number of proliferative ATII cells in VAD lungs compared 
with control lungs. Calculated averages showed 44.2 ± 1 in VAD lungs and 72.4 ± 4. 
The reduction in the number of ATII cells in VAD lungs could be due to cell 
differentiation of the cell population to ATI cells as from morphological studies we 
deduced epithelial damage where both cells are located for the regulation of surface 
tension (ATII) and the process of gas exchange (ATI). Because we did not carry out 
double labelling of ATII and ATI cells, we can only hypothesize that this was the 
cause of ATII cell reduction in VAD lungs as it has been well documented that ATII 
cells not only proliferate into more ATII cells, but differentiate into ATI cells, as 
these cells do not have the capacity to do so themselves in a diseased or injured 
environment. Proliferation of Clara cells was only detected in very small numbers in 
VAD bronchioles and not in control bronchioles (Fig 3.2.9b). However, proliferation 
of basal cells were highly detected in control lungs (Fig 3.2.9a). Even though the 
two groups detected two sets of proliferative cells from the bronchiole, cell counts 
were still carried out. Basal cell counts in control lungs gave an average of 101.2 ± 2 










Immunoblots of PCNA revealed high levels of proliferation in the two groups. This 
high level of proliferative activity in both groups can be justified as both Clara and 
ATII cells were not isolated for this technique, so we can only surmise that high 
proliferative activity could be due to other cellular populations interacting with 
PCNA in the lung (Fig 3.2.11). 
 
 
Table 3.2.3: Average proliferative cell counts of airway progenitor cells  
Primary Antibody Control Lungs  VAD Lungs  
PCNA/CC10 82.4 ± 4 44.2 ± 1 
PCNA/SP-C 101.2 ± 2 43.5 ± 5 
 
 
3.2.4: DISCUSSION. Defective airway epithelial repair has been proposed as an 
early event in the initiation of chronic airway diseases. Chronic defects in reparative 
capacity and cellular composition may further contribute to disease progression and 
susceptibility to exacerbation. This implies that normal functions for facultative 
progenitor and stem cells are compromised. Evidence suggests this may be the case 
from the analysis of biomarkers for epithelial remodelling that are used to follow the 
severity and progression of lung disease. This study has provided evidence that 
vitamin A is at least one of the components that promote ATII cells and surfactant 
secretion, but not Clara cells in postnatal lungs. We know this to be true because 
there was a decrease of ATII cells synthesis of surfactant in the VAD lung group, 
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but expression levels of Clara cells seemed in part, unaffected. ATII cells not only 
serve to maintain lung epithelial cells, but also provide surfactant to reduce surface 
tension of the air/liquid interface lining the alveoli and enabling respiration. Vitamin 
A seems to play an important role in regulating surfactant synthesis.  
 
During lung epithelial injury, ATII cells proliferate and then differentiate into ATI 
cells that replace the injured cells and restore the alveoli. Vitamin A is thought to be 
necessary for this process. The precise mechanism for the action of vitamin A is not 
known, but RA appears to be involved. There was no high proliferative activity in 
SP-C-positive ATII cells in the VAD lung group, signifying that vitamin A initiates 
ATII proliferation (Tei, Moccia et al. 1999). It is possible that all SP-C expressing 
ATII cells have the potential of being transformed, but lung injury may only initiate 
a small population of uncharacterised ATII cells for instance, those expressing low 
levels of SP-C and presumably processing proliferative potential in various 
conditions or those residing at specific anatomical locations. Without markers 
currently available to define subpopulations of ATII cells, it is not possible to assess 
transformation potential of distinct subpopulations of ATII cells, if they do exist. It 
is also uncertain how the transformation potential of ATII cells is compared to other 
lung epithelial cells such as Clara cells, BASCs, ciliated cells, goblet cells and ATI 
cells under various conditions. Perhaps distinct cell types are susceptible to specific 
insults and a more in depth investigation is required to delineate the molecular basis 





The role of vitamin A in preventing inflammation is related in part to its interaction 
with leukocytes. Inflammation occurs in the microcirculation and can be 
characterised by the movement of fluid and leukocytes from the blood to the 
extravascular tissue. Vitamin A appears to be most effective against the most 
prevalent proinflammatory leukocyte, the neutrophil. Vitamin A deficiency appeared 
to initiate innate immunity because we observed macrophages in the VAD lungs 
which are known to help initiate specific defence mechanisms. These cells also 
express the phenotypes, M1 killer and M2 macrophages which are involved in tissue 
repair. It is more likely that the macrophages seen in our VAD rat lungs were M1 
because structurally, they appear oval in shape, whereas M2 are more elongated. The 
macrophages we observed in the alveolar epithelia were oval. Also M2 are thought 
to be less inflammatory and less active in the killing of bacteria (Rosas, Thomas et 
al. 2010, Moreira and Hogaboam 2011). However, investigations of these 
macrophages were not examined, but this would be an interesting aspect to peruse.  
 
Levels of CC10-positive Clara cells in the bronchiole airway epithelia are reduced in 
chronic lung diseases such as asthma and CF. However this is not true in our VAD 
rat model where we only saw a reduction when compared with control groups, 
therefore we concluded that there was not any differences in the expression of these 
cells in the bronchioles, even though statistical analysis signified a slight significant 
difference. What we demonstrated in an environment depleted of vitamin A, CC10-
positive cells are still present throughout the tracheobronchial tree of postnatal rats 
suggesting that epithelial remodelling may involve altered differentiation or subset 
of (variant) of Clara cells critical bronchiolar epithelial recovery because these 
CC10-positice Clara cell structure was dissimilar to CC10-positive cells in control 
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lungs. This supports the notion that there exists a population of bronchial epithelial 
cells that are CC10-positive in rats that maybe a subset of Clara and non-Clara cells 
(Bolton, Pinnion et al. 2008).  Clara cells in control groups displayed a classical 
dome-shape, apical protrusion (cap), whereas VAD groups appeared bigger with no 
dome shaped top. Also, we found that PCNA-positive cells in the bronchiole 
epithelia to be restricted mainly to the basal cells, indicating that bronchial CC10-
positive Clara cells do not serve a proliferative stem cell-like role like true Clara 
cells. Many studies have shown the expression of Clara cells in the alveolar epithelia 
as well as in the bronchioles, but in our study, we did not observe this. This, 
however does not suggest that these cells demonstrated are not “true” Clara cells, but 
suggests that they may have slightly different functions, according to their location 
and structure and also bearing in mind that the epithelia has been dramatically 
damaged. It is interesting to speculate that it may be owing to the Clara cell’s 
defensive role of the epithelia the high numbers present in the VAD lungs.  
 
Nkx2.1is a critical determinant of the lung’s epithelium gene expression and lung 
differentiation (Lazzaro, Price et al. 1991, Bohinski, Di Lauro et al. 1994, Bruno, 
Bohinski et al. 1995, Stahlman, Gray et al. 1996). Through immunohistochemistry 
and immunoblots, it was shown to have a critical role in SP-C expression, but not for 
the Clara cells. The conclusion of this was driven by the fact that when SP-C 
expression was downregulated in the VAD lungs, TTF-1/Nkx.2.1 expression was 
also downregulated, whereas CC10 expression did not alter. This supports the role of 
NKx2.1 in protein expression in relation to respiratory alveolar epithelium in that it 
is one of the driven forces of ATII activation. Clara cell expression maybe 
independent of TTF-1/Nkx.2.1 regulation, postnatally, or that the Clara cells present 
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are in fact variants and may be regulated through another pathway. Through the 
pattern of staining, it would appear that TTF-1/Nkx2.1 was not detected in ATI cells 
or in ciliated cells in the conducting airways, suggesting that the differentiation of 
the subsets of cells from progenitor cells is associated with the loss of TTF-1/Nkx2.1 
expression, since ATI cells are generated by terminal differentiation from ATII cells. 
TTF-1/Nkx.2.1 staining was detected primarily in the nuclei as was SP-C positive 
ATII cells in control alveoli and was weakly detected in the bronchiole epithelium. 
However, TTF-1/Nxk.2.1 immunostaining was almost absent in the regions of ATII 
positivity after injury associated with VAD. TTF-1/Nkx.2.1 immunostaining was not 
particularly prominent in the bronchiole epithelium of control lungs, although there 
was staining lining cuboidal cells where regeneration would take place. There was 
very minimal staining in VAD lungs signifying the importance of vitamin A for 
normal lung maintenance.  
 
 
3.2.5: SUMMARY. Understanding the role of airway progenitor cells in lung injury 
may play in the development or exacerbation of lung disease is critical for the 
development of cell and molecular therapy. Significant new insights into cellular and 
molecular mechanisms of epithelial maintenance have been made in recent years 
that provide insights into the pathophysiology of lung disease. Collectively, our data 
supports the hypothesis that Nkx2.1 and ATII cells and vitamin A are crucial 








EXPRESSION OF MUCINS IN VAD 








OBJECTIVE: Vitamin A deficiency (VAD) alters the phenotype of airway 
epithelium and attenuates the epithelial defense system. Many studies have reported 
an association of VAD with respiratory disease. In this study, we investigated 
changes of glycoprotein secretion in a VAD postnatal rat model. Areas of the 
bronchiole epithelium where goblet cells are present were evaluated in both VAD 
and control animals. Upon histological evaluation, we found there was a significant 
increase in the level of glycoprotein secretion in the VAD rat compared with the 
control rat. When examining secretory levels of the major mucin proteins and those 
associated with respiratory diseases, we found that there was a significant increase in 
MUC2 and MUC5B and a relative increase in MUC7 protein in VAD animals. 
There did not appear to be a substantial change in MUC5AC secretion between the 
two groups. In this study we concluded that we found mucus hypersecretion along 
with hyperplasia and metaplasia in VAD rat lungs and that the increase in MUC2, 
MUC5B and MUC7 may contribute to the susceptibility to airway infection linked 
to VAD suggesting dysfunction in lung function.    
 
3.3.1: INTRODUCTION: The day to day bombardment of foreign particles inhaled 
from the environment into the airways can be a hindrance for the normal functioning 
of the respiratory system by damaging the lining of the epithelium along the lungs. 
One way in which the lung is able to combat such an onslaught is through the 
secretion and mechanism of a viscous substance known as mucus, produced by 
goblet cells embedded in the epithelium of the respiratory tree (bronchi and 




Fig 3.3.1: Transmission electron micrograph (TEM) showing through the surface 
Mucus enriched in glycoproteins and water which gives it its viscous characteristics. 
Rogers. 2008 
 
Mucus removes unwanted foreign airway particles that enter the respiratory tree by a 
process known as mucociliary clearance (Vestbo, Prescott et al. 1996, Jeffery and Li 
1997, Houtmeyers, Gosselink et al. 1999, Maestrelli, Saetta et al. 2001, Daviskas, 
Robinson et al. 2002, Rogers 2007). Mucus itself is a non-Newtonian fluid that has 
both viscous (liquid) and elastic (solid) properties (Rogers DF. 2008, King M. 2006). 
Viscosity represents energy loss, whereas elasticity represents energy storage. 
Consequently, the effectiveness of mucociliary clearance has a direct relationship 
with elasticity, whereby kinetic energy from beating cilia is transmitted to mucus 
10µm 
  Goblet cells  
   Basal cells  
    Mast cells  
Bronchial Vessel  
Ciliated cells  
121 
 
and an indirect relationship with viscosity (limited loss of energy) (Rogers DF. 
2008). Conversely, the effectiveness of coughing has an indirect relationship with 
elasticity (to limit elastic recoil) and a direct relationship with viscosity and therefore 
creates an adverse effect on the mechanics of breathing (Rogers DF. 2008, King M. 
1989).   
 
Within this non-Newtonian media lay antiseptic enzymes such as lysosomes, 
immunoglobulins, inorganic salts and proteins such as lactoferrin and glycoproteins 
(mucopolysaccharides and mucins). These components are secreted by the goblet 
cells, serving a role in the airway defence.    
 
The histochemical analysis of secretory glycoproteins present in a cell population of 
normal airway mucosa provides information in regards to changes occurring in a 
disease state. In human airway disease, secretory hyperplasia is always accompanied 
by a shift in pH of the heterogeneous population observed in normal circumstances. 
This shift greatly favours an increase (hypersecretion) in the secretion of acidic 
glycoproteins which is associated with keratinisation of the mucosa. A change in pH 
is often observed in airway conditions such as asthma, cystic fibrosis (CF) and 
COPD, where the function of mucus is greatly changed from a protective role to one 
that contributes to the respiratory disease (Rogers 2007) (Houtmeyers E et al. 1999, 




The relationships between mucus hypersecretion and pathological mechanisms of 
VAD and airway obstruction are poorly understood. Although early epidemiological 
studies of occupational cohorts failed to associate mucus hypersecretion with rapid 
progression of VAD, some more recent population-based studies reported an 
association of chronic mucus hypersecretion with accelerated decline in FEV1 and 
also an involvement in airway infection (Vestbo et al. 1996, Kim et al 2012). The 
question of whether mucus hypersecretion cause annoying, but innocuous symptoms 
or are instead aetiologically related to long-term VAD remains unanswered.  
 
3.3.2: AIM: Chronic mucus hypersecretion along the respiratory mucosa is one 
consequence of respiratory diseases. Research has shown that depletion of vitamin A 
is a contributor to such conditions, therefore we would expect to see an increase in 
the expression of glycoproteins in our VAD animals. Lung sections and 
homogenized lung tissue from VAD and control animals were used to examine the 
level of glycoprotein expression secreted from goblet cells. This was achieved by 
histology (ABPAS staining), immunohistochemistry (MUC2, MUC5AC, MUC5B 
and MUC7 DAB staining), SDS-PAGE electrophoresis (MUC5B and MUC7 
Coomassie/PAS staining) and western blotting (MUC2, MUC5AC, MUC5B and 
MUC7 immunostaining). SDS PAGE and western blots bands were scanned with 
ImageJ (downloaded from the National Institute of Health, USA). Band intensity of 
MUC proteins were compared between VAD and control lungs. These findings were 





3.3.3: RESULTS.  
ABPAS DEMONSTRATION OF GLYCOPROTEIN EXPRESSION: A number 
of outcomes were concluded from ABPAS staining. Firstly, there was a clear change 
in pH composition of secretory glycoproteins in VAD animal groups. Expression of 
these proteins from this group contained a large population of strongly acidic, but 
very few neutral glycoproteins. Its control counterpart contained a small even 
heterogeneous population of acidic and neutral glycoproteins (Fig 3.3.2). As 
expected, its control counterpart contained a small heterogeneous population of 
acidic and neutral glycoproteins. The total number of positive goblet ABPAS cells 
was counted to determine hyperplasia in the bronchi epithelial tree. Five non-
overlapping fields of bronchioles containing secretory goblet cells were analysed 
under brightfield microscope. The average cell counts of active secretory goblet cells 
was calculated using the unpaired student’s t-test. Statistical analysis showed that 
there was an increase in the number of goblet cells secreting glycoproteins in VAD 
lungs (±) in comparison with control lung groups (±) (Fig 3.3.2). Acidic and neutral 
glycoproteins were also calculated using the student’s t-test. Statistical analysis 
showed an increase in the number of acidic glycoprotein secretion in VAD lungs (±) 
and showed a reduction in the number of neutral glycoprotein secretion (±) when 
compared with secretions levels in control lungs (±) for acidic and (±) for neutral 









Fig 3.3.2: ABPAS staining demonstrating the localization and secretory distribution of acidic and neutral glycoproteins in control (a) 










Fig 3.3.3: Histogram of the average number of secretory goblet cells in control (grey) and VAD (red) rat lungs. VAD rat lungs show a 






Fig 3.3.4: Acidic and Neutral expression level comparison in control and VAD lungs. Graph displays the amount of acidic 
glycoproteins has increased substantially in comparison to control lungs giving a strong indication that acidic glycoprotein secretion is 
strongly stimulated by VAD. 
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Secondly, the morphology of goblet cells in VAD lungs were examined. They 
showed the shape of goblet cells in these lung to be columnar rather than oval as 





Fig 3.3.5: ABPAS demonstration of secreted glycoproteins in goblet cells. Black 
arrows in figure (a) and (b) point to the changes in goblet cell structure in control 
and VAD lungs.  
 
Thirdly, VAD lungs showed frequently populated secretions of acidic glycoproteins along 
the respiratory tree compared with control lungs, where secretions were sparse confirming 
that VAD diet exacerbate damage to the bronchiole epithelium by causing a change in the 
level of acidic glycoprotein secretion most likely caused by inflammation and bacterial 
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Fig 3.3.6: Increased number of acidic glycoprotein secretion in postnatal VAD rat 
lung. Bronchiole epithelium also appears damaged suggesting inflammation caused 
be dietary VAD. ABPAS histochemical staining. Scale bar: 50µm 
 
Next we evaluated the expression levels of the two major mucin proteins (MUC) in 
the respiratory system; MUC5AC and MUC5B along with two associated MUC 
proteins with airway disease, MUC2 and MUC7. The measurement of secretory 
mucins, MUC5B and MUC7 from lung homogenates was examined by comparing 
Coomassie-PAS stained SDS gels of VAD (Lane 2) and control (Lane 1) samples 
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(Fig 3.3.7). MUC5B and MUC7 proteins were measured by calculating the band 
intensity using ImageJ analysis programme. The major mucin protein found in VAD 
lungs was MUC5B (Lane 2, top band). As expected, a low levels of MUC5B was 
expressed in control lungs (Lane 1, top band). MUC7 staining was harder to detect, 
but there was a slight increase in the protein in VAD lung homogenates (Lane 2, 




Fig 3.3.7: SDS-PAGE gel electrophoresis on homogenised lungs samples from 
control (lane 1) and VAD (lane 2) animals. Gels were stained with Coomassie 
Brilliant Blue R250 (CBB) and then periodic acid Schiff’s reagent (PAS). Lanes 1 
and 2 were loaded with 15µl of sample. M = Marker 
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Calculations confirmed visualised observations of stained MUC bands. MUC5B 
glycoprotein showed that there was a significant increase in VAD homogenate lung 
samples (one-way AVONA), but no significant increase with MUC7 in VAD 
homogenates compared with control samples (Fig 3.3.8, Table 3.3.1). This indicated 





















Fig 3.3.8: Band intensity of MUC5B and MUC7 proteins in control and VAD lung homogenates. Graph displays an increase of 
MUC5B secretion in VAD lungs, but an unchanged level of MUC7 secretion when compared with control samples.   
132 
 
Table 3.3.1: MUC protein expression in VAD and control homogenates. Results are expressed as a percentage of MUC levels in 
control and VAD ± standard error of the mean. One-way AVONA indicated whether there was a difference in diet groups. * Indicates 
the proteins significant difference from VAD samples after t-test, where P<0.05 followed by the Bonferroni correction where P<0.016.  
MUC Proteins n Control VAD ANOVA Results 
MUC5B 5 58.2 ± 15.0 70.3* ± 4.6 P<0.05 





Immunohistochemistry of MUC Expression: All four MUC proteins were stained 
on 5µm sections taken from control and VAD lungs and analysed using a brightfield 
microscope. MUC5AC and MUC5B expression was only detected in the bronchiole 
airway epithelium, whereas both MUC2 and MUC7 expression was detected in both 
alveolar and bronchiole airway epithelium (Fig 3.3.9a - l). Sections from VAD lungs 
showed an increase of MUC2, MUC7 (alveolar and bronchiole epithelium) and 
MUC5B and MUC7 (bronchiole epithelium), figs b, d, h, j and l. There did not 
appear to any change in the level of expression with MUC5AC (bronchiole 
epithelium), figs f. Expression pattern of MUC2 staining was distinctly different in 
VAD airways compared with control airways (a - d). In VAD alveolar epithelium 
(b), MUC2 staining showed nuclear overexpression of the protein, whereas MUC2 
expression in control alveolar epithelium showed clear nuclear staining. Protein 
expression showed a clear outline of each positively stained nuclei (a) and was less 
in number compared with MUC2 expression in VAD alveolar epithelium. MUC2 
protein in the bronchiole epithelium of VAD lungs (d) also showed overexpression 
compared with bronchiole epithelium in control lungs (c). Expression of this protein 
was mostly prominent on top of goblet cells forming a “cap”. Expression of MUC2 
positivity showed granulation in these caps. There was also expression located long 
the basement goblet cells on the epithelium. In control bronchioles, positive MUC2 
staining appeared flat on the surface of goblet cells with very little granulation. 
Expression of MUC2 was also seen on the basement of goblet cells, but unlike 
expression seen in VAD bronchioles, expression was intermittent in control 
bronchioles. The average cell counts of MUC2 and MUC7 in alveolar airways of 
VAD and control lungs were as follows; 84.5 ± 3cm³ (VAD) v 52.3 ± 2cm³ (control) 
for MUC2 and 26.3 ± 4cm³ (VAD) v 36.6 ± 9cm³ (control). Average cell counts for 
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MUC2 in bronchiole airways were 67.9 ± 4cm³ (VAD) v 29.2 ± 6cm³ (control); 
MUC7 average counts were 27.8 ± 1cm³ (VAD) v 63.5 ± 5cm³ (control). Next we 
examined MUC5AC and MUC5B protein expression. These proteins were only 
detectable in the bronchiole airway epithelium (e-h). Both pattern of MUC5AC 
staining was intense, but clearly defined goblet cell structure (e and f). Goblet cells 
in VAD lungs did appear granular, whereas some, but not all goblet cells in control 
lungs gave a granular appearance. Staining pattern of MUC5AC surrounded the 
whole of goblet cells. The caps situated on top of the goblet cells in VAD lungs 
appeared to show more MUC5AC expression and was more intense. Average cell 
counts for MUC5AC was 111.0 ± 2cm³ (VAD) v 102.3 ± 8cm³. MUC5B expression 
in VAD bronchiole epithelium (g) showed an increase compared to MUC5B 
expression in control bronchiole epithelium (h). Unlike the pattern of staining seen 
in MUC5AC where goblet cells were clearly defined in both control and VAD lungs, 
staining of MUC5B in VAD bronchioles showed ill-defined goblet cells. MUC5B 
staining showed its characteristic cap feature in goblet cells in control bronchioles. 
The average cell counts of MUC5B expression was 100.8 ± 7cm³ (VAD) v 68.1 ± 
4cm³ (control).  A summary of MUC protein expression in both alveolar and 
bronchiole airway epithelium are shown in fig 3.3.10 and fig 3.3.11 and calculations 











Fig 3.3.10: Graph shows the average number of MUC2 and MUC7 protein 
expression in the alveolar airway epithelium of VAD lung groups compared with 
control lung groups. Here the graph shows an increase in MUC2 and a slight 
increase in MUC7 in VAD lungs indicating that increase of MUC2 and MUC7 











Fig 3.3.11: Graph showing the average number of MUC2, MUC5AC, MUC5B and 
MUC7 expression in goblet cells in the bronchiole airway epithelium of control and 
VAD lungs.   There is a clear indication that the expression levels of MUC2, 
MUC5B and MUC7 have an increased response to VAD diet and that MUC5AC 
expression levels is mostly unaffected.      
 
Western blots shown in figure 3.3.12 are representative of lung homogenate samples 
extracted from control and VAD animals. Lung homogenates from these groups of 
animals were stained with MUC proteins previously used for IHC detection (Fig 
3.3.9). All four MUC proteins were present in VAD and control homogenate 
samples. In VAD samples (Lane 2), MUC2, MUC5B and MUC7 proteins were 
strongly detected and showed upregulation compared with these proteins detected in 






expression levels between VAD and control samples. The WB results appeared to 
collaborate with staining results obtained from IHC staining (Fig 3.3.9).  
 
     
 
Fig 3.3.12: Western blot analysis of MUC proteins in lung homogenates of control 
(Lane 1) and VAD (Lane 2) animals. WB were probed with antibodies against 






3.3.4: DISCUSSION. The study in this chapter was performed to gain knowledge 
about the way in which deficiency of vitamin A contributes to mucus hypersecretion 
of the airways. We used a VAD postnatal rat model to highlight the importance of 
vitamin A for mucus homeostasis.  
 
Vitamin A depletion affects goblet cells in various ways depending on the tissue or 
species. Hypersecretion is accompanied by goblet cell hyperplasia and glycoprotein 
metaplasia. Chen et al. found that an increase in goblet cell number is due to changes 
of stored and secreted mucus. In our study, after staining tissue sections with 
ABPAS we found that VAD lungs showed goblet cell hyperplasia and metaplasia 
(Fig 3.3.2). In VAD lungs there was a striking change in what would be described as 
“normal” heterogeneity of glycoproteins in the bronchiole airway epithelium in 
healthy bronchiole airways. The use of ABPAS staining allowed us to observe a 
transformation of a low heterogeneity population of glycoprotein secretion to a 
population that consisted mainly of large population of acidic glycoproteins. 
Previous experiments using irritated lungs by sulphur dioxide and tobacco smoke 
also demonstrated the same changes seen in VAD lungs (Jeffery et al. 1997). There 
is literature concerning studies in vivo that strongly suggests vitamin A is involved 
in the process of glycosylation (Chan et al. 1987, Rosso et al. 1981). pH change of 
glycoproteins seen in VAD lungs could be caused by an alteration in the process of 
glycosylation with the removal of specific glycan linkages, such as highly 
reproducible reduction in some sialic acid linkages following immune activation of 




Secreted high molecular weight mucin is important in many functions performed in 
the bronchiole airways and in this study this was clearly demonstrated by IHC 
staining and immunoblotting lung samples of VAD and control animals. We focused 
on four airway mucins associated with airway diseases, MUC2, MUC5AC, MUC5B 
and MUC7. MUC5B and MUC7 were semiquantified by scanning PAS-stained gels 
because this method proved to be reproducible. There was variation between the two 
animal groups in their relative amounts of secreted mucins produced and this 
reflected the significant difference amongst MUC2, MUC5B and MUC7 in VAD 
lung samples. We observed an increase in MUC2 expression in the alveolar and 
bronchiole airway epithelia of VAD lungs (Fig 3.3.9B and D). These results were 
similar to a study where MUC2 mRNA was shown to be upregulated during 
inflammation or bacterial infection initiated by vitamin A deficiency (Guzman et al. 
1996). This study alongside our postnatal rat model suggests that MUC2 may play 
an important role in airway mucus hypersecretion. However, we did not see a 
change in the expression levels with MUC5AC protein between VAD and control 
samples. There may be a few explanations as to why this is so; first MUC5AC may 
not be involved in mucus hypersecretion of the VAD pathway and second; 
MUC5AC may respond differently in diseased rat lungs from other species such as 
human lungs. In the human lung, MUC5B is expressed in glands, but in rat lungs 
used in this study, MUC5B was located in goblet cells (Fig 3.3.9g and h), (Davies et 
al. 1999, Reid et al. 1997). Like MUC5AC, patients with chronic airway conditions 
show an upregulation of MUC5 (Burgel et al. 2007, Caramori et al. 2004, Groneberg 
et al. 2002a, Kamino et al. 2005, Kirkham et al. 2002). In sputum obtained from 
COPD airways, the abundance of MUC5B exceeds that of MUC5AC, a pattern 
which is reversed in healthy airways (Kirkham et al. 2008). An increase of MUC5B 
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secretion demonstrated by IHC was also observed in our VAD lungs (Fig 3.3.9g and 
h) and was confirmed by protein levels detected by immunoblots and statistical 
analysis (Fig 3.3.11 and 3.3.12). It could be argued that an increase from this protein 
was in response to inflammation and perhaps an increase in bacterial activity. These 
levels could also have been a counteractive response to increasing secretion of 
MUC2 which is also associated with increase in bacterial infections in the 
respiratory and gastrointestinal tracts. Finally, we examined expression levels of 
MUC7 in VAD lungs. MUC7 has been reported to be expressed in the trachea and 
salivary glands containing acinar cells by Northern blot and RT-PCR analysis (Iwase 
et al. 2002). In our study, MUC7 was found to be expressed in low levels in both 
alveolar and bronchiole airway epithelium in control rat lungs. It was shown to be 
elevated, to some degree in VAD rat lungs of both located areas (Fig 3.3.9 i-l). Cell 
counts gave a significant value of P>0.05 for both epitheliums, signifying MUC7 
response to depletion of vitamin A. This data was also confirmed by immunoblot 
analysis (Fig 3.3.12), where expression levels of this protein was upregulated. These 
abnormal levels of MUC7 expression could due to its functional role as protective, 
much like MUC2 and MUC5B. Upregulation of these mucins suggest modulation of 
structure of protein in VAD lungs.  
 
The contribution of mucus hypersecretion to airflow limitation is problematic as an 
array of mechanisms leading to this process is still being discovered (Rogers 2007, 
Kirkham et al. 2002). Different MUC proteins appear to be present in the respiratory 
system of VAD lungs. MUC5AC and MUC5B are the major MUC proteins in 




The importance of MUC5B glycoproteins in inflammatory airway diseases such as 
VAD and asthma is unclear, but it may relate to differences in propensity for 
bacterial colonisation of the lungs. Like COPD patients, VAD patients are prone to 
pulmonary infections (Rogers. 2007, Davis. 2001). As observed in our postnatal 
VAD rat model, MUC2 and MUC7 protein are expressed in control lungs, but in 
relatively low levels. The distribution of these proteins in comparison to VAD lungs 
show similar pattern of expression, but are upregulated. It has been reported that 
both MUC2 and MUC7 mRNA are upregulated in the airways of smokers, but is 
found in small amounts in COPD patients (Kirkham et al. 2002, Davis et al. 1999). 
These findings are suggestive in that there are differences in goblet cell phenotype 
between airway inflammation. Changes in the phenotype of goblet cells suggest 
changes in mucus viscosity, leading to a change in mucus composition. This in turn 
altering interactions of mucus with other components of the airway liquid interface. 
Although these changes are considered to be involved in the pathophysiology of 
hypersecretion, the relative contribution of each change in relation to disease 
development and clinical symptoms needs to be resolved.  
 
Facilitating mucus clearance and changing the viscoelasticity of mucus; a change in 
viscosity and elasticity will depend upon whether mucociliary clearance or coughing 
is required. Decreasing viscosity may not markedly change mucus clearance by itself 
and may require the upregulation of surfactant protein, designed to regulate surface 




3.3.5: SUMMARY: Patients with chronic airway conditions which include 
inflammation as part of its clinical feature show an increase of MUC expression on 
surface goblet cells are likely to affect the composition and biophysical properties of 
airway mucus. Our data shows that VAD induces mucus hypersecretion in postnatal 
rat lungs. Interestingly, secretory levels of MUC5B in VAD lungs were much 
greater than expected. Increased expression of MUC2, 5B and 7 suggest modulation 
of these proteins caused by depletion of vitamin A because in control lungs there 
was much reduced expression. Cessation of mucus hypersecretion will not solve the 
underlying cause of chronic airway disease in VAD patients. Overall, mucus 
hypersecretion is a clinical feature that needs further investigation via mechanism (s) 
and transportation of mucus especially as apart from its protection role, it also has a 

















MORPHOLOGY AND MORPHOMETRIC 
ANALYSIS OF REGENERATIVE RETINOIDS 








OBJECTIVE: For the study of retinoid regenerative efficacy in lung injury, we 
experimentally generated an emphysematous-like model using an anti-inflammatory 
steroid, dexamethasone in postnatal mouse lungs. First we examined the architecture 
of dexamethasone-treated lungs (its parenchymal components) and measured its 
alveoli surface area. Like in the VAD postnatal rat lungs (Chapter 3.1), these lungs 
showed a vast reduced gas-exchanging surface area and an increase in 
vascularisation. Most importantly, there was an increase in Lm measurements. The 
second objective was to examine the efficacy of selective retinoid ligands in the 
process of regeneration. We achieved this by not only comparing these treated lungs 
with dexamethasone lungs, but also comparing with tRA because this active form of 
RA has been shown in numerous studies to reverse the effect of experimentally-
induced emphysematous-like features in the adult lung. From our study we found 
that the most effective and efficient retinoid ligand was RARα. Its morphological 
features and Lm values were the closest to tRA, followed by RARγ, RARβ then 
lastly pan-RXR. The data generated allowed us to speculate whether singular or 
combined forms of retinoid ligands work better in reversing damaged lung structure 









4.1.1: INTRODUCTION. Chronic Obstructive Pulmonary Disease (COPD) has 
become a social toll Worldwide and since 2007, is now considered to be the fourth 
leading cause of mortality in the UK. Through the increase in incidence rates, it has 
become more evident that there is a requirement for better therapeutic preventions 
than what is currently available (lung transplantation or oxygen therapy). The 
problem with therapies such as transplantation is finding a suitable donor which is 
time consuming and limited to a small population of patients. It is universally agreed 
that early detection and intervention, as well as far more specific and effective 
therapies for this debilitating disease is required. One possible way to treat such 
disease would be to find a way to induce diseased lung tissue to self-regenerate. 
Unfortunately, a significant barrier for such regenerative therapies is that damaged 
adult alveolar tissue seems incapable of self-renewal.  
 
There is increasing interest in the mechanism(s) underlying COPD. In mice, there 
has been an increase investigating the hallmarks of COPD; namely emphysema. To 
approach this, most studies examining the mechanisms behind emphysema have 
employed quantitative analyses on histological sections by the use of the mean chord 
intercept (Chord) length (MILI) or the mean airspace chord length (Lm) technique 
(Maden 2006). Lm is a useful and popular parameter or peripheral lung structure as it 
describes the mean distance of airspace (Knudsen, Weibel et al. 2010). The crux of 
the use of Lm is that it is not considered as a robust measurement of internal lung 
structure as it is significantly affected by lung volume changes due to simple 
inflation conditions or to altered elastic recoil (Knudsen, Weibel et al. 2010). Also 
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Lm measurement is considered to be a measurement of the entire acinar airspace, 
with alveoli and alveolar ducts combined rather than just a measurement of alveolar 
size, since probing lines explores the entire inner complexity of the airspace 
(Knudsen, Weibel 2010). Nevertheless, this measurement is appealing because it 
gives a simple and direct indication of a structural size and any changes that may 
have occurred in the lung, be that in human or experimental pathology relevant to 
human lung disease (Knudsen, Weibel et al. 2010, Hautamaki et al. 1997, Kang et al. 
2008, Mall et al. 2008, Morris et al. 2003). 
 
The discovery that alveolar regeneration can be induced by the vitamin A 
metabolite, RA represents a significant step in the intervention for a potential 
therapeutic cure for the disease.  
 
The molecular mechanisms behind the induction of alveolar regeneration through 
agents such as RA and/or its receptor agonist ligands is an important and exciting 
topic. Current investigations are underway establishing RA and receptor agonist 
ligands as therapeutic agents for chronic lung diseases. Specific RAR molecules 
involved in the promotion of regeneration has only recently been identified and on 
the basis of developmental studies, certain conclusions have been made. All 
components of RA signalling pathways are present during alveolar development, the 
binding proteins, RAR synthesising enzymes and finally the RARs and RXR (Hind, 




4.1.2: AIM. Treatment of dexamethasone in postnatal mouse pups was used to 
generate emphysematous-like features, both morphologically and morphometrically. 
These lungs also showed reduced gas-exchanging Sa. The difference between this 
model and previous COPD/emphysematous models was destructive agents were 
introduced in adult animals after they had fully matured, whereas is dexamethasone 
was introduced to newborn pups before their lungs were fully matured. Therefore 
the dexamethasone model is “distruptive” and a “destructive” model. We used a 
selection of RAR ligand to assess their regenerative properties in dexamethasone 
lungs via morphology and morphometric analysis. The results are discussed in 4.1.3. 
 
4.1.3: RESULTS. Dexamethasone-treated lungs displayed enlarged alveoli airspace 
throughout the lung (Fig 4.1.1). Alveoli cell walls appeared thin and in some cases, 
showed a presence of lymphocytic infiltrates. ATII cells in these cell walls appeared 
squamous and irregular in shape. There were areas where these cells formed clusters. 
Like VAD, an increase in vascularisation was also observed. Increase in 
vascularisation could have been due to oxidative stress due to inefficient anti-
oxidant response in these lungs. This damage suggest a contribution to structural and 
functional impairment. This may contribute to COPD pathology, inducing apoptosis, 
tissue damage as well as airway inflammation since airway epithelial cells respond 
to increased ROS levels by producing cytokines/chemokines that promote 
inflammatory cells to areas of damaged tissue. On average, this group had increased 
from 68.1± 1.0µm (control group) to 94.3 ± 2.1µm (dexamethasone group, Fig 














Fig 4.1.1: Morphology and morphometric 
analysis of dexamethasone lungs (b and d) 
compared with control lungs (a and c). H&E 
staining for general morphology. Representative 
transverse sections show typical structures of 
alveoli seen in postnatal dexamethasone and 
control mouse lungs. Alveolar airspace has 
greatly increased in dexamethasone lungs. Cell 
walls are much thinner and there is an increase in 
vascularisation in response to inflammation. Scale 
bar = 50µm 
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We examined the effects of tRA as an addition to dexamethasone-treated lungs. tRA 
was administered to dexamethasone lungs at a concentration of 20mg/ml. These 
animals were sacrificed at P90 and tRA regenerative efficacies were examined. 
These lungs were compared with dexamethasone and control lung groups (Fig 
4.1.2c). Morphological features of dex-tRA treated lungs showed small pockets of 
enlarged alveoli, but the majority of these lungs seem to resemble control 
morphological features (Fig 4.1.2a and c). In comparison with dexamethasone-
treated lungs, there appeared to be a marked increase alveolar cell wall thickness and 
increase in vascularisation. Alveolar septa were short and stumpy in dex-tRA lungs 
in comparison to dexamethasone lungs whose septae was similar to VAD lungs, 
long, thin and extended (Chapter 3.1, Fig 4.1.2b and c). This process coincided with 
an increase of alveolar volume and percentage recovery (Table 4.1.1). The average 
Lm value for this group was 81.6 ± 2.0µm (Fig 4.17). There was however some 
variation in regeneration and recovery response in this group. Of the eight animals 
generated, only two sample lungs showed complete regeneration as defined by Lm 
values close to control values (69 - 75µm). Two animals showed no response 
(Lm>85µm) so in terms of percentage regeneration, dex-tRA lungs showing 
complete regeneration gave a value of 75%, whereas dextRA lungs showing no 
response gave a value of only 25%. The mean Sa of dex-tRA groups showed a slight 
increase of 345.4 ± 18.1cm² compared with dexamethasone group whose value was 
305.5 ± 11cm². Even though there was a slight difference between dex-tRA and 













a. Lung Morphology  b. Lung Morphology  c. Lung Morphology  
Control Mouse   Dex Mouse   Dex-tRA Mouse   
Fig 4.1.2a-c: Lm. Morphology of postnatal mouse lung (H&E staining). Representative transverse sections show typical structure of 
alveoli seen in postnatal dex-tRA mouse lungs (c) compared with dexamethasone (b) and control mouse lungs (a). Black lines represent 






We examined the regenerative capacity of the ligand receptor agonists also 
administered in dexamethasone lungs. These animals were given a concentration 
dose of 2mg/ml, 10 times less than dex-tRA animals. This level was deemed to be 
less toxic for the ligands than the 20mg/ml dose used for tRA. These ligand groups 
were compared to regenerative properties of tRA. The first ligand to be examined 
was RARα. Fig 4.1.3a - c shows representative structural features of dex-RARα. 
H&E staining of these lungs demonstrated similar regenerative morphology and 
morphometric response to dex-tRA treatment. There was a reduction in 
vascularisation which would suggest in a positive response to inflammation and in 
the levels of cytokine/chemokine activity. In terms of Lm values, this group 
produced similar values as tRA lung groups (82.8 ± 3µm, Table 4.1.1). However, 
dex-RARα gave a slightly less recovery rate value than dex-tRA; 44%. The overall 
significant value of dex-RARα compared with dex-tRA was greater than 0.05 





Next we examined the regenerative efficiency of the induction of RARβ in 
dexamethasone-induced emphysema. The addition of this receptor was shown to 
have no morphological or morphometric improvement from dexamethasone-treated 
lungs (Fig 4.1.4b and c). H&E staining demonstrated a strong morphological 
similarity between dex-RARβ and dexamethasone lung groups. This receptor group 
showed enlarged airspace with thin cell walls and there was a slight increase in 
vascularisation when compared with control lug groups (Fig 4.1.4a - c). Their 
alveolar septae were short and stumpy. The average Lm values of this group was 
84.6 ± 2.3µm (Table 4.1.1). In terms of its recovery, this group gave a percentage 
value rate less than dex-tRA and dex-RARα lung groups which was 49%. However, 
dex-RARβ Lm values were closest to dex-RARα whose values were 82.8 ± 3.0µm, 
44% recovery (Table 4.1.1). This group also produced lower Sa average value of 
274 ± 13.8cm², which in comparison with dex-tRA of 345.4 ± 18.1cm² gave a 
difference of 70.6cm² and dex- RARα (302.2 ± 18.5) gave a difference of 27.4cm². 
Comparing dex-RARβ group with control groups (434.7 ±7.5cm²) gave a 
considerable difference of 159.9cm². This difference was even higher than control 
versus dex values (305.5 ± 10.5cm²) which gave a difference of 31.3cm².  So in 
summary of this retinoid performance, dex-RARβ gave poor performance in terms 





The next retinoid we examined for regenerative efficacy was RARγ in the 
dexamethasone group. Morphological, the induction of this retinoid showed pockets 
of “normal” looking alveoli structures, but in general, this group presented enlarge 
areas of airspace (Fig 4.1.5c). Their cell walls appeared thinner than dexamethasone 
lungs (Fig 4.1.5b). Their alveolar septa were short. Like RARα, there was a 
reduction in vascularisation in this group, again suggesting a positive response to 
inflammation. The average Lm value of this group was 87.1 ± 2.0µm (Table 4.1.1). 
In terms of a recovery response, this group delivered a percentage value of 28%, 
which was 21% lower than dex-tRA and was 72% less than the control group. When 
comparing this group with previous retinoid treatments, there was a difference of 
16% with dex-RARα and a 9% difference with dex-RARβ (Table 4.1.1). In spite of 
this increase in Lm values in comparison with the dex-tRA group, dex-RARγ Lm 
values were closest to dex-RARα (82.8 ± 3.µm). Statistically, when comparing dex-
RARγ Lm’s with the dexamethasone group, a significant value of p<0.05 was 
achieved indicating that this group was not as efficient was tRA. Sa values of dex-
RARγ lung group gave an average value of 338.7 ± 24.0cm², a difference of 6.7cm² 



















a. Lung Morphology  b. Lung Morphology  




c. Lung Morphology  
Dex-RARγ Mouse   
Fig 4.1.5a-c: Lm. Morphology of postnatal mouse lung (H&E staining). Representative transverse sections show typical structure of 
alveoli seen in postnatal dex-RARγ mouse lungs (c) compared with dexamethasone (b) and control mouse lungs (a). Black lines 
represent where the measurements for Lm are calculated. Cell walls of dex-RARγ lungs (c) appeared thin, similar to dexamethasone 
lungs (b). There were pockets of alveolar population where structure and size appeared normal. Scale bar = 50µm 
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The final retinoid we examined was a combination of ligands for RXR and for the 
purpose of this thesis was termed pan-RXR. On the surface, this retinoid group 
showed morphological features similar to control lungs (Fig 4.1.6a and c). Alveolar 
airspace and cell wall thickness appeared “normal” and identical to control lungs. 
There appeared to be a slight increase in vascularisation in comparison to control 
lungs; alveolar septae were slightly pointed. ATII cells were inconsistent in 
structure. Some appeared oval in shape whilst others squamous-like, but both 
structures were small in appearance (Fig 4.1.6b and c). The average Lm value of this 
group was 94.0 ± 3.0µm (Table 4.1.1). This value was the highest amongst the other 
retinoid treatments and was identical to dexamethasone average values; 94.3 ± 
2.1µm. This was the second time where morphological features contradicted Lm 
values. Differences in Lm values were as follows; 12µm with dex-tRA, 11.2 µm 
with dex-RARα, 9.4 µm with dex-RARβ and 6.94 µm with dex-RARγ. A non-
statistical value of 0.7460 was given when compared with dexamethasone lungs, 
deeming this retinoid treatment the worst of the retinoid groups in terms of a 
regenerative response. In comparison to dex-tRA treatment, there was a significant 
difference of 0.0079, confirming dex-panRXR lack of response to dexamethasone 
destruction. When comparing this groups Sa (242.6 ± 20.9cm²) with dex-tRA, it 
gave a an enormous difference of 102 µm. When evaluating dex-panRXR’s data 
with the previous retinoid treatments, the differences were as follows; 59.6cm² with 












a. Lung Morphology  b. Lung Morphology  




c. Lung Morphology  
Dex-panRXR Mouse   
Fig 4.1.6a-c: Lm. Morphology of postnatal mouse lung (H&E staining). Representative transverse sections show typical structure of 
alveoli seen in postnatal dex-panRXR mouse lungs (c) compared with dexamethasone (b) and control mouse lungs (a). Black lines 
represent where the measurements for Lm are calculated. Cell walls of dex-panRXR lungs (c) appeared thin, similar to 





















Fig 4.1.7: Regenerative Efficacy of retinoid response to dexamethasone effect on airway morphology. Graph shows a 
summary of how receptor agonists of retinoids respond individually to damaged lungs. RARα showed similar response to 
dexamethasone as the retinoid, tRA. This was followed by RARβ, RARγ. Pan-RXR showed no recovery response.  
* * 
Table 4.1.1: Measurements of Control, Dex, tRA, RARα, RARβ, RARγ and panRXR Lungs 




Mean Volume  
(cm²) 
Mean Sa (cm²) Mean Sa/volume 
Ratio 
Control 10 68.1±0.9 100 0.740 ± 0.015 434.7 ± 7.5 589.0 ± 7.8 
Dex 21 94.3±2.1 0 0.717 ± 0.028 305.3 ± 10.5 428.5 ± 9.5 
tRA 8 81.6±2.0 49 0.702 ± 0.038 345.4 ± 18.1 492.7 ± 13.5 
RARα 15 82.8±2.8 44 0.633 ± 0.050 302.2 ± 18.5 490.7 ± 16.1 
RARβ 15 84.6±2.3 37 0.579 ± 0.035 274.8 ± 13.8 479.9 ± 11.6 
RARγ 7 87.06±2.3 28 0.734 ± 0.047 338.7 ± 24.0 465.8 ± 14.4 
panRXR 8 94.0±2.5 0 0.561 ± 0.048 242.6 ± 20.9 436.3 ± 13.7 
ANOVA test: Data are presented as ± SEM. Table shows a summary of the difference in airspace, Sa/volume and recovery. Dex = 
Dexamethasone, tRA = all-trans-Retinoic acid, RARα = Retinoic Acid Receptor-Alpha, RARβ = Retinoic Acid Receptor-Beta, RARγ = Retinoic 
Acid Receptor Gamma, panRXR = Retinoid X receptor, Lm = Mean chord length, Sa = Surface area
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4.1.4: DISCUSSION. It is evident that the growth and maintenance of postnatal 
lungs are affected by the action of vitamin A’s active form tRA along with its 
receptor molecules, the retinoids, RAR and RXR. Numerous studies involving a 
variety of animal models have shown vitamin A to have both proliferative and 
apoptotic characteristics, an essential requirement for the normal structure and 
functioning of healthy lungs.  
 
tRA has been shown to rescue the lungs of mice and rats from dexamethasone-
induced induced inhibition of postnatal lung formation (Massaro and Massaro 1996, 
Hind and Maden 2004, Stinchcombe and Maden 2008, Seifart, Muyal et al. 2011). In 
addition, several experimental studies in rats and mice suggest that regeneration of 
lost alveolar can be achieved by tRA in the elastase and cigarette-induced 
emphysema (Massaro and Massaro 1997, Belloni, Garvin et al. 2000, Seifart, Muyal 
et al. 2011). However, a number of studies have failed to demonstrate a beneficial 
effect of tRA in other emphysematous models and indeed any beneficial effects in 
human patients (March, Barr et al. 2002, Lucey, Goldstein et al. 2003, Fujita, Ye et 
al. 2004, March, Cossey et al. 2004, Yoshimatsu, Nan-ya et al. 2009, Seifart, Muyal 
et al. 2011). Clinical trials that have taken place with patients of the disease have so 
far been marginal (Mao, Goldin et al. 2002, Mao, Tashkin et al. 2003, Roth, Connett 
et al. 2006, Frankenberger, Heimbeck et al. 2009, Seifart, Muyal et al. 2011). The 
reasons for these discrepancies are still unclear, although potential mechanisms 
underlying the beneficial effects of tRA in dexamethasone-induced impairment of 
alveolarization have been suggested. Only little is known about the molecular 
mechanisms contributing to its potential regenerative effects in the smoking or 
elastase-induced models of emphysema (Liebeskind, Srinivasan et al. 2000, Mao, 
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Goldin et al. 2002, Mao, Tashkin et al. 2003, Maden 2006, Massaro and Massaro 
2006, Roth, Connett et al. 2006, Zhao, Wang et al. 2006, Seifart, Muyal et al. 2011).  
 
There have also been studies where naturally occurring and synthetic retinoids have 
been used to demonstrate their regenerative abilities in animal models of respiratory 
diseases, namely emphysema, thereby signifying their potential use as therapeutic 
agents for such airway diseases. However, like most primary studies, there have 
been concerns surrounding dosing and the nature of retinoid(s) used as 
administration can lead to numerous side effects including skin irritation, lipid and 
bone toxicity and severe interference with normal embryonic development 
(teratogenic). To counteract these effects, receptor agonists have been developed 
with the intention of only activating subsets of genes in the retinoid pathway 
(Martin, Bernardon et al. 1992, Nagpal and Chandraratna 2000, Dawson and Zhang 
2002, Farmer, Zhi et al. 2003, Piu, Gauthier et al. 2005, Maden 2006). The results 
have led to specific retinoid agonists having effects on for example, promoting 
growth and cell death, gene induction and epithelia metaplasia; thus enabling 
researchers to decipher the many different characteristics of these retinoids and 
closely scrutinise the each retinoid agonist plays in the respiratory system (Sun, Yue 
et al. 2000, Pendino, Dudognon et al. 2003, Maden 2006).   
 
Focusing on the dexamethasone postnatal mouse model, we first demonstrated the 
lost of alveolar structure using this steroid and then examined the regenerative 
therapeutic efficacies of tRA and a range of four naturally occurring and synthetic 
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retinoid receptor agonists (RARs and RXRs) after administration via histology 
morphology and morphometric parameters (the measurement of alveolar airspace).  
 
As previously discussed in the introduction of this chapter and chapter 1 (1.5), 
dexamethasone permanently impairs the process of alveolarization, the critical stage 
of alveolar formation, which in healthy conditions forms the classical honeycomb 
features seen in mature lungs. By impairing this process, abnormally enlarged 
alveolar airspaces is generated with extremely thin alveolar cell walls, thus creating 
increased alveolar airspace (Lm) values and a much reduced gas exchanging Sa and 
also impairs ATII cell replication (Massaro and Massaro 1986, Chytil 1996, Hind 
and Maden 2004). Dexamethasone is used to treat infant with lung disorders such as 
bronchopulmonary dysplasia (BPD), but only as a short-term treatment, as long term 
will lead to the clinical features mentioned above. To amend this architectural 
damage, Hind and Maden showed this model to be highly responsive to tRA because 
new septae was induced, resulting in an increase in the number of alveoli, a decrease 
in Lm values and an increase in gas exchanging Sa.  
 
Individually, we examined retinoid agonist receptor molecule regenerative efficacies 
after the administration of dexamethasone-induced emphysema and compared 
results with tRA treatment of these dexamethasone lungs in this study. The first 
retinoid we examined was RARα. This retinoid group of lungs showed increase in 
septal thickness and a significant decrease in alveolar airspace when compared with 
dexamethasone-treated lungs. An increase in ATII cell population was indicative of 
alveolar regeneration. Comparing RARα-treatment with tRA-treatment showed 
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strong correlation between the two treatments, indicating that RARα may be 
considered potentially as a good candidate for alveolar regeneration. Overall 
calculated values for this group showed that this retinoid was only slightly higher 
than tRA; 82.8 ± 3.0µm (RARα) and 81.6 ± 2.0µm (tRA) for Lms. The average 
difference was only 1.2µm and there was only a 5% less recovery rate in this 
retinoid group compared with tRA treated groups with a p value difference of 
0.6667, confirming RARα’s strong regenerative properties. Perhaps, it could be 
argued, because of its high performance, if this retinoid had continued slightly 
longer, it could be argued that it may have shown even better results than tRA, as 
RARα is known to enhance alveolar septation and is required for normal 
morphogenesis (Mahadeva and Shapiro 2002). The next two retinoids examined 
were RARβ and RARγ. These two retinoid groups showed similar structural 
performances. Both alveolar cell walls were extremely thin and in fact resembled 
structural features seen in dexamethasone treated lungs. Both groups showed areas 
of ATII cells located in the alveolar epithelia to be squamous-like, a feature also 
seen in the dexamethasone group, but unlike the RARγ group, RARβ group showed 
a slight increase in vascularisation, again similar to the dexamethasone group. 
Previous studies have shown that RARβ has positive regenerative properties in 
injurious lungs. Studies have also been shown to be required for morphogenic 
formation as well as gene expression in the form of Fgf10 (fibroblast growth factor) 
and bud formation in the lung (Desai, Malpel et al. 2004, Desai, Chen et al. 2006). It 
was demonstrated when endogenous RARβ is deactivated, Fgf10 expression is 
disrupted which is a significant feature as Fgf10 possess broad mitogenic and cell 
survival and is involved in a variety of biological processes including embryonic 
development, cell growth, morphogenesis, tissue repair, tumour growth and 
166 
 
invasion. However, this was not established in this study. It may be that in the 
dexamethasone postnatal mouse model, RARβ needs to be administered at a much 
earlier stage of injury. RARβ non-responsiveness to regeneration has also been 
shown in clinical trials where genetically induced emphysematous patients showed 
no obvious lung function improvement, but showed mild side effects, which 
included skin irritation. On the other hand, RARγ is supposedly expressed in the skin 
and lung of adult mice. It is highly expressed in lung fibroblasts immediately after 
birth, so it is surprising that this retinoid showed a poor performance in our postnatal 
model (Kastner, Krust et al. 1990, McGowan, Harvey et al. 1995, McGowan, 
Jackson et al. 2000). Morphometric analysis calculating the overall performance of 
the retinoids used was slightly contradictory with RARγ agonist when comparing its 
regenerative efficacy with tRA. For example even though morphologically, RARγ 
gave some good structural alveolar features, morphometric analysis showed that this 
retinoid was in fact the worst of the RAR agonists in terms of recovery. Values were 
almost identical to dexamethasone-induced emphysematous lungs and indeed gave a 
non-significant p value of p=0.7460, confirming that in this instance, RARγ is 
perhaps not required during the postnatal period of lung development. panRXR was 
the only retinoid that did not give a recovery response. In previous regenerative 
studies of emphysematous animal models RXR showed recovery, but using 
individual compounds of receptor molecules. However, in our model, maybe 
because we used a combination of the receptors counteracting with each other, 
regeneration was not accomplished. The order of efficacies was as follows: tRA> 
RARα>RARβ. Because the other two compounds were not statistically significant, 





Data obtained from this study implies that the mechanism of alveolar regeneration 
by retinoids involves the action of an RAR and not a RXR agonist, although, as just 
mentioned, panRXR made it difficult to determine its true efficacy. Nevertheless, the 
regenerative action of RAR is a common finding in retinoid biology because a 
RAR/RXR heterodimer is receptor dimer. On the basis of this study, it would seem 
that the agonist RARα is the active heterodimer component in alveolar regeneration. 
The fact that RARα has been shown to play a role in alveolus formation, not in the 
immediate postnatal period, but between the ages of 14 to 50 days supports our 
agonist data because this is the exact period we administered retinoid treatment. So 













4.1.5: SUMMARY. The lung is a major tissue for storage of retinol as retinyl esters 
(Liu 2005, O'Byrne, Wongsiriroj et al. 2005, Gudas 2012). Exogenous RA can 
stimulate retinol uptake and storage in the lung. From the data and previous studies 
presented, we can conclude that the three RAR molecules play distinct roles in the 
mouse lung. RARα is need for alveoli population in the postnatal period whereas 
RARβ functions to inhibit alveoli formation, thus creating a balanced equilibrium 
and that RARγ may produce new alveoli, but at a much slower rate. RARγ is known 
to be required for the first few weeks after birth for the completion of lung formation 
(Gudas 2012). It may be that a combined effect of RARα and RARβ may be 
required to not only produce new alveoli, but to also prevent overproduction of new 
















THE REGENERATIVE EFFECT OF 
RETINOIDS ON AIRWAY PROGENITOR 













OBJECTIVES: Respiratory diseases trigger airway progenitor cells such as Clara 
cells of the bronchiole airway epithelium and ATII cells of the alveolar airway 
epithelium. The present study was designed to examine Clara and ATII cells in 
response to injury and repair of the airway epithelium following the administration 
of retinoid ligands after induced emphysematous created by dexamethasone in 
postnatal mouse lungs. By using biomarkers CC10 (for Clara cells), SP-C (for ATII 
cells), PCNA (for proliferation) and TTF-1 (for Nkx2.1 transcription marker), we 
were able to demonstrate changes in expression and function of these airway 
progenitor cells. Expression of ATII cells in dexamethasone-treated lungs showed a 
much reduced cell population in the alveolar epithelium when compared with 
control animals. It suggested that this was due to cell differentiation of ATII cells to 
ATI cells. There was no immediate change in the level of expression with Clara cells 
in bronchiole airway epithelium of dexamethasone animals when compared with 
control animals, however, there were distinctive cellular changes of these progenitor 
cells. The structure of these cells appeared squamous-like and irregular in shape 
alone the bronchiole epithelium and there was no real evidence of Clara cell 
proliferation, suggesting functional alteration. Both dex-tRA and dex-RARα lung 
groups showed a reduction in Clara cell population but Clara cell proliferation 
indicating bronchiole epithelial regeneration. Dex-RARβ, RARγ and pan-RXR lung 
groups showed basal proliferation, but not Clara cell proliferation suggesting repair 






4.2.1: INTRODUCTION. The main function of progenitor cells in the airway 
epithelium is homeostasis and repair if defected walls of the airways (Giangreco, 
Arwert et al. 2009). These defects may be due to trauma brought on by mechanical 
malfunction that requires replacement of epithelial tissue. In airway diseases such as 
asthma, COPD and CF, the airway epithelium is damaged and subsequently requires 
repair or regeneration to take place (Hajj, Baranek et al. 2007, Coraux, Roux et al. 
2008, Burgess, Hu et al. 2009, Tzortzaki and Siafakas 2009).  
 
Repair or regeneration of damaged airway epithelia by disease is a major field where 
progenitor cells have an essential role. However, in contrast to some tissues, such as 
gut, haematopoietic system, skin and hair follicles, adult progenitor cells in the lung 
are ill defined. Adult progenitor cells are not immortal and show decreasing 
telomere length with increasing age of the individual, which may result in the 
inability to repair/regenerate the onset of damage created by chronic disease. The 
possibility to manipulate adult progenitor cells later in life could potentially improve 
chronic airways diseases such as emphysema.  
 
The wall of the trachea and bronchi in the normal mammalian airway consist of a 
surface epithelium with ciliated, brush, basal and secretory cells that rest on a 
basement membrane, followed by layers of connective tissue and smooth muscle and 
finally cartilage, the bronchiole lack cartilage. The epithelium in the major bronchi 
and proximal bronchioles is a ciliated, pseudostratified epithelium with ciliated 
columnar cells as the predominant cell type; in the distal bronchioles the epithelium 
consists of a single cell layer. The ciliated columnar cells reach the basal lamina 
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with slender basal processes the function of the brush cells of the airway epithelium 
is not completely known (Shebani, Shahana et al. 2005). These cells lack cilia and 
may be involved in detoxification, act as a sensor for airway surface liquid or may 
have a chemoreceptor function. Various secretory cells (goblet cells in the trachea, 
bronchi and proximal bronchioles, Clara cells in the bronchioles and intrapulmonary 
airways) comprise around 20% of the bronchial and nasal epithelium and produce 
airway secretion (fluid and mucus). In addition, Clara cells secreted Clara cell 
secretory protein, an immuno-regulatory protein (Synder, Drobniewski et al. 2009). 
The walls of the alveoli consist of squamous ATI and surfactant-producing ATII 




Fig 4.2.1: Cellular mechanism of regeneration of ATII cells and differentiation of 




Under healthy conditions, there is to a certain degree cell turnover in the airways. 
Tissues with a relatively slow cell turnover, use self-renewal of differentiated cells 
as a strategy for tissue regeneration (Rawlins and Hogan. 2006). In addition, damage 
to the airway epithelium occurs frequently e.g. due to the components of smoke, air 
pollution or bacterial and viral infections, either from direct effects of these 
microorganisms or due to an inflammatory reaction that follows infection. Normally 
in the case of small lesions, airway epithelium possesses repair mechanisms that 
restore normal structure. However, if the damage becomes chronic, e.g. in COPD 
patients, the repair process is more extensive and is called airway remodelling (Folli, 
Descalzi et al. 2008). Airway regeneration appears to be controlled by bronchial 
epithelial and endothelial cells of the bronchial vasculature (Zani, Cordischi et al. 
2008). Of these two cell types, the bronchial epithelial cells have received by far the 
most attention whereas little is known about the role of endothelial cells (Rawlins, 
Hogan. 2008, Rawlins, Okubo et al. 2009). ATII cell injury impairs normal 
production, secretion and recycling of pulmonary surfactant. This in turn leads to 
loss of surface tension-reducing phospholipids, alveolar instability and collapse 
(Lewis, Jobe. 1993, Greene, Wright et al. 1999).  
 
Additional work suggest that Clara cells and macrophage signalling is critical for the 
response to injury as measured by production of epithelial and macrophage specific 
chemokines and cytokines. This process is initiated by secretion of paracrine 
signalling molecules from macrophages such as tumour necrosis factor (TNF)-α that 
target the airway epithelium as an intermediate signalling cell type required for 
production of neutrophilic chemotatic factors (Elizur, Adair-Kirk et al. 2008). 
Collectively, these results indicate that the distal airway and respiratory epithelial 
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cells play a prominent role in providing important immuno-regulatory properties 
essential for the regulation of innate immunity. 
 
Among the many functions of Clara cells is secretion of Clara cell secretory protein 
and is the predominant protein product of emphysema whose expression 
precipitously declines in COPD. Data suggest that epithelial secretion is 
compromised as a result of epithelial remodelling and Clara cell injury in the setting 
of COPD. Through precise differentiation of cell types organized within functional 
zones, relative to anatomical location, the epithelium plays an active role in host 
defence. Collectively, this data indicates that airway epithelial specification, 
effective repair and maintenance are critical for lung homeostasis. Defects to these 
processes or significant epithelial remodelling may contribute to COPD through 
altered epithelial function and perturbations to the host defence properties of the 
lung.  
 
Understanding the aetiology and progression of COPD is complicated due to the 
complex network of cellular cross-talk present in the lung. Defective airway 
epithelial repair has been proposed as an early event in the initiation of COPD and 
chronic defects in reparative capacity and cellular composition may further 
contribute to disease progression and susceptibility (Holgate, Holloway et al. 2004). 
This implies that normal functions for facultative progenitor and stem cells are 
compromised. Evidence suggesting that this may be the case comes from analysis of 
biomarkers of epithelial remodelling that have been used to follow severity and 




4.2.2: AIM. tRA plays a key role in the development and differentiation of many 
cell types within the lung. Transcriptional factors mediate the majority of RA 
functions and other transcriptionally active RA metabolites. (Gudas. 2012). The 
mechanisms that control levels and activities of enzymes that produce metabolites 
such as RA from retinol are not quite fully understood (Linke, Dawson et al. 2005, 
D’Ambrosio, Clugston et al. 2011, Kumar and Duester. 2011, Lee, Kim et al. 2011). 
Importantly, levels of endogenous retinoids are altered in many different diseases 
contributing to the pathophysiology. In many cell types, RA promotes cell 
differentiation and proliferation.  
 
The aim of this study was to establish lung regeneration from retinoid ligands 
through progenitor cell growth. We examined ATII and Clara cell population with 
view to proliferative and transcriptional activity of these two cell populations. The 
basic behaviour of progenitor cells, their molecular regulators and how each is 
impacted by disease would provide novel insights into the pathogenesis of disease 
and reveal new therapeutic targets that may allow modifications in the outcome of 
disease. Furthermore, understanding the effects of abrogating epithelial repair on 
modulation on the epithelial function will be equally important, especially as it 







4.2.3: RESULTS. IF Single labelling detection of Progenitor Cells: To 
investigate whether retinoid ligands promote repair/regeneration in dexamethasone-
induced emphysema, we ran a series of experiments examining the airway 
progenitor cells, Clara (bronchi tree) and ATII (alveolar) cell expression along with 
transcriptional and proliferation activity in postnatal mouse lungs. Table 4.2.1 
summarises the number of Clara cells expressed as the percentage mean of 
bronchiole airway epithelial cells. In control lungs the Clara cell marker, CC10 was 
demonstrated in the bronchiole epithelium. Expression was achieved via IF labelling 
of paraffin embedded sections measuring 5µm in thickness. CC10-positive Clara 
cells in these lungs displayed the classic tall columnar dome-shape with a “cap” on 
top of each cell (Fig 4.2.2a). Cells were not shown to be expressed throughout the 
bronchiole epithelium, there were patchy areas of staining in each bronchiole 
confirming no cellular expression. Bronchioles in dexamethasone-treated lungs 
demonstrated an increased level of expression of CC10-positive Clara cells in 
comparison with control lungs (Fig 4.2.2b). However, structural differences between 
CC10-positive Clara cells in dexamethasone and control in the bronchiole 
epithelium were evident. Cells in this group did not display the classical tall 
columnar dome shape with a cap on top; instead some presented themselves as flat 
(shown in Fig 4.2.2b) whereas others appeared dysplastic. It is conceivable that an 
increase in CC10-positive Clara cells would be detected in this group of lungs as 
Clara cells play an important defensive role and contribute to the degradation of 
mucus production by the upper airways. Statistical analysis revealed an average cell 
count of 253 ± 4.4 in dexamethasone lung groups compared with control lung 




We compared the response of Clara cells to the induction of tRA after 
dexamethasone lung injury (Fig 4.2.2c). The morphology of these cells in this group 
appeared tall columnar similar to that observed in control lung groups. There were a 
few differences in this group in comparison to control groups. Cells were thinner of 
suggesting less secretory CC10 protein. Cells were tightly packed along the 
epithelia, but there was a reduction in the number of positive cells. The average cell 
count was 134.8 ± 7.3. There was a significant difference between dex-tRA and 
dexamethasone lung groups; the p value was <0.01. Its classical domed cape shape 
situated on the tops of cells had also returned.  
 
We next examined the effect of RARα ligand on Clara cells. Morphology of these 
cells in this group showed a bigger improvement in this group. These cells were not 
only tall columnar and domed shaped with a cap on the apical surface of each cell, 
but more importantly, they appeared more filled out than positive CC10-Clara cells 
in dex-tRA lung groups (Fig 4.2.2d). Cell population in dex-RARα group had also 
improved in comparison to dex-tRA lungs. They had risen from 134.8 ± 7.3 to 146.3 
± 7.0. Again, the significant value in the difference of Clara cell response in 
dexamethasone and dex-RARα was p<0.01.  
 
The morphological appearance of CC10-positive Clara cells in dex-RARβ lungs 
appeared damaged (Fig 4.2.2e). These cells looked severely dysplastic and had lost 
their classical morphological appearance; they were squamous-like in shape. There 
were areas along the bronchiole epithelium where CC10 expression was intermittent. 
Cell counts in this group of lungs were difficult to calculate because it was difficult 
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to view them as individual cells. Nevertheless, the average cell count for this lung 
group was 128.5 ± 2.0 compared to dexamethasone (253 ± 4.0) and control (189.4 ± 
13.2). This group expressed fewer cells than dex-tRA lung group (134.8 ± 7, Fig 
4.2.4). Again, when this group of regenerative lungs were compared with 
dexamethasone, there was a significant difference, p <0.01 (Table 4.2.1). 
 
Next, we examined the effects of RARγ ligand. The morphology of CC10-positive 
Clara cells showed much improvement in cell morphology when compared with 
Clara cells of dexamethasone lungs (Fig 4.2.2f). Cell morphology was similar to 
dex-RARα, but again like CC10-positive Clara cells in dex-RARβ lungs there was 
not much improvement in the level of expression and therefore showed no 
significant difference between the two groups, but was between dex-RARγ (123. 9 ± 
6) and dexamethasone (253 ± 4) groups. The p value was also <0.01.  
 
The final retinoid to be examine for Clara cell response to regeneration was 
panRXR. Clara cells that were positive for CC10 were tall columnar in morphology 
and were domed-shaped (Fig 4.2.2g). Cells in this group had a low expression. Cells 
that were present were evenly spaced with areas of absent cells (127.4 ± 8, Fig 4.2.3 
and 4.2.4). Compared with other retinoid ligands, this number proved to be less than 
any of the other retinoid ligands used for regeneration of dexamethasone lungs. 
















Fig 4.2.3: Graph shows mean Cell counts of CC10-positive Clara cells (±) SEM in the bronchiole epithelium of dexamethasone 
and various retinoid ligand treatments. Statistical analysis was done by one-way ANOVA and Bonferroni post-test. P<0.01 * 
represents P=0.004. Average cell counts show an increase in CC10-positive Clara cells in dexamethasone lung groups suggesting 
a response to injury/bronchiole repair with reduction of cells in retinoid ligands. The reduction of cells in retinoid ligand lung 
groups could suggest the ligands response to inflammation promoted by dexamethasone.    
  * 
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Table 4.2.1: One-way ANOVA followed by Bonferroni post-correction test for CC10-positive Clara cells in postnatal mouse lungs  
 Control Dex tRA RARα RARβ RARγ Pan-RXR 
Mean 208.40 253.00 134.75 146.267 128.467 123.857 127.375 
SD 41.81 20.15 20.44 28.96 7.51 15.03 21.49 
SEM 13.22 4.40 7.23 7.48 1.94 5.68 7.6 
N 10 21 8 15 15 7 8 
Dexamethasone treated lung showed a significant increase of CC10 levels of secretion compared to retinoid treated lungs. This could signify a 
response to inflammation. 
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SP-C/ATII positive cells were restricted to the alveolar airway epithelium. 
Expression demonstrated in control lungs showed SP-C/ATII cells surrounding 
alveoli nuclei. These cells were cuboidal in shape and fairly uniform (Fig 4.2.4a). 
Most cells in this lung group appeared enlarged and granulated possibly indicating 
cell proliferation. There was no indication of SP-C staining demonstrating ATI cells 
in these lungs. Following dexamethasone treatment, SP-C/ATII cells were less 
cuboidal, much thinner in structure. These cells did show granulation, but also cells 
that were squamous-like suggesting proliferation and differentiation taking place 
along the alveolar epithelium (Fig 4.2.4b). The average cell counts for control and 
dexamethasone groups were as follows; 312.6 ± 13.6 and 282.9 ± 5 respectively (Fig 
4.2.5, Table 4.2.2).  
 
We examined the effect of tRA on the cellular structure and population of ATII 
cells. tRA proved to be most efficient in the reversal of dexamethasone effects on 
this cell population. The average cell count for this group was 336.6 ± 21 (Fig 4.2.5). 
The difference between dexamethasone and dex-tRA lung groups gave a p value of 
0.01. Morphologically, SP-C/ATII cells in this group were similar to those observed 
in control lungs, cuboidal, large and granular (Fig 4.2.4c). There were some cells 
that had lost their morphology structure. These cells were squamous-like, so could 
have been ATII cells, there did not appear to be as much of these cells present in this 
group as there were in the dexamethasone group.  
 
Dex-RARα lung group had a higher SP-C/ATII population than dex-tRA and control 
groups but cellular structure was irregular and did not appear granular (Fig 4.2.4d). 
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Cells in this group were much smaller and quite spacious. Cell numbers for this 
group were as follows; 372.7 ± 9.9 (Fig 4.2.5, Table 4.2.2). SPC-ATII cells 
presented in dex-RARβ lung group had a low population. Morphological appearance 
was similar to cells shown in dex-RARα, small, spacious and non-granular. They did 
not appear cuboidal. Average cell count for this group was 183.1 ± 7 (Fig 4.2.5, 
Table 4.2.2). There appeared to be a mixture of ATII and ATI cells in dex-RARγ 
with no appearance of granulation (Fig 4.2.4f). Finally, we examined the efficacy of 
pan-RXR. The morphology of ATII cells were mostly squamous-like in appearance 
and were small. These cells were very similar to cells observed in RARβ and RARγ 
lung groups (Fig 4.2.4g). Cell counts for this group was 127.4 ± 8 (Fig 4.2.5, Table 
4.2.2). Comparing these three retinoid ligand with tRA showed that their 
regenerative performance was less efficient and RARα was proven to be the overall 
best ligand in terms of this mouse model. The overall outcome of this study showed 
ATII to respond to dex-RARα readily than the other retinoid ligands. The other three 
ligands may have had a lower ATII population, but from observations of IF staining 







Table 4.2.2: One-way ANOVA followed by Bonferroni post-correction test for SP-C/ATII cells in Postnatal mouse lungs.  
 Control Dex tRA RARα RARβ RARγ Pan-RXR 
Mean 312.6 282.9 336.6 372.7 183.1 127.4 123.9 
SD 42.9 21.2 59.8 38.3 26.8 22.1 40.2 
SEM 13.6 5.0 21.1 9.9 7.0 15.1 14.2 
N 10 21 8 15 15 7 8 
Dexamethasone treated lungs shows a significant decrease in expression of SP-C protein and therefore a decrease in the number and 
structural abnormality of ATII cells secreting surfactant. This suggests damage has occurred to the alveolar airway epithelium. Equally, 
tRA and RARα lung groups show an increase in the expression of SP-C and therefore an increase in the number of ATII cells and a 




IHC detection of Nkx2.1 using the antibody TTF-1 showed similar pattern of 
expression observed with SP-C/ATII cells in the alveolar and bronchiole airway 
epithelia in control lungs (Fig 4.2.6 and 4.2.7). TTF-1 staining was strongly 
expressed in alveolar epithelium. Expression in dexamethasone treated lungs was 
also strong, but there was a reduced number of cell population. The average cell 
count for control and dexamethasone were 320.5 ± 10 and 279.7 ± 3 respectively. 
This correlation was deemed statistically different; >0.01 (Fig 4.2.8, Table 4.2.3). 
This reduction of TTF-1 staining coincided with expression of SP-C/ATII cells in 
dexamethasone lungs. Dex-tRA lungs showed much improvement in TTF-1 
expression. Expression was strong. Pattern of staining was uniform in expression in 
alveolar epithelium and indicated epithelial regeneration. This expression was 
extremely similar to that observed in control lungs (Fig 4.2.7c). Expression in this 
group of lungs suggests tRA aids the promotion of alveolar epithelial 
repair/regeneration. Average cell counts for TTF-1 in this group was 346.7 ± 13.3 
confirming upregulation of Nkx2.1 transcriptional activity in alveolar epithelia. 
Expression of TTF-1 in dex-RARα showed to be spacious and strongly stained. 
Again expression was similar to TTF-1 expression in control lungs, cells were 
cuboidal and nuclear. Calculation confirmed an upregulation of TTF-1 staining in 
this group when compared with tRA, control and dexamethasone lung groups (Fig 
4.2.6d). The average cell counts of TTF-1 staining in this group was 388.9 ± 9.4 (Fig 
4.2.8, Table 4.2.3). Expression of TTF-1 in dex-RARβ was low, as was SP-C/ATII 
staining. There were very few cells in the region of the alveolar epithelium, any 
present in the location was quite hard to detect. Average cell counts for TTF-1 was 




Dex-RARγ also gave low detection, but were much higher than dex-RARβ. Cellular 
expression was also easier to detect in this group of lungs, but cells presented in this 
group of lungs were sparse (Fig 4.2.6f). Average cell counts for this group was 205.7 
± 11 (Fig 4.2.8, Table 4.2.3). Finally we examined expression pattern of TTF-1 in 
dex-panRXR. Staining was similar to dex-RARα. Positive cells were cuboidal and 
nuclear in morphology and strong in expression (Fig 4.2.6g). There were areas 
where the staining was sparse, but nevertheless, expression was high. Cell counts for 
this group was 236 ± 13 (Fig 4.2.8, Table 4.2.3).  
 
TTF-1 expression in the bronchiole epithelium was strong in control lungs. Cells 
were tall columnar in morphology (Fig 4.2.7a). There were obvious differences in 
the expression of TTF-1 staining in dexamethasone. Firstly, there was a reduction of 
TTF-1/Nkx2.1 staining and the morphology of these cells were squamous-like along 
the bronchiole epithelium (Fig 4.2.7b). The average cell count of these cells were 
266.5 ± 9 in control lungs and 115.3 ± 1.1 in dexamethasone lungs (Fig 4.2.8, Table 
4.2.3). These values too gave a significance of >0.01. The level of expression 
observed in dexamethasone lungs suggest that SP-C/ATII cells are dependent on 
Nkx2.1 signalling, but not CC10/Clara cells in this particular mouse model. TTF-1 
staining in dex-tRA bronchiole was weak and appeared to have altered pattern of 
expression from that of control. TTF-1 appeared to be outlining goblet cells lining 
the epithelia. Cellular expression of TTF-1 in this group of lungs was less than 
control and dexamethasone. Expression seem to coincide with CC10/Clara cell 
staining where there was a much reduced number of cells in control and 
dexamethasone groups. This suggests tRA may not be involved in bronchiole 
repair/regeneration. The average cell count of TTF-1 was 196.6 ± 5 (Fig 4.2.8, Table 
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4.2.3). TTF-1 expression in the bronchioles of dex-RARα was columnar and 
strongly stained. There were areas where there was no staining, same patterning as 
control lungs (Fig 4.2.6d). This suggests that RARα is also vital for the 
repair/regeneration process in bronchiole epithelium and therefore repair and 
regeneration of the lung as a whole. Average cell counts for this group of lungs was 
as follows; 188.1 ± 16 (Fig 4.2.8, Table 4.2.3). Staining in the bronchioles of dex-
RARβ lungs was strong, squamous-like in appearance and very similar to 
dexamethasone lung group (Fig 4.2.7e). Expression in the bronchiole was much 
better than that seen in alveolar epithelium in this lung group. Average counts was 
117.6 ± 3.0. Staining was irregular in dex-RARγ. Pattern of staining was not tall 
columnar, expression of TTF-1 was shown to be apical (Fig 4.2.7f). Average cell 
count was 95.0 ± 2 (Fig 4.2.8, Table 4.2.3). Mean was, in comparison with 
dexamethasone less, suggesting that RARγ may not have a major role in bronchiole 
repair/regeneration. Expression of TTF-1 was similar to dex-RXR expression (Fig 
4.2.7g) suggesting that these ligands are not exclusively involved in bronchiole 
epithelial repair/regeneration. The average cell count for this group was 108.4 ± 2.  
 
Overall in sequence, dex-RARα followed by dex-tRA gave the most positive results 
in promoting TTF-1 transcription activation for regeneration to occur. This set of 
results coincided with previous data obtained in this thesis where both derivatives 
















Table 4.2.3: One-way ANOVA followed by Bonferroni post-correction test for TTF-1 Expression in parenchyma  
Alveolar Control Dex tRA RARα RARβ RARγ Pan-RXR 
Mean 320.5 279.7 346.7 388.9 113.1 205.7 236.0 
SD 32.09 14.42 51.64 36.32 9.77 31.14 35.47 
SEM 10.15 3.15 13.33 9.38 2.52 11.77 12.54 
Bronchiole Control Dex tRA RARα RARβ RARγ Pan-RXR 
Mean 266.5 115.3 196.6 188.1 117.6 95.0 108.4 
SD 28.91 49.72 19.83 60.12 24.91 6.47 6.46 
SEM 9.14 10.85 5.12 15.52 6.43 2.44 2.28 
N 10 21 8 15 15 7 8 
Dexamethasone shows expression confirms its effect on epithelial cells in response to injury. There is a correction of TTF-1 and SPC 
expression. Where there is a reduction of TTF-1, there is also a reduction in SP-C and vice versa when TTF-1 is upregulated in alveolar 
epithelium suggesting TTF-1 regulates ATII secretory surfactant postnatally. However, where there was a reduction of TTF-1 there was 
an upregulation of CC10/Clara cell in the bronchiole epithelium suggesting that these cells are independent of transcriptional regulation 
postnatally in this model of injury.  
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IF double labelling of CC10 and SP-C with PCNA: Following the demonstration 
of Clara and ATII cells during and after lung injury, we investigated cellular 
proliferation as part of bronchiole/alveolar repair/regeneration of the epithelium. As 
noted, Clara cells generally proliferate at a slow rate. In order to establish cellular 
proliferation, we employed PCNA which is known to be important for DNA 
synthesis and DNA repair. We first examined Clara cell proliferation. 
 
We noted that there was high proliferative activity within the bronchiole epithelia of 
control lungs. Amongst this, basal cell proliferation was extremely high, but no 
presence of Clara cell proliferation (Fig 4.2.9a). There was also no Clara cell 
proliferation observed in dexamethasone lungs. There were also fewer proliferating 
basal cells in this lung group (Fig 4.2.9b). Nevertheless, we carried out basal cell 
counts. The average counts for these cells was 85 ± 3 in control and 49 ± 1 (Fig 
4.2.10, Table 4.2.4). When examining dex-tRA, we observed Clara cell proliferation 
within the bronchiole epithelia (Fig 4.2.9c). There was strong colocalisation between 
CC10/PCNA, however, this feature was not prominent throughout the epithelium. 
Expression suggested damage to the bronchiole epithelia caused by dexamethasone 
was going through the process of repair/regeneration in this lung group. The average 
cell counts for this group was 70 ± 5 (Fig 4.2.10). Because this cell count was for 
Clara cell proliferation and not basal cell, we did not compare statistical analysis 
with dexamethasone and control groups. The same proliferative results seen in dex-
tRA lungs were seen in dex-RARα (Fig 4.2.9d). Just as was observed in dex-tRA, 
not all Clara cells underwent proliferation, but like in dex-tRA lung group, we 
concluded that this showed a degree of bronchiole epithelial repair/regeneration. 
Again, because control and dexamethasone lung groups did not show Clara cell 
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proliferation we did not compare dex-RARα with either group. We did however 
calculate a comparison between dex-tRA and dex-RARα (Fig 4.2.10). The average 
cell count for this group was 80 ± 4 compared with dex-tRA (70 ± 5). The p value 
between these two groups was <0.05 deeming this non-significant. Dex-RARβ 
showed basal cell but not Clara cell proliferation (Fig 4.2.9e). The average cell count 
for this group was 50 ± 1. Comparing this average with dexamethasone showed no 
significant difference between the two groups (Fig 4.2.10). Again there was no 
presence of Clara cell proliferation in dex-RARγ lungs and very little basal cell 
proliferation (Fig 4.2.9f). The average cell count for this group was 80 ± 2 (Fig 
4.2.10). Finally dex-panRXR were examined. Like dex-RARβ and dex-RARγ, this 
group did not show any Clara cell proliferation, but did show basal cell proliferation. 
This was seen along the bronchiole epithelium (Fig 4.2.9g). The average cell count 
was similar to control lungs; 83 ± 3 (Fig 4.2.10).    
 
Both basal and Clara cells are involved in bronchial repair and regeneration. From 
the results of the cell counts (Fig 4.2.10) we concluded that dex-RARβ gave the least 
repair/regenerative response to epithelial damage because basal cell numbers were 








Fig 4.2.9:  IF double-labelling of proliferative Clara cells in postnatal lungs. 
Control, dexamethasone, dex-RARβ, dex-RARγ and dex-panRXR lung groups did 
not express proliferative Clara cells, but did express basal cell proliferation. There 
was no significant difference between dexamethasone and dex-RARβ. There was a 
low number of proliferative basal cells in dexamethasone lungs (not shown). Dex-
tRA and dex-RARα lung groups expressed. Scale bar = 100µm 
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Control: CC10/PCNA Dexamethasone: CC10/PCNA Dex-tRA: CC10/PCNA 

























































            Table 4.2.4: One-way ANOVA followed by Bonferroni post-correction test for Basal/CC10 proliferation in Bronchiole  
Bronchiole Control Dex tRA RARα RARβ RARγ Pan-RXR 
Mean 85 49 70 80 50 80 83 
SD 8.7 6.8 20.5 16.4 6.3 6.6 7.6 
SEM 3.0 1.0 5.0 4.0 1.0 2.0 3.0 
N 10 21 8 15 15 7 8 
tRA and RARα were the only two lung groups that demonstrated Clara cell proliferation. All the other lung groups demonstrated basal 
cell proliferation, but not Clara cells.  
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During epithelial injury, ATII cells are said to not only proliferate, but to also 
differentiate into ATI one cells. There is evidence to suggest that irritants such as 
cigarette smoke can induce alternations of surfactant producing cells (Hohlfield et al. 
1997). In the dexamethasone lung, the number of proliferative SP-C positive ATII 
cells had greatly decreased 62.8 ± 2 (Fig 4.2.11b, Fig 4.2.12, Table 4.2.5). This 
could possibly be due to ATII cells transdifferntiating into ATI cells. Like chapter 
3.2, we did not carry out experiments demonstrating cell differentiation with SP-C 
positive ATII cells, so we can only assume this to be the case. There was a high 
level of ATII cells in control lungs (Fig 4.2.11a). This is a process not necessary 
seen in human lungs. High proliferative performance of ATII cells in control lungs 
maybe mouse species-related as this expression pattern is not seen in all mouse 
models.   
 
When examining dex-tRA lung group, morphologically, we observed strong 
proliferative activity of ATII cells (Fig 4.2.511c). There was strong colocalisation of 
these two proteins within the alveolar airway epithelia. This showed that ATII cells 
responded well to tRA, suggesting that tRA is a good repair/regenerative agent in 
this mouse model.  Again, no differentiation markers were used to decipher as to 
whether these cells were also differentiating into ATI cells nor did we stain for ATI 
cells to suggest restorative population of ATI cells, thus confirming as to whether we 
could conclude that there was alveolar epithelia repair. Nevertheless, this result was 
a good starting point for examining regenerative epithelia in this lung group. The 
average cell count from this group was 84.2 ± 2.2 confirming high proliferative 
performance in this group (Fig 4.2.12, Table 4.2.5).  Dex-RARα lung group showed 
a high degree of colocalisation between PCNA and SP-C-positive ATII cells (Fig 
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4.2.11d). In fact this group showed hyperproliferative activity of ATII cells because 
virtually all SP-C-ATII cells were positive for PCNA. There was also strong 
proliferative activity along the alveolar epithelium which were not SP-C/ATII cells.  
 
Dex-RARγ showed a significant number of proliferating ATII cells in the alveolar 
epithelia (Fig 4.2.11f). Cells were sparse and the number of proliferative cells was 
almost half the number of the overall average number of ATII cells present in this 
group. The average cell count for this group was 78.5 ± 9 (Fig 4.2.12). This was a 
significantly high difference of proliferative promotion between lung groups. It also 
gave a statistical p value of p = <0.01. The performance of this group matched the 
performance of dex-tRA lungs, and p value between these two groups was >0.05, 
making this difference non-significant signifying identical functioning of the groups.    
 
Dex-panRXR lungs showed a number of proliferating ATII cells. The majority of 
these cells showed proliferation occurring around capillary epithelia (Fig 4.2.11g). 
This group of lungs showed a clustered population of proliferative ATII cells, but 
due to the overall morphology of the lungs the actual number of proliferative cells 
present was not as much as expected. However, this group proved to contain more 
proliferative ATII cells than in dexamethasone lung groups (Fig 4.2.11b) and dex-
RARβ. The average cell count for this group was as follows; 47.4 ± 8.1in 
comparison with dexamethasone lung group; 62.8 ± 2 (Fig 4.2.12, Table 4.2.5). 
From this statistical analysis, it showed that this retinoid had made a concerted effort 











            Table 4.2.5: One-way ANOVA followed by Bonferroni post-correction test for ATII proliferation in Alveolar Epithelium  
Alveolar Control Dex tRA RARα RARβ RARγ Pan-RXR 
Mean 103.5 62.8 84.2 78.5 47.4 70.8 72.4 
SD 6.2 3.4 5.2 6.4 6.3 7.1 6.7 
SEM 3.0 1.0 5.0 4.0 1.0 2.0 3.0 
N 10 21 8 15 15 7 8 
tRA and RARα was shown to the best promoters of proliferative activity in both alveolar and bronchiole (Table 4.2.4) and therefore 
good promoters of repair/regeneration in the dexamethasone postnatal mouse model.  
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To further confirm expression changes of Clara and ATII progenitor cells along with 
their transcription and proliferative activity in dexamethasone and retinoid groups, 
we measured the protein levels. Treatment of dexamethasone was shown to slightly 
increase in CC10 levels, but a decrease in the expression levels of SP-C and TTF-1, 
strongly suggesting that in postnatal mouse lungs, surfactant is still regulated by 
TTF-1 transcription activity, but Clara cells are dependent of this transcription factor 
(Fig 4.2.13, lane 2). There was also an increase in proliferation in comparison to 
control groups (Lane 1).  When comparing CC10 and SP-C expression levels in 
regenerative groups (Lanes 3-7), CC10 expression levels were much lower in all five 
groups compared to dexamethasone and control groups. However, when examining 
SP-C expression, dex-tRA and dex-RARα lungs showed upregulation in comparison 
with dexamethasone groups, followed closely by dex-panRXR. Dex-RARβ was 
shown to have no improvement on the promotion of SP-C after dexamethasone 
treatment. Again, expression of TTF-1 mirrored similar results to SP-C expression 
levels where increase expression levels were observed in dex-tRA and dex-RARα 
and to a lesser extent, dex-panRXR lungs. All seven groups showed proliferative 
activity, dexamethasone and dex-RARβ lung groups showed the least amount of 





4.2.5: DISCUSSION. Pulmonary lung diseases are difficult to understand because 
there are such numerous components that each has its role in the clinical features 
that is poorly understood at a molecular level. The cause is often unknown and 
diagnosis through morphology may represent different disease processes. Both 
bronchiole and alveolar epithelia are early sites of damage after pulmonary insult. 
Repair of the alveolar epithelium is thought to occur by the proliferative activity of 
ATII cells with subsequent differentiation into ATII cells, thus restoring the normal 
air/liquid interfacial barrier. There is a need, particularly in lung diseases such as 
COPD/emphysema, to find effective and long lasting therapeutic treatments as there 
is currently none available. One such candidate for the task is RA and its natural and 
synthetic analogue; the retinoid receptor agonist. Vitamin A is essential for normal 
development and maintenance of epithelial tissue including the respiratory system.  
Retinoids mediate a variety of essential cellular processes including embryogenesis 
and also influences cell growth and differentiation of adult cells (Swift, Hays et al. 
2008). These processes are mediated by retinoid receptors, members of the steroid 
hormone nuclear receptor superfamily, the retinoic acid receptors, RARs and the 
retinoid X receptors, RXRs. 
 
As the airway epithelium is critical to the normal functioning of the lung, attempts to 
study this tissue layer have been carried out for decades. A number of animal and 
human in vivo and in vitro models have been elevated which mimic the airway 
epithelium in the postnatal body and which might contribute to an in-depth level of 
understanding of injury repair mechanism. Relevant models of the airway epithelium 
could also enable drug metabolism studies, the dissection of pathways important in 
207 
 
control of permeability and the study of a wide range of cellular processes at a 
molecular level.  
 
Pulmonary surfactant and Clara cell secretory protein (CCSP) are synthesised and 
secreted primarily by ATII and Clara cells in alveoli and bronchiole epithelium in 
lungs. Deficiency or disruption of these secretory proteins causes respiratory 
distress. Surfactant facilitates the spreading and enhances the stability of 
phospholipids in the alveoli and plays an important role in host defence; the role of 
CCSP is mainly defence in the form of anti-inflammatory and immunomodulatory 
functions. Transcriptional regulation of surfactant and CCSP proteins by hormones 
and tissue-specific transcription factors is the key step for elucidation of surfactant 
homeostasis in lung development and postnatal respiratory adaptation. We examined 
pattern of expression of Clara and ATII cells in our dexamethasone-induced injured 
postnatal lungs with the use of retinoid ligands for the promotion of alveoli and 
bronchiole epithelial repair/regeneration.   
 
The pattern of expression of SP-C positive ATII cells was significantly altered and 
exhibited a patchy appearance in these damaged lungs. Effective proliferation and 
differentiation of ATII cells is thought to be critical for both repair of damaged 
alveolar epithelium and the prevention of intra-alveolar fibrous tissue deposition. 
The loss of SP-C protein expression in some areas of this lung group may represent 
areas where attempted ATII cells repair was not sufficient in restoring the normal 
alveolar space. It is also possible that these areas contained less differentiated ATII 
cells that lack SP-C protein.  The airway epithelium in this model be have been 
subjected to a higher dose of dexamethasone due to the subcutaneous route of 
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administration, thus enhancing the toxic effect. Therefore the examination of the 
airway epithelium is an important step in determining the applicability of this model 
of lung injury in human respiratory situations.  
 
Examination of CC10 in dexamethasone lungs revealed severe damage to the 
bronchiole airway epithelia and may have exacerbated an inflammatory response 
which is thought to set the stage for further damage, i.e. the development of fibrosis.  
 
We examined the bronchiole epithelium for changes in the distribution and altered 
morphology of Clara cells. There was a significant increase in the number of Clara 
cells present in this group of lungs, whereas in studies where for example, 
bleomycin treatment has been employed to create injury, the results have shown a 
dramatic loss in Clara cell production although bleomycin showed epithelial cell 
damage, a feature also seen in the dexamethasone model (Daly et al. 1996). This 
finding could be related to the nature of dexamethasone, as in normal circumstances, 
it is used as an anti-inflammatory drug to treat inflammatory and autoimmune 
conditions. It has been suggested that dexamethasone does not suppress Clara cell 
production, but does severely alter the morphology and therefore the overall 
functional role of this cell, but how, if true requires further investigations.  
 
There was additional loss of Clara cells expression in all three lung groups. It may 
be that in the case of the retinoid ligands maybe sensitive or respond differently to 
toxic agents within the Clara cell population, or that subpopulations of Clara cells 
are produced in response to retinoid activity. The pronounced loss of CC10 protein 
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in the bronchiole airway epithelia in this model may be due to the route of 
administration of these retinoids and differential Clara cell sensitivity.  
 
In tRA and RARα lung groups, there were significantly higher numbers of these 
cells with high proliferative activity, which mimicked CC10 protein expression seen 
in the bronchiole airway epithelium. This highly productive activity of both 
progenitor cell populations in these retinoids is suggestive that both tRA and RARα 
are strongly involved in alveolar and bronchiole airway epithelial remodelling. ATII 
proliferation was seen in the other three retinoid agonists RARβ, RARγ and 
panRXR, but the level of SP-C protein expression did not match levels seen on tRA 
or RARα.  
 
tRA and RARα was shown to be important for the stimulation of SP-C protein 
expression at transcriptional level. RAR signalling pathway is well known to be 
critical in epithelial cell differentiation and proliferation on many tissue, but little is 
known about the pathway interacts with and is determined by tissue-specific factors 
in the respiratory system. We demonstrated that tRA and RARα stimulates both 
CC10 (Clara cells) and SP-C (ATII cells) through TTF-1 (Nkx2.1) transcriptional 
activity. To determine whether other RAR ligands directly influenced interaction of 
Clara and ATII cells with Nkx2.1, we examined RARβ, RARγ and panRXR. These 
ligands gave mixed results. Expression of Clara and ATII cells in RAR, RARγ and 
panRXR lung groups appeared to be independent of proliferation and transcriptional 
activity. It is true that these ligands produced less Clara and ATII cell stimuli, but 
the level of Nkx2.1 expression was even less. Proliferative activity was unusually 
high in RARβ. RARβ is known to inhibit proliferation especially in tumorigenesis 
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i.e. a growth inhibitor, however, this group did fail to show any proliferative 
relationship between Clara and ATII cells. RARα was the only ligand that showed 
both sets of progenitor cell populations to be dependent upon Nkx2.1 transcriptional 
activity postnatally.  
 
Bronchiole and alveolar epithelial repair was shown to be taking place in tRA and 
RARα lung groups where there was co-localisation of PCNA and CC10/SP-C -
positive Clara and ATII cells. Proliferative cells in the bronchioles of 
dexamethasone lungs was restricted to basal cells. The fact that basal cell 
proliferation was present in dexamethasone lungs may suggest that basal cells have a 
role in bronchiole epithelial repair in this animal injured model. Clara cell structure 
in dexamethasone lungs were altered in morphology. There is a possibility that these 
cells detected were a subset variant of what we know are Clara cells. Interestingly, 
we also observed the same fate of Clara/basal cell population in RARβ, RARγ nor 
pan-RXR treated lung groups. Morphology, Clara cells in these groups also showed 
alterations. This observation could merely suggest that these ligands have no direct 
response to dexamethasone damage inflicted on the bronchiole epithelia in terms of 
progenitor cell activation, but are more likely to be involved in basal cell activation 
in the repair/regeneration of bronchiole epithelia repair of this model.  
 
Data generated from IF labelled SP-C-positive ATII cells in dexamethasone treated 
lung group suggest that ATII cells function as progenitor cells in the alveoli and 
proliferate and differentiate into ATI cells. Single fluorescent labelling showed some 
areas to demonstrate squamous cells (ATI) along the epithelium of alveoli alongside 
cuboidal cells (ATII) embedded in the alveoli epithelium. This observation may 
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explain the reduced number of ATII cells detected via IF and immunoblot in these 
lungs. Similarly with CC10-positive Clara cell results, both tRA and RARα showed 
higher levels of ATII population and high proliferative activity. This highly 
productive activity of proliferative progenitor cells in tRA and RARα is suggestive 
that these two ligands are strongly involved in airway epithelial remodelling. ATII 
proliferative activity in the other three ligands were also observed, but the level of 
SP-C protein was much reduced in comparison with tRA and RARα. This implies 
that these ligands, RARβ, γ and panRXR give rise to only small clones of daughter 
cells and that there is a low rate of differentiation into ATI cells. Interestingly, while 
ATII cells do give rise to ATI during retinoid-induced repair, the rate of 
differentiation of RARβ and RARγ appeared significantly lower than during 
dexamethasone-induced lung injury. This puts forward the idea that dexamethasone 
injury promotes the production of local signals that enhance the conversion of ATII 
cells to ATI cells.  
 
RAR stimulation on target proteins in the process of repair/regeneration depends on 
multiple proteins factors interacting with various functional domains. In addition to 
tRA and RARα ligand interacting with Nkx2.1, tRA and RARα strongly interacts 
with proliferation factors including PCNA. tRA and RARα interact with other 
transcriptional and proliferation factors, but these were not explored in this study 
with dexamethasone mouse model, but is worthwhile examining.   
 
 
4.2.6: SUMMARY. Chronic lung injury leads to permanent alternations to both 
cellular and extracellular components that lead to a permanent decline in lung 
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function. In asthma and COPD, it has been shown that airway epithelial damage 
contributes to airway remodelling possibly due to altered regulation of the repair 
process (Jeffery 2001, Holgate, Holloway et al. 2004). Regeneration/repair involves 
two processes; cell migration and cell proliferation. There are numerous studies 
where SP-C protein has been seen expressed in alveolar ducts suggesting that this 
cell population to represent a progenitor cell population for both Clara and ATII 
cells in the developing and in damaged lungs. In the case of the dexamethasone 
mouse model we did not witness either cell populations migrating into each other’s 
respective epithelium domain. Nevertheless, these airway epithelial cells are unique 
in their expression of SP-C protein and CC10 proteins and may represent progenitor 


















EXPRESSION OF MUCINS IN RETINOID 









OBJECTIVE: Airway mucus protects and maintains the health of the respiratory 
system. Its production is orchestrated by the environment, therefore individual 
variations in mucus composition, quantity and rheology is likely to confer 
differences in disease susceptibility and response and may also result in 
environmental specific suitability. Glycoproteins, known as mucins are considered 
to be the major components of mucus.  
 
In this study we examined changes in the distribution of secretory glycoproteins; 
acidic and neutral secreted from goblet cells in dexamethasone and retinoid-treated 
groups and compared with control and retinoic acid (tRA) groups. We also 
examined the major airway mucins normally found in healthy lungs (MUC5AC and 
MUC5B) as well as mucins associated with injury to the airways (MUC2 and 
MUC7). A predominate population of acidic glycoprotein was observed in 
dexamethasone and dex-panRXR treated lungs. Other retinoid ligands dex-RARα, 
dex-RARβ and dex-RARγ showed a mixed population of acidic and neutral 
glycoproteins of varying degrees. Further examination of mucin proteins showed an 
increase in MUC2, MUC5B and MUC7 protein expression in dexamethasone treated 
lungs. There were mixed results with retinoid treated lungs. MUC2, MUC5B and 
MUC7 showed an improvement in expression in all retinoid lungs in comparison to 
dexamethasone treated lungs. MUC5AC was inhibited by dex-tRA and dex-RARβ 
lungs, but displayed similar reduced levels with Dex-RARα and dex-panRXR lungs 





Variability in results was sufficient to demonstrate that mucin glycoproteins are a 
major constituent of airway insult associated with mucociliary clearance, changes in 
the composition of mucin glycoproteins and that a balance in population is vital for 


















4.3.1: INTRODUCTION.  Mucus hypersecretion is a feature pathologically linked 
to chronic respiratory diseases such as asthma, cystic fibrosis (CF) and chronic 
obstructive pulmonary disease (COPD) (Vestbo 2002, Turner and Jones 2009).  The 
pathophysiology of this feature is defined as airway obstruction, airway flow 
limitation, ventilation-perfusion mismatch and impairment of gas-exchange (Rogers 
2007).  In the large airways (tracheobronchial tree), mucus is produced in goblet 
cells and submucosal glands whereas in the small airways (bronchioles) the only 
source of mucus secretion is in the goblet cells (Rogers 2007, Turner and Jones 











Fig 4.3.1: Typical respiratory epithelium. Pseudostratified columnar epithelium with 




Airway mucus is composed of two forms, a secretory liquid (periciliary) form that 
allows the cilia to beat and a gel-form on the surface of the cilia whose thickness 
varies between 2 and 20µm (Nicod 1999). The flow of the gel forming mucus is 
referred to as the mucociliary transport (Nicod 1999). The physiological properties 
of mucus are provided mainly by mucins, which are mucopolysaccharides or 
glycoproteins and proteoglycans secreted from the surface epithelial cells and glands 
(Nicod 1999).  Phospholipids are also secreted by the epithelial cells and 
submucosal glands of the airways weakening the adhesion of the mucus, altering its 
physical properties. The gel forming mucus acts as a barrier to bacteria causing them 
to adhere to the gel (Nicod 1999).  It also protects the airway epithelium from 
dehydration, chemical particulates and nasally inhaled airway irritants (Leikauf, 
Borchers et al. 2002).   
 
Normally, only a few mucus-secreting cells are active in healthy individuals. 
However, in respiratory diseases such as those named above, elevated numbers of 
goblet cells are coupled with excessive mucus secretion. This increase in goblet 
secretory cells is often termed as hyperplasia (Jonathan Turner and Carol E Jones. 
2009).  Following injury by chemical irritants, the initial phase of the restoration of 
the mucosal epithelium consists of a rapid migration of epithelial cells to the 
wounded site followed by their spreading to re-establish the integrity of the luminal 
surface (Leikauf GD et al. 2002). This process has extensively been studied in the 
intestinal tract, but also occurs in the airways in animal models of airway diseases 




Epithelial restoration is mediated in part by a family of small, apically secreted 
peptides and distinctive disulfide-bonded domain structures of which creates a trefoil 
configuration that confers resistance to degradation by proteases and extremities of 
pH. The histochemical evaluation of mucins has revealed a heterogeneous 
population comprising of neutral and acidic glycoproteins. The use of the simple 
histological technique, Alcian Blue Periodic Schiff’s Reagent (ABPAS) has enable 
us visualise this heterogeneous population. Studies of airway glycoproteins in lung 
disease have demonstrated shifts in the proportion of this heterogeneous 
environment to one mostly consisting of acidic glycoproteins and also a change in 
goblet cell size.  
 
The two major airway mucin proteins are the gel forming MUC5AC and MUC5B. 
MUC5AC is normally located in goblet cells, whereas MUC5B is essentially 
detected in the mucosal cells of the submucosal glands and gland ducts (Copin, 
Buisine et al. 2001). Therefore it is generally thought that MUC5AC expression is 
stronger in the trachea and main bronchi where goblet cells are plentiful (Copin, 
Buisine et al. 2001). The intensity of the expression of MUC5AC decreases in the 
epithelium of segmental bronchi, but remains strong at the joining proximal ciliated 
duct and surface epithelium, while MUC5B is expressed in some goblet cells 
(Copin, Buisine et al. 2001). MUC2 protein is generally weakly expressed on the 
surface of the airway epithelium, in some goblet cells and within the submucosal 
glands in mucus cells as well as in some of the serous cells; therefore, MUC2 is not 
generally thought as being a prominent secretory gel-forming mucin protein in the 
respiratory airways (Copin, Buisine et al. 2001). Consequently, numerous studies 
have suggested that MUC2 may have a role in the pathogenesis of inflammatory 
219 
 
airway disorders (Fig 4.3.2), (Hovenberg, Davies et al. 1996, Copin, Buisine et al. 
2001). Moreover, transcriptional activation of MUC2 by Pseudomonas aeruginosa 
lipopolysaccharide may play a role in the pathogenesis of CF (Li, Dohrman et al. 
1997, Copin, Buisine et al. 2001). Transcriptional activation of MUC2 and its 
location in pluripotential stem cells or basal cells suggest a role of MUC2 in 
epithelial renewal in airways (Copin, Buisine et al. 2001).  
 
 
Fig 4.3.2: Processes that impact on mucus obstruction of the airways. A normal 
airway epithelium (left) exposed to pathogens or environmental agents that activate 
inflammatory and/or immune mediators may initially respond by mucin 
hypersecretion from goblet cells and submucosal glandular cells (not depicted). In 
chronic conditions, hyperplastic airway epithelium (right) results, reflecting division 
of goblet cells, differentiation of progenitor cells and/or transdifferentiation of 
airway epithelial cells. Callaghan-Rose M et al. 2001. Am J Respir. Cell Mol. Biol. 
25: 533-537  
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MUC5B and MUC7 are defined mutually and exclusively to their cellular 
compartments within submucosal glands, mucus acini and a subpopulation of serous 
acini (Copin, Buisine et al. 2001). This differential expression of mucin proteins in 
submucosal glands might reflect the differences in the differentiation state of these 
two cell types in response to a variety of airway insults (Copin, Buisine et al. 2001, 
Rogers 2007).  
 
4.3.2: AIM. The aim of this study was to investigate the importance of mucus in 
airway function and to establish its effects in injured and lungs undergoing recovery. 
We showed that in injury, mucus hypersecretion occurred via the lungs ‘natural’ 
defence mechanism, but this hypersecretion resulted in causing more damage to the 
airways than protection. We also observed goblet cell hyperplasia in these lungs. In 
some of the regenerative lung groups, we a reverse effect of mucus hypersecretion 
and goblet cell hyperplasia that had occurred in the injured lungs. Previous studies 
have examined mucus hypersecretion under various conditions and have shown RA 









4.3.3: RESULTS: ABPAS staining demonstrated a mix population of acidic and 
neutral glycoproteins along the bronchi and deep into the bronchiole epithelia of 
control lungs. Most goblet cells had an oval structure to them. ABPAS staining was 
easily detected in small amounts (Fig 4.3.3a). This observation reflected the number 
of actively secreting goblet cell, 5.9 ± 1.0 and 6.1 ± 1.0 (Fig 4.3.4, Table 4.3.1), 
showing a balanced heterogamous acid to neutral glycoprotein ratio. Goblet cells 
were effected in two major ways by the administration of dexamethasone. Firstly, 
goblet cells secreted more acidic glycoproteins and was reflected on the number of 
AB stained glycoproteins and secondly, goblet cells present in these lungs were 
mostly columnar in shape (4.3.3b). Compared with control lungs, dexamethasone 
lungs showed some airway inflammation with an increased amount of luminal 
mucus. The average of these cell counts in dexamethasone treated lungs were as 
follows; 27.4 ± 3.4 for acid glycoproteins and 11.5 ± 1.0 for neutral glycoproteins 
(Fig 4.3.4, Table 4.3.1). This suggest the insult of lung injury caused by 
dexamethasone not only promotes mucus hypersecretion, but also a change in the 
airways environment thus effecting mucociliary clearance.    
 
We then examined the response of secretory glycoproteins to dex-tRA. AB-positive 
acidic glycoproteins showed basal stained cells, but not goblet cells. Goblet cells 
present in these lungs were shown to mainly secrete neutral glycoproteins. These 
cells were scattered along the bronchiole epithelium. They were oval in shape, 
situated on top of AB stained basal cells (4.3.3c). Neutral glycoproteins seemed to 
play a dominate role in these treated lungs than previously observed in 
dexamethasone lungs, where it was acidic glycoproteins that was dominate. Despite 
basal and not goblet cells secreting acidic glycoproteins, we still carried out cell 
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counts to get an idea of mucus secretion. Cell counts for acidic glycoproteins was 
10.5 ± 2.0 and 13.3 ± 11.5 for neutral glycoproteins (Fig 4.3.4c, Table 4.3.1).     
 
In order to get an overall view of the effectiveness of each retinoid ligand after 
dexamethasone damage, we compared calculated numbers of secretory goblet cells 
in dex-tRA and dexamethasone lungs. First we examined dex-RARα lungs. Lungs in 
this group showed a much heterogeneous environment for glycoproteins, although 
numbers for each protein population was not identical. Numbers of both population 
were greater than numbers in dex-tRA, suggesting that this particular ligand did not 
have a direct impact on reducing mucus hypersecretion and therefore mucociliary 
clearance, but did have a positive effect on a heterogeneity environment for the lung 
(Fig 4.3.3d). The average cell counts for acidic and neutral glycoprotein secretions 
in these lungs were 22.3 ± 1.0 (acidic) and 25.5 ± 2.4 (neutral). The significant 
difference was p<0.05 when compared with dex-tRA.  
 
The second retinoid ligand group we examined was dex-RARβ. Secretory goblet cell 
in this group was much harder to count as there was an abundance of secretory 
neutral glycoproteins and goblet cells were extremely irregular in shape (Fig 4.3.3e 
and 4.3.4). Acidic glycoproteins positive for AB were located in basal cells. The 
bronchiole epithelium of these lungs looked ‘metaplastic’. Goblet cells were oval in 
shape and quite densely populated. Average cell counts for these lungs were as 
follows: 15.3 ± 2.3 (acidic) and 28.4 ± 4.3 (neutral). Neutral glycoprotein secretions 
were almost twice the number of acidic secretions. When comparing these averages 
with dexamethasone lungs, neutral glycoprotein secretions in dex-RARβ calculated 
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to be 2.5 times more. The significant difference for this group was p<0.05 when 
compared with dex-tRA (Table 4.3.1). 
 
Next we examined dex-RARγ. This group appeared to have almost equal numbers of 
acidic and neutral glycoprotein secretions (Fig 4.3.4). Cells that were positive for 
both populations were oval, but slightly flat in shape and evenly spaced along the 
respiratory mucosa (4.3.3f). There were areas along the bronchiole epithelia where a 
mixed population was observed. The average number of secretory glycoproteins in 
this group was 21.4 ± 2.0 for acidic and 23.0 ± 7.1 for neutral glycoproteins. Even 
though dex-RARα groups showed similar secretory response, its measurements were 
greater than dex-RARγ. 
 
The last retinoid ligand group that was examined for glycoprotein secretion was dex-
panRXR. The majority of secretory glycoprotein was acidic. Goblet cells appeared 
relatively tall, but oval in shape (Fig 4.3.3g). Secretory goblet cells were not entirely 
evenly distributed. There were areas where secretions were highly populated and 
there were areas where secretory glycoproteins seemed to be situated on the surface 
of goblet cells. There was very few neutral glycoprotein secretions (data not shown).  
 
The average counts for this group was 30.8 ± 11 for acidic glycoproteins and 7.5 ± 
3.4 for neutral glycoproteins. Its acidic secretions were a fraction more than 
dexamethasone groups with its neutral glycoproteins being slightly less than 
calculated secretions in the dexamethasone group. When comparing values in dex-
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panRXR with values in dex-tRA, they revealed a significant increase of acidic 
glycoproteins by four times and a decrease of neutral glycoproteins by at least six 
times (Fig 4.3.4, Table 4.3.1).  
 
The overall measurements of acidic and neutral glycoprotein secretions is 
summarised in figure 4.3.4, table 4.3.1. The graph (Fig 4.3.4) shows that acidic 
glycoproteins was greatly stimulate by dexamethasone and dex-panRXR ligands and 
that neutral glycoproteins was stimulated by dex-RARα and dex-RARβ ligands. The 
overall measurements of RA ligands indicated that dex-RARγ had the closest 
stimulatory pattern of reaction to dex-tRA even though the amount of glycoproteins 















Table 4.3.1: Acidic and neutral glycoprotein secretions from dexamethasone, and retinoid ligand treated postnatal mouse lungs. Results 
are expressed as percentage of control, dexamethasone and retinoid ligand lungs, ± standard error of the mean. One way AVONA 
indicated whether there was a difference in the retinoid ligand groups from tRA lungs. * Indicates a significant difference of acidic and 
neutral glycoproteins from tRA after a t-test, where P<0.05 followed by the Bonferroni correction where P<0.016.  
Lung Group N ACIDIC GLYCOPROTEINS NEUTRAL GLYCOPROTEINS 
Control 10 5.3 ± 1.0 6.1 ± 1.0 
Dexamethasone  21 27.4 ± 3.4  11.5 ± 1.0 
dex-tRA 8 10.5 ± 2.0 13.3 ± 11.5 
dex-RARα 15 22.3* ± 3.0 25.5* ± 2.4 
dex-RARβ 15 15.3* ± 2.3 28.4*± 4.3 
dex-RARγ 8 21.4* ± 2.0 23.0*  ± 7.1 
dex-panRXR 7 30.8* ± 11.0 7.5 ± 3.4 
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We then focused our attention in the investigation of mucin protein expression in 
samples examined for secretory glycoproteins. We selected four airway mucins, 
MUC2, MUC5AC, MUC5B and MUC7. As previously mentioned, both MUC5AC 
and MUC5B are the major muc proteins found in the respiratory system, where 
MUC5AC is greater than MUC5B under normal conditions. MUC2 and MUC7 are 
known to be secreted in low volumes in healthy lungs, compared with MUC5AC 
and MUC5B. In abnormal conditions, MUC2 and MUC7 are known to elevate 
substantially. Interestingly differentiation and expression of all four proteins have 
been shown to be RA or retinol-dependent (Gray et al. 2001).  
 
We first examined MUC5B and MUC7 expression levels by using homogenates of 
our selected retinoid ligand-treated lungs by SDS-PAGE electrophoresis. These 
samples were loaded onto a gel of equal volume and examined by staining with 
Coomassie (CBBR20), followed by PAS for the detection of glycoproteins (Fig 
4.3.5). MUC5B was the most obvious mucin protein detected by CBB/PAS. As 
expected with homogenates from control lungs, levels of MUC5B and MUC7 
staining intensity was low (Lane 1). Dexamethasone homogenates (Lane 2) showed 
greater MUC5B expression and a slight increase in MUC7 when compared with 
control samples. Both dex-tRA and dex-RARα homogenates showed a reduced 
expression level of MUC5B and MUC7 (Lane 3 and 4). MUC5B staining was 
relatively strong, but there was no presence of MUC7 in dex-RARβ samples (Lane 
5). Both dex-RARγ and dex-panRXR (Lanes 6 and 7) showed an increase in 




MUC5B and MUC7 expression were semiquantified using ImageJ followed by one-
way ANOVA test. Quantification of MUC5B and MUC7 confirmed expression 
levels. Calculated bands of intensities are shown in figure 4.3.6, table 4.3.2. 
Calculated MUC5B band from dexamethasone samples contained the highest 
protein concentration, 77.5 ± 2 and was significantly different from control samples 
(45.1 ± 13.9). Dex-tRA and dex-RARα had similar readings, 48.1 ± 12.3 and 49. 4 ± 
14.9 respectively and therefore was not significantly different. MUC5B expression 
levels in dex-RARβ showed a difference compared with dex-tRA (55.1 ± 12.6). 
Conversely, MUC5B concentration readings from dex-RARγ and dex-panRXR were 
significantly different from dex-tRA. Both groups were the highest out of the 
retinoid ligands 69.0 ± 8 and 71.3 ± 9 respectively.  
 
Calculated band intensities for MUC7 were much lower than MUC5B calculated 
bands and were as follows. Control samples gave an average value of 4.1 ± 1.0. In 
comparison to control samples, dexamethasone average for MUC7 was 7.5 ± 3.4. 
Dex-tRA gave an average of 3.3 ±11.5. Average MUC7 band intensity for dex-
RARα was 5.5 ± 2.4. Dex-RARβ gave an average less than dex-tRA, 2.4 ± 4.3. Dex-
RARγ gave the highest average for MUC7 amongst the retinoid ligands, 9.3 ± 














Fig 4.3.5: Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)  demonstrating MUC5B and 
MUC7 from postnatal mouse lung homogenates stained with Coomassie  Brilliant Blue R (CBBR20) and periodic 
acid Schiff’s reagent (PAS) of varying treatments (15µl loaded into each lane). Sample lanes are as follows: Lane 1: 
Control, Lane 2: Dexamethasone, Lane 3: dex-tRA, Lane 4: dex-RARα, Lane 5: dex-RARβ, Lane 6: dex-RARγ and 
Lane 7: dex-panRXR. M = Molecular Marker    
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Fig 4.3.6: Graph shows the average band intensity of MUC5B and MUC7 taken from treated lung homogenates. Significant increase of 
MUC5B in dex-RARγ and dex-panRXR and increase of MUC7 in dex-RARγ following Bonferroni correction. * P<0.01 
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Table 4.3.2: Band intensity of MUC5B and MUC7 protein following treatment to induce emphysematous-like features and various 
retinoid ligand treatment to reverse the insult effects of dexamethasone. Table indicates proteins which show a significant increase of 
both sets of protein. * indicates significance after Bonferroni correction. 
Treatment N Average MUC5B 
band Intensity 
ANOVA Results Average MUC7 
band Intensity 
AVONA Results 
Control 10 45.1 ± 13.9  P<0.01 4.1 ± 1.0 Not Significant 
Dexamethasone  21 77.5* ± 2.0  P<0.01 7.5 ± 3.4  Not Significant 
dex-tRA 8 48.1 ± 12.3  Not Significant 3.3 ± 11.5 P<0.01 
dex-RARα 15 49.4 ± 14.9 P<0.01 5.5 ± 2.4 Not Significant 
dex-RARβ 15 55.1 ± 12.6 P<0.01 2.4* ± 4.3 P<0.01 
dex-RARγ 8 69.0  ± 8.0 P<0.01 9.3  ± 7.1 P<0.01 
dex-panRXR 7 71.3 ± 9 P<0.01 6.3 ± 2.0 Not Significant  
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In addition to Coomassie-PAS staining of MUC5B and MUC7, we examined the 
expression of MUC2 and MUC5AC in treated lung homogenates via 
western/immunoblots (Fig 4.3.7, Table 4.3.3). Positive bands were developed using 
chemiluminescent detection. MUC5B and MUC7 expression levels matched the data 
obtained from lung homogenate staining with Coomassie/PAS of SDS-PAGE gels. 
As expected, all four muc proteins showed an increase in expression with 
dexamethasone homogenate samples (Lane 2). Data generated demonstrated that 
dexamethasone promotes mucus hypersecretion, in particular MUC2 and MUC5B, 
where these two muc proteins showed the greatest increase in comparison to control 
samples. MUC5AC and MUC7 from dexamethasone sample’s increase was at a 
much lesser degree in comparison with control samples. MUC2 and MUC5B 
responded well to dex-RARα and dex-RARβ treatment (Lanes 4 and 5). MUC7 
responded well to all retinoid ligand treated lungs (Lanes 4-7). In control lungs, 
MUC2 and MUC5AC were mainly seen in epithelial goblet cells, whilst MUC5B 
and MUC7 were seen in mucus and serous cells of the submucosal gland, 
respectively. In dexamethasone lungs, goblet cell hyperplasia was observed along 
with an increase in mucus secretions with all the muc proteins used in this study 





                                    
Fig 4.3.7: Immunoblot analysis of mucin proteins in lung homogenates of control, dexamethasone and 
retinoid treatments. Immunoblots of lung homogenates were probed with antibodies against mucins 
MUC2, MUC5AC, MUC5B and MUC7. Molecular weights varied from 39 – 600kDa 
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ANOVA t-test followed by Bonferroni correction confirmed variation of muc protein expression with retinoid ligands (Fig 4.3.8a-d).  
 
Fig 4.3.8a: Average measurement of MUC2 expression from lung homogenates of varying retinoid ligands. As demonstrated in this 
graph, MUC2 shows gradual decrease of MUC2 secretion. In terms of comparison with dex-tRA treatment, MUC2 hypersecretion 




Fig 4.3.8b: Average measurement for MUC5AC expression from lung homogenates from varying retionoid ligands. The graph shows 





Fig 4.3.8c: Average measurements of MUC5B expression from lung homogenates of varying retinoid ligand treatments. As 
demonstrated by the graph, dextRA and all of the retinoid ligands have similar expression levels. Dexamethasone was shown to grossly 




Fig 4.3.8d: Average measurements of MUC7 expression from homogenates of varying retinoid ligands. Dex-tRA  
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4.3.4: DISCUSSION: The main function of secreted mucins is their involvement in 
mucosa protection. Their cellular and tissue distribution are altered in pathological 
respiratory conditions and therefore are a vital component when diagnosing airway 
diseases. As in all cases of disease, it is important not only to focus on what goes 
wrong in chronic airway diseases associated with mucus hypersecretion, but also in 
the normal innate immune defence role that mucus (mucins) play in healthy tissues. 
For a long time, mucus hypersecretion was largely neglected as a clinical feature of 
COPD, but now it is a recognised important clinical characteristic, particularly for 
the role of mortality and morbidity associated with this disease. The severity of 
mucus hypersecretion in COPD patients can range from mild secretions to 
hospitalisation which if not treated, eventually leads to respiratory failure.  
 
The aim of treating mucus hypersecretion is normally to alter rheological properties 
of bronchial mucus production; in affect, to reduce airway obstruction; to enhance 
mucociliary clearance and to promote expectoration (Kim 1997). There are 
strategies that have been put in place to reduce hypersecretion. Firstly to inhibit 
mucus hypersecretion by using pharmacological agents to stimulate ciliary activity 
and improve mucociliary interactions and last, to enhance coughing to enable mucus 
clearance by changing the rheological properties of mucus, again, by 
pharmacological means or by physical movement from smaller to larger airways 
from where it can be eliminated by coughing (Kim. 1997).  
 
Studies have shown that retinoid ligands can inhibit the expression of 
proinflammatory processes, implicating them as regulators of immune and 
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inflammatory responses. This implies that retinoid ligands possess anti-
inflammatory properties that may prove useful in the treatment of inflammatory lung 
disease exasperated by mucus hypersecretion.    
 
Exposing mice to dexamethasone resulted in goblet cell metaplasia and hyperplasia, 
leading to mucin overproduction and mucus hypersecretion in postnatal lungs. We 
did not examine effects dexamethasone may have impacted on inflammatory 
mediators such as cytokines and neutrophil elastase, but it is well documented that 
these inflammatory agents contribute to excess mucin synthesis and mucus secretion 
in airways, so we can summarise that the same effect may be the reason for an 
increase of mucin expression that occurred in dexamethasone lungs.     
 
Exposing mice with dexamethasone induced goblet cell hyperplasia in bronchial 
epithelium and upregulated MUC2, MUC5B and to a lesser extent MUC7 protein 
expression in postnatal lungs. These changes were associated with airway 
inflammation. From the data provided by this investigation, it is plausible that lung 
insult created by dexamethasone causes mucus hypersecretion by promoting an 
increase in muc protein expression, in particular MUC2 and MUC7 which are two 
muc proteins associated with airway disease. During chronic airway disease, 
upregulation of mucin expression in response to insults is known to be exaggerated 




Introducing retinoid ligands to dexamethasone treated lungs reduced goblet cell 
hyperplasia and airway occlusions due to mucus hypersecretion.  
 
Data suggests that tRA and RARα may have important roles in regulating processing 
related to airway mucus hypersecretion and airway hyperresponsiveness, indicating 
that vitamin A and its ligand show potential as targets to develop treatments for 
COPD/emphysema. Previous studies including chapter 3.3 have shown that 
deficiency of vitamin A is associated with altered mucus expression and that a 
reduction of this vitamin can attenuate COPD in vivo experimental models.  
 
These results suggest that retinoids are required for proper lung maturation and 
response to injury. It would be interesting to explore whether retinoid induction to 
injured lungs have an essential role in the pathway through which 
monocytes/macrophage-derived micro-particles activate cytokines such as NFκB 
and ultimately induce the upregulation of proinflammatory mediators in postnatal 
lungs and whether RARα has the ability to downregulate proinflammatory protein 
expression.  
 
4.3.5: SUMMARY. Mucus hypersecretion is therefore a complex pathologic 
process that involves the mechanisms that are responsible for hyperplasia and 
degranulation of mucus-secreting cells and the attraction of inflammatory cells. 
Mucins are an important component of host defence, but they represent an important 
cause of airway obstruction when secreted in excess.  Whether goblet cells or 
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submucosal gland cells are the principal sources of mucins in airway secretions in 
COPD/emphysema or in other airway diseases is not known. In disease states, it is 
likely that the relative contribution of goblet cells and gland cells varies according to 
airway level, disease severity, and disease type. In COPD patients, it is clear that 
goblet cells contribute mucins to airway secretions and that retinoids are involved in 








































5. GENERAL DISCUSSION 
5.1: EPIDEMIOLOGY.  Early diagnosis and treatment can markedly slow the 
decline of lung function and hence lengthen the period in prolonging the patient’s 
life. An estimated 3 million people have COPD in the UK, although for around 2 
million of this group remain undiagnosed. According to healthcare calculations, in 
the UK alone, the economic burden is around £1.2billion per annum and is steadily 
rising. This includes direct healthcare costs and factors such as lost income tax, 
payment of state benefits and productivity loss due to COPD. These calculations are 
based on the current age of retirement; if this is increased then the economic impact 
will inevitably rise (Fig 5.1).   
 
 
Fig 5.1: The prevalence of COPD is influenced by age as indicated in the figure 
above. The diagnosed prevalence for individuals between the ages of 45-54 years is 
<1% increasing to >5% for individuals aged 65 years and older.  National costing 




5.2: ADVANCES IN RESEARCH. Most research on COPD has largely focused 
on effects of environmental factors such as initiators and causative agents, with little 
attention given to underlying or predisposing conditions. Despite the recognition of 
COPD as a multi-component disease, exacerbations are defined only in terms of 
respiratory symptoms: worsening of dyspnoea, cough and/or sputum production that 
is acute in onset and may warrant a change in regular medication regiment (Pauwels 
et al, 2001, Rodriguez-Roisin 2000).  
 
There is no doubt that management of COPD/emphysema has greatly improved with 
the introduction of more effective treatments and the use of non-pharmacological 
interventions, such as pulmonary rehabilitation and non-invasive ventilation, but due 
to an increasing number of patients with COPD and indeed those dying from the 
disease, there is a pressing need for the development of new therapies especially as 
existing treatments are unable to reduce the progression of the disease (Barnes et al. 
2005, Rennard 2004, Sutherland et al. 2004). New therapies could give rise to 
existing drugs such as β2-agonists and anticholinergic drugs which help with 
breathing problems by dilating the airways in the lungs (bronchodilators) and protect 
the airways from spasms that cause the narrowing of airways as well as reducing 
mucus hypersecretion.  
 
There have been important advances in the current understanding of the cellular and 
molecular biology of COPD and through this knowledge, newer therapies are being 
developed for COPD specifically targeting inflammation of which is considered  a 
major feature of this disease as it is presumed that it is the inflammatory processes 
which lead to structural changes occurring in COPD lungs and hence the scientific 
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rationale for the development of anti-inflammatory drugs, but in order to decipher 
which drug(s) are most effective, research has employed the use animal models (Fig 
5.2 Barnes et al. 2005, Barnes et al. 2003, Barnes et al. 2002, Barnes et al. 2004).  
 
  
Fig 5.2: Targets for COPD therapy based on the current understanding of the 
inflammatory mechanisms. Cigarette smoke and other irritants activate macrophages 
in the respiratory tract that release neutrophil chemotatic factors, including 
interleukin (IL-8) and leukotriene B4 (LTB4). These cells then release protease that 
break down connective tissue in the lung parenchyma resulting in emphysema and 






5.3: MURINE MODELS OF AIRWAY DISEASE. There are both pros and cons 
of using animal models instead of human clinical studies. Murine models especially, 
have the advantage of short experimental cycles and are easy to study over time in a 
controlled environment. They allow for convenient specimen collection and a broad 
range of different animal models allow for investigation of mechanistic pathways for 
many diseases. Another advantage is that they are easy to breed and to house. The 
disadvantage is that sometimes it is difficult to make direct comparisons with human 
diseases, which reveals significant differences in sensitivity between murine and 
humans. For example, mice and rat lungs are considerably different in structure from 
that of the human lung. The airways of humans are unique, with far more branches 
than in other species, especially mice and rats and the outcome of specific treatments 
in both species is not necessary the same in humans. However, the obvious 
advantage of being able to exam systemic affects, have driven us to further develop 
the methods and protocols to improve the similarities to human diseases.    
 
 
5.4: ROLE OF VITAMIN A IN AIRWAY DISEASE. The role of vitamin A in 
structure, function and maintenance of the lung is one of profound importance and 
therefore has had extensive research on these topics. In its active form, RA controls 
regular differentiation as ligands for RAR and RXR and is involved in the 
integration (gap junction formation) of cell formations. Vitamin A plays a 
substantial role in the respiratory epithelium and the lung. In VAD, the incidence of 
respiratory diseases is considerably increased and repeated respiratory injections can 
be influenced therapeutically by vitamin A supplementation (VA). In addition to the 
importance of VA for lung function, VA is also responsible for the development of 
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many tissues and cells as well as for embryonic lung development. Studies have 
shown that control occurs by different expressions of retinoid receptors as well as by 
time-dependent changes of the VA metabolism respectively via cellular VA binding 
proteins (CRBP: cytoplasmic retinoid binding protein; CRABP: cytoplasmic retinoid 
acid binding protein). 
 
VA (retinol) and RA play a crucial role in lung development during embryogenesis; 
in terms of interactions with the genome, RA appears to be the most active of the 
retinoids. RA affects many aspects of lung development ranging from branching 
morphogenesis to structural remodelling during alveolarization. VA may also be 
involved in surfactant synthesis as VAD during gestation reduces the expression of 
surfactant protein A, B and C in foetal rat lungs. The role of RA in alveolarization 
and lung regeneration has received much attention. These effects are apparently 
mediated by elastin synthesis; endogenous retinoid production increases tropoelastin 
expression in vitro, whereas VAD during pregnancy reduces elastin staining in foetal 
lung. There is considerable interest in the possibility that RA treatment may be able 
to regenerate alveoli in human adult emphysematous lungs. As preterm infants can 
be VAD, they are often supplemented with VA to reduce oxygen requirements and 
treat lung injury, presumably by enhancement of alveolarization.  
 
Malnutrition is a major problem, not only in developing countries, but also in 
westernised countries where there are pockets of poverty. Nutritional restriction or 
deficiency in adults has long been known to have adversely affect lung function and 
structure via alternations in pulmonary surfactant, respiratory control or respiratory 
muscle function. Poor nutrition can lead to the breakdown of structural proteins in 
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the lung which may exacerbate COPD. Poor nutrition is also known to impair 
immunity of lungs. We have shown in our VAD postnatal rat lung leads to the loss 
of airway structures, namely the thinning and fewer alveoli as well as the 
development of squamous metaplasia of the bronchial epithelia. However, this affect 
is only achievable if chronic as demonstrated in chapter 3.1 where we examined 
morphology and morphometric parameters. We demonstrated emphysematous-like 
features are achievable in VA depleted lungs of postnatal rats. Restoration to normal 
histological state occurs after VA repletion, which in experimental murine models 
has been shown to confer emphysematous-like features. Serious clinical 
manifestations of VAD in children create an increased risk of respiratory infection 
which is associated with changes in the respiratory epithelium (McDowell et al. 
1990).  
 
The processes underlying nutritional emphysema remains unclear, but components 
of lungs most affected by postnatal starvation is the alveolar septum. Nutritional 
emphysema maybe largely due to the breakdown of structural proteins of the 
septum, in particular, elastin and collagen, however, starvation must be severe to 
induce these changes. In the rat, it has been shown that starvation causes a reversible 
reduction in the activity of lysyl oxidase is involved in post-transitional cross-linking 
of elastin and collagen. Elastase treatment of rat lungs induces a form of emphysema 
that more closely resembles conditions in humans than starvation suggesting that 
elastin breakdown may be involved in the human disease. Of interest it has shown 
that nutritional emphysema in postnatal animals is reversible, caloric restriction in 
mice reduce the number of alveoli and alveolar surface area, as occurs in human 
emphysema, but re-feeding fully reverses these changes. This suggest that alveolar 
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walls are able to regenerate following their destruction due to deficient nutrition in 
murine animals.  
 
Up to now, the use of retinoids in clinical trials has been limited because of their 
pharmacological and side effects, as it has been well documented that excess 
amounts of VA have teratogenic effects, embryonically, as well as having a role in 
osteoporosis, but the mechanisms through which retinoids restore emphysematous 
features are gradually being elucidated. Their complexity results from the large 
number of proteins involved in cell differentiation and proliferation (Blomhoff 1994, 
Bogos et al. 2008, Gorodischer 1993, Eskild et al. 1994, Penniston et al. 2006).   
 
5.5: AIMS OF PROJECT. For the overall project, we wanted to assess therapeutic 
effects of ligands in retinoid-selective agonists in lungs administered with 
dexamethasone at a dosage of 4mg/kg to induced emphysema and to show that VA 
in the form of these naturally occurring and synthetic forms are important for the 
continuation of structural function and maintenance of the respiratory system, 
postnatally. To assess the role of retinoids in postnatal lungs, we used a nutritional 
approach. By generating postnatal VAD rats from the age of 3 months we 
determined the function of retinoids in these lungs. We demonstrated VAD rat lungs 
were morphologically and morphometrically different from age and sex-match 
control rat lungs. The alveolar septal walls of VAD rat lungs appeared thinner, with 
fewer and larger alveoli. There was a reduction in lung volume and evidence in 
alveolar enlargement i.e. emphysema. Results from morphometric analysis of VAD 
demonstrated a progressive increase in Lm, (a parameter widely used to evaluate the 
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severity of emphysema in animal models), from 6 months to 1 year animal groups 
compared with control groups. To demonstrate restoration of injured lungs induced 
by dexamethasone, we used the same Lm parameter we used for the examination of 
VAD rat model. There is evidence from animal models that exposure of the 
developing lung to high concentrations of dexamethasone inhibits alveolus 
formation and decreases lung surface area. We were able to demonstrate this feature 
in our postnatal mouse model (chapter 4.1). As expected, we found that both 
airspace areas and airspace volume density, Lm values too had greatly increased 
when comparing with control groups and that both model groups were significantly 
different p<0.05 from their control counterparts showing a shift in airway 
distribution, thus underlying structural changes.  
 
There are concerns of this parameter regarding its properties to assess pulmonary 
emphysema quantitatively partly relating to the fact that the reference volume is 
frequently not considered, making its interpretation difficult (Knundsen et al. 2010, 
Hsia et al. 2008, Mitzner 2008, Weibel et al. 2007). Moreover, this parameter 
involves both alveolar space and alveolar duct space taken together. In addition, 
because it is only a mean, it cannot reflect the heterogeneity of pathological 
alternations, a typical feature of emphysema (Knunsden et al. 2010, Ito et al. 2004, 
Russi et al. 1999). Nevertheless, using this parameter we were able to determine that 
there were no differences in the mean lung volumes associated with exposure to 
dexamethasone or treatment with the retinoid ligand RARβγ or panRXR. They were 
unable to reverse dexamethasone effects on airspace size, airspace volume or the 
increase in vascularisation, but differences were found in airspace size and volume 
with tRA and RARα in comparison with dexamethasone animal groups, although 
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vascularisation appeared to show an increase with tRA animal groups in comparison 
with control groups. Similarly dexamethasone-treated animal displayed a decrease. 
RARγ and panRXR did not however reverse the dexamethasone effect on secondary 
alveolar structure. They were unable to alter airspace size or airspace volume density 
in the lungs of animals exposed with dexamethasone.  
 
Overall morphological and morphometric data suggest that inhibition of septal 
formation may occur via different mechanisms with dexamethasone accounting for 
the ability of RA and retinoids to mitigate the effects of dexamethasone in 
alveolarization in postnatal animals. It is possible that the dose chosen for retinoid 
ligands throughout this study was not optimal to ameliorate the effects of 
dexamethasone on lung alveolarization. In these studies, the dose and routine of 
administration for tRA and retinoid ligands and dexamethasone were identical to 
those used by Hind and Maden (2004) in which tRA attenuated the reduction in 
alveolar number and body mass-specific surface area caused by dexamethasone 
administration  
 
VA also appears to be involved in protecting the lung from dexamethasone injury. 
Our data indicates that after the addition of these retinoids, some (RARα and RARγ) 
efficiently reversed the effects of dexamethasone damage to the lung structure 
signifying, as have many experimental designs have, that these retinoids are positive 
regulator of restorative respiratory structures and that retinoids such as RARβ 
provide a very poor performance on reversing the effects of dexamethasone, thus 
signifying this retinoid as a negative regulator of restorative respiratory structures. 
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Along with tRA, RARα and RARγ showed an increase number of alveoli, but not 
total surface area of damaged lungs which may suggest that a prolonged treatment, 
rather than an increase in dose of these retinoids may completely restore alveolar 
structure. 
 
Because retinoids may stimulate antioxidant defences and act as antioxidants, they 
may protect the lungs from damage by oxygen free radicals generated through direct 
exposure and by inflammatory cells. All of these findings are consistent with clinical 
observations of the therapeutic benefits of VA supplementation on postnatal lungs, 
but do not assess the effects of retinol on dexamethasone-induced changes on lung 
morphology such as those seen in BPD.  
 
5.6: MUCUS HYPERSECRETION. Mucus production itself is troublesome to 
many patients with COPD, yet little is known regarding the mechanisms of mucus 
hypersecretion, the benefits and risks associated with increased mucus production, or 
the means whereby mucin secretion, its composition and mucociliary clearance 
might be therapeutically regulated. Therefore, research is needed to expand our 
understanding of molecular and cellular mechanisms of mucus metaplasia and 
excess mucus production. Studies of submucosal glands of the small airways are 
especially needed because these glands are probably most important in COPD and 
have  
attracted relatively little research interest. In the classical phenotype of chronic 
bronchitis, mucus hypersecretion is the key presenting symptom and its contribution 
to airflow obstruction and has been the subject of debates for a long time (Prescott et 
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al. 1995, Cox 1972). However, results of several recent epidemiological studies have 
shown an association between mucus hypersecretion and patients with COPD. In a 
22 year mortality survey of 1061 working males, respiratory mucus hypersecretion 
was found to constitute more than a negligible public health problem (Cerveri et al. 
2010, Vesbo et al. 2006). In the Copenhagen City Heart Study, chronic mucus 
hypersecretion was found to be significantly and consistently associated with both 
an excess in FEV1 decline and an increase of subsequent hospitalizations due to 
COPD (Cerveri et al. 2010, Melton 2002). This topic has subsequently been the 
subject of a Novartis Foundation symposium, which quoted these epidemiological 
studies and concluded that dealing with inflammation in COPD patients might not be 
sufficient enough and that clearing mucus from the airways might provide a better 
opportunity to treat the inflammation and offer relief to the patient (Cerveri et al. 
2010, Vestbo et al. 2002).  The hypothesis that inflammation accounts for all 
features of pathobiologcal processes involved in alveolar destruction and airway 
remodelling in COPD slightly over simplifies the overall polymorphic and multi-
factorial nature of inflammation in COPD and consequently, has led to major 
therapeutic advances in the treatment of COPD (Cerveri et al. 2010). Several 
observations, particularly related to the progressive nature of COPD, raise some 
questions that have not been adequately addressed such as; why does it take decades 
for the disease to develop? Why do some patients experience a rapid decline in lung 
function while others live for a long time with stable airflow obstruction? Why does 
inflammation persist despite smoking cessation? Why do corticosteroids have little 





Mucins are extremely heterogeneous in their oligosaccharide structure; therefore its 
population can be divided into subsets depending on which epitope of mucin is to be 
measured. We used histochemical, immunohistochemical and western blots to 
analyse stimulatory effect of experimentally injured lungs and injured lungs 
undergoing regeneration on mucin production. Both VAD and dexamethasone 
animal groups showed acidic glycoproteins being greater in secretion than neutral 
glycoproteins. These groups also showed a significant increase in the amount of 
acidic glycoproteins secreted compared with control animals.  
 
There are a number of questions that need to be addressed as regards to the data 
obtained with this investigation and the mucins used. Firstly, the role of individual 
MUC protein products are not entirely clear, as it is possible that many subsets of 
mucins may exist in terms of different biological glycosylation and sulfation, which 
may have different biological functions either alone or in association with its 
accessory proteins. For example, from the data obtained from our mucus 
hypersecretion, we concluded that an increase in certain airway mucins that might be 
beneficial to the airway defense and that other types may be detrimental to 
mucociliary clearance simply from the standpoint of the rheological properties that 
is determined by the structure of mucins. Thus it was extremely important to try to 
ascertain the role of individual airway mucin proteins in injured and regenerative 
lung. Like airway challenged diseases, dexamethasone showed an increase in all 
muc proteins used, especially in muc proteins not normally present in airway 
epithelia. What was interesting about this study was that dex-tRA and dex-RARβ 
were both negative for MUC5AC and both showed low protein expression of 
MUC5B. As far as we are aware, this response has not been noted in any other muc 
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protein study, repeats of these two protein perhaps need to be reassessed to confirm 
the results presented, but it could be that many differences in the cells of origin of 
mucus cells depend upon the nature of the injury that induces the mucus metaplasia 
and that tRA and RARβ are not involved in MUC5AC and MUC5B pathway. We 
also noted an increase in basal cell proliferation after VAD and dexamethasone 
challenge. We speculated that the increase in basal cell-containing epithelia may 
allow an early and rapid response of the airway epithelia to an injury.   
 
Even if mucus production appears to be particularly important in COPD, its precise 
role in the development and progression of the disease is not completely understood. 
Hogg et al. have proposed that mucus could increase in the small airways, either 
because it is produced in excess by goblet cells stimulated by neutrophil elastase or 
oxygen free-radicals or because it is unable to flow out as a result of impaired mucus 
clearance (Cerveri et al. 2010, Hogg et al. 2007). The mucus could also stick to 
airway walls, thus contributing to luminal occlusion and lung function decline 
because of its viscosity.  
 
The most prominent effect of retinoid ligand treatment obtained in these studies was 
the reduction of mucus hypersecretion. Expression of airway mucus proteins, 
MUC5AC and MUC5B as well as MUC2 and MUC7 was most noted in tRA and 
RARα treated lungs. There was also a more balanced population of acidic and 
neutral glycoproteins in these treated lungs suggesting that these two groups of 
treated lungs are involved in the regulation of mucociliary clearance. The 
mechanisms by which RARα alters mucin expression are unknown, however, the 
257 
 
lungs containing both tRA and RARα bind to specific DNA sequences near 
promoters of responsive genes and exert effects on transcription.  
Although information concerning protein activation by RA binding to RAR is 
limited, RA has been demonstrated to alter protein expression. Therefore it is 
plausible that changes in expression of mucin protein regulated by tRA and RARα 
are major factors in alterations of mucus hypersecretion and that a decrease in mucin 
expression restores some lung function, resulting in greater survival of 
dexamethasone lung injury.  
 
Although the doses used for all retinoid ligand treatment during these studies 
prevented impairment of septation/induced alveolar formation, progenitor cell 
response or mucus hypersecretion in postnatal mice lungs, further investigations 
relating to these studies are warranted.      
 
5.7: PROGENITOR CELLS IN REGENERATION. Prior animal studies of 
allergic lung disease have largely focused on the murine bronchiole epithelium and 
suggested that Clara cells are the cells of goblet cells after an allergen challenge. A 
decrease in the number of Clara cells accompanied by an increase in the number of 
mucus secreting goblet cells in the bronchiole epithelia of OVA-challenged mice 
suggest that in this region of the airway, Clara cells convert to mucus cells (Saganta 
et al. 2012, Reader et al. 2003). Furthermore, using the OVA mouse model of airway 
disease, Evans et al. Observed mucin expression in a subset of Clara cells, again 
suggesting that Clara cells serve as progenitors of goblet cells. These observations 
were also consistent with another study showing that mucus cells produced in the 
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airways of OVA-treated mice include many ultrastructural characteristics of Clara 
cells documented by electron microscopy (Saganta et al. 2012, Evans et al. 2004, 
Hayashi et al. 2004). However, this study could not exclude the possibility that there 
was also contribution of some small airway ciliated cells to goblet cell pool. This 
study also did not address the cell of origin of mucus cells in pseudostratified basal 
cell-containing airway epithelium. We noted that a reduction of Clara cells was not 
achieved with both VAD and dexamethasone lungs, instead there was not only a 
slight increase, but a much reduced level of proliferative cells, which suggests that 
Clara cells present in both lung models maybe variants of the cell and may perhaps 
function differently. How the function of these cells are altered was not investigated, 
but may be an interesting topic to examine along with possible functional changes in 
the retinoid treated lungs as Clara cells were seen to proliferate in some retinoid 
treated lungs. Although proliferation of the bronchiole epithelium was exclusively in 
the basal cell in dexamethasone lungs, the increase of mucus-secreting goblet cells 
suggests that mucus cells directly arise from Clara or basal cells that themselves will 
not replicate at any time during the administration of dexamethasone before they and 
Clara cell populations are meant to replenish non-replicating basal and/or Clara cells 
that may be converted to ciliated or mucus cells. It would be interesting to assay 
whether replicating progenitor cells are necessary to fuel a continual supply of new 
mucus cells in chronic models of COPD. The results presented also suggest that 
dexamethasone and VAD exert inflammatory properties through different 
mechanisms. Dexamethasone and VAD had a profound effect on ATII cells where 
numbers were much reduced due to a reduction of alveoli epithelia and perhaps due 
to the process of differentiating into damaged ATI cells. Nevertheless, it is clear that 
the transcription factor Nkx2.1 still has a profound role in the regulation of ATII 
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cells and is equally affected by airway injury, because when there is a decrease in 
NKx2.1, there is also a decrease in SP-C-positive ATII cells and when there is an 
increase of Nkx2.1, then there is an increase in SP-C protein.  Both VAD rat and 
dexamethasone mouse lungs led to a reduction in the pulmonary surfactant content, 
reduced lung compliance and a reduction of lamella bodies in ATII cells these 
effects may be due to a reduced availability of the substrates necessary for the 
syntheses of surfactant proteins. In adult rats, caloric restriction caused by a 
reduction in pool size of pulmonary surfactant proteins.   
 
The stimulation of alveolar regeneration is an exciting possibility for disease-
modifying therapy of COPD. Fundamental advances in this area are likely to derive 
from animal studies of alveolar development in the late foetal and postnatal periods. 
Such research might include gene expression and proteomic analysis of the 
developing lung, studies of the regulation of expression of relevant genes, studies of 
the coordination of vascularisation and lung development and repair, use of 
transgenic mice to evaluate the role of specific growth factors in the lung and 
investigations of the mechanisms whereby toxins impair lung growth. In addition, 
studies of alveolar regeneration in adults of multiple species are needed to determine 
the capacity of mature lungs for alveolar re-growth and the conditions under which 
alveolar regeneration can occur.  
 
Finally, the development of new animal models of COPD is important for 
hypothesis testing regarding the pathogenic mechanisms of COPD. Topics of special 
interest include the biochemical basis of lung growth, damage and repair; the 
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necessity and sufficiency of specific inflammatory and mucus pathways for the 
development of small airways disease and the reversibility of lung damage. Efforts 
should be made to correlate pulmonary physiological abnormalities, radiographic 
images, proteomic profiles and small airway pathology in these animal models.     
 
5.8: SUMMARY. The classical approach to COPD has encompassed different 
disorders in a unique entity under a variety of imprecise definitions and diagnostic 
criteria. The current definition fails to take into account the heterogeneity of the 
disease and does not reflect the different phenotypic distinctions which may be 
associated with differing natural histories, clinical features and response to 
treatments. The problem with disregarding the heterogeneity of COPD is that not all 
individual patients respond to a given treatment and therefore the opportunity to 
optimize therapy may be missed. Studies have identified different clusters of COPD 
patients based on both clinical and physiological characteristics. These include 
exacerbations, rapid decline of lung function, airway hyperresponsiveness, impaired 
exercise tolerance and emphysema. This large heterogeneity of COPD phenotypic 
distinctions may explain the failure of some large clinical trials to achieve statistical 
significant effects on primary outcomes.  
 
Whether there is alveolar destruction, disruption of alveolar repair or a failure of 
further of alveolar formation is not yet known, but it seems likely that this model 
















6.1: INTRODUCTION. Although the results present in this thesis have provided 
some insight into the many roles of retinoids in postnatal lung regeneration, these 
findings have also opened further lines of research which are worth pursuing. The 
ultimate goal of respiratory research is the hope that the gas exchanging surface area 
can be manipulated in the human lung. One such parameter relating to respiratory 
disorder and repair are rheological features of muc proteins and the ultimate effect 
they impose on breathing. As previously mentioned throughout this thesis, mucins 
are essential for the protection of internal epithelial surfaces. Molecular responses 
involving mucin production and secretion in our VAD and dexamethasone may be in 
response to infectious agents in the airway and may ultimately effect rheology and 
be a contributor to lung malfunction.  
 
Since mucus was first implicated in COPD/emphysema, a number of hypothesis 
have been advanced to explain the characteristics of thick mucus. Like CF, it was 
thought that mucus was abnormally synthesised, but investigations have uncovered 
little data to indicate this to be true. Changes in sulfation and fructose to sialic acid 
ratios may be a factor involved in changes of mucus (mucin) composition in both 
dexamethasone and VAD animal models in relation to an increase of inflammation 
and infection, aspects of the study which is worth pursuing.  
 
Mucins themselves tends to aggregate and immobilise, thereby obstructing ductal 
and luminal passages. This may imply that it is not that the mucin produced is 
abnormal, but the manner and conditions under which mucins are released results in 
the organs pathological fate (Quinton. 2008).  
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It would be interesting to examine whether mucus secreted by COPD/VAD animals 
is thick and sticky like mucus secreted in CF patients. It is generally believed that in 
CF, the “thickness” and “stickiness” of mucus is due to dehydration. Two general 
concepts have been devised for this theory, the first being from observations in the 
airways and airway-derived cells, that fluids are hyper-absorbed by the epithelium 
into which mucins are secreted and therefore is not adequately hydrated (Quinton. 
2008, Boucher. 2007). It is thought that this rationale shared with normal or CF 
phenotypes, but this does not necessarily mean that this rationale is not true for 
COPD/emphysema airways or for the explanation occurring in the animal models 
used in this thesis. The second explanation/theory of dehydration is ascribed to 
hypo-secretion of fluids (Quinton. 2008, Trout et al. 1998, Joo et al. 2006). The 
problem with this theory is that hypo-secretion assumes that once mucins are 
secreted, are without access to fluid which seems unlikely as secretory epithelium 
affected organs are highly permeable to water (Quinton. 2008). Therefore there must 
be another factor involved in mucus hypersecretion and change in mucin 
composition. Quinton. 2008 has proposed that bicarbonate secretion (HCO3־) may 
be the cause of mucus dehydration (thickness and stickiness) and mucin 
compositional change and may also be occurring in the animal models used in this 
thesis. The concept behind this is thus; gel forming mucins protect the apical 
surfaces of epithelial tissues. These molecules are compacted and stored 
intracellularly as granules with high concentrations of calcium ions (Ca++). These 
cations shield repulsive forces of fixed negative charges on mucins to prevent their 
expansion in forming mucus gels. Ca++ also forms electrostatic divalent bridges 
between fixed negative charges that further stabilise mucins and oppose expansion 
(Quinton. 2008, Perez-Vilar et al. 2005). Once the granule is released, HCO3־ is 
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critical to sequester Ca++ and H+ away from mucin anions by complicating with 
them, i.e. HCO3־ and its equilibrium form             , react with condensed mucins to 
form H2CO3, CaHCO3+ and CaCO3 and reduce the activity of Ca++ and H+ in the 
mucin solution. Once unshielded, the electrostatic anionic forces rapidly expand the 
mucin macromolecules. There are no other anions of significance in secreted fluids 
capable of effectively complicating these cation. The only other significant anion, 
Cl- cannot buffer H+ or chelate Ca++ because both HCl and CaCl2 are highly 
dissociable (Quinton. 2008). Quinton proposes that in CF, the lack of HCO3־ in the 
extracellular medium of mucins impairs calcium removal, prevents normal mucin 
expansion and promotes stasis of mucus in the ducts or on the luminal surfaces of 
affected organs. This action could be happening in dexamethasone/VAD lungs and 
is worth pursuing. How is retinoid ligands involved in the reversal effect of the 
HCO3־ theory, if true in these models and thus in human lungs? Are any of the 
retinoid ligands used throughout this thesis able to reverse the thickness and 
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